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Inflammation is a stereotypical physiological response to infections and tissue injury; it initiates pathogen killing as well as tissue repair processes
and helps to restore homeostasis at infected or damaged sites. Acute inflammatory reactions are usually self-limiting and resolve rapidly, due to the
involvement of negative feedback mechanisms. Thus, regulated inflammatory responses are essential to remain healthy and maintain homeostasis.
However, inflammatory responses that fail to regulate themselves can become chronic and contribute to the perpetuation and progression of disease.
Characteristics typical of chronic inflammatory responses underlying the pathophysiology of several disorders include loss of barrier function,
responsiveness to a normally benign stimulus, infiltration of inflammatory cells into compartments where they are not normally found in such
high numbers, and overproduction of oxidants, cytokines, chemokines, eicosanoids and matrix metalloproteinases. The levels of these
mediators amplify the inflammatory response, are destructive and contribute to the clinical symptoms. Various dietary components including
long chain v-3 fatty acids, antioxidant vitamins, plant flavonoids, prebiotics and probiotics have the potential to modulate predisposition to chronic
inflammatory conditions and may have a role in their therapy. These components act through a variety of mechanisms including decreasing inflam-
matory mediator production through effects on cell signaling and gene expression (v-3 fatty acids, vitamin E, plant flavonoids), reducing the pro-
duction of damaging oxidants (vitamin E and other antioxidants), and promoting gut barrier function and anti-inflammatory responses (prebiotics
and probiotics). However, in general really strong evidence of benefit to human health through anti-inflammatory actions is lacking for most of
these dietary components. Thus, further studies addressing efficacy in humans linked to studies providing greater understanding of the mechanisms
of action involved are required.
Preamble
Inflammation is a normal host defence mechanism that
protects the host from infection and other insults; it initiates
pathogen killing as well as tissue repair processes and helps
to restore homeostasis at infected or damaged sites. It is
typed by redness, swelling, heat, pain and loss of function,
and involves interactions among many cell types and the pro-
duction of, and responses to, a number of chemical mediators.
Normally, the host is tolerant to microbes and other environ-
mental components that do not pose a threat. This tolerance
involves only a limited host response or an active response
that is tightly controlled. Where an inflammatory response
does occur, it is normally well regulated in order that it
does not cause excessive damage to the host, is self-limiting
and resolves rapidly. This self-regulation involves the acti-
vation of negative feedback mechanisms such as the secretion
of anti-inflammatory cytokines, inhibition of pro-inflammatory
signalling cascades, shedding of receptors for inflammatory
mediators and activation of regulatory cells. As such, and con-
trolled properly, regulated inflammatory responses are essential
to remain healthy and maintain homeostasis. Pathological
inflammation involves a loss of tolerance and/or of regulatory
processes. Where this becomes excessive, irreparable damage
to host tissues and disease can occur. Typically, diseases or con-
ditions with a well-recognised inflammatory component are
treated with general or specific anti-inflammatory pharmaceuti-
cals. However, since many dietary components may influence
various elements of inflammation, nutrition may play a role in
predisposing to inflammatory conditions and altered nutrition
may be useful in therapy of such conditions. A workshop was
held in Oporto, Portugal, on 29–31 May 2006. The workshop
aimed to consider the role of inflammation in various diseases
and conditions, to identify common and unique mechanisms
and markers of inflammation, and to review and consolidate
evidence that dietary components can influence inflammatory
processes and to understand their mechanisms of action. The
present paper is based upon the presentations made at the
workshop and the subsequent discussions.
General aspects of the inflammatory process
Inflammation may be classified into four types, the mechanisms
of which in part overlap: (i) inflammation caused by innate and
acquired immunity against infectious agents, in which cells are
activated and mediators released to prevent or combat infection
and remove foreign material; (ii) inflammation caused by differ-
ent inhaled agents (‘irritants’) like diesel exhaust particles,
ozone and endotoxin; (iii) allergic inflammation, in which
specific IgE antibodies bound to mast cells upon cross-linking
by allergen cause the immediate release of a number of inflam-
matory mediators and activation of inflammatory cells; and
(iv) neurogenic inflammation, mediated by the neural system.
Common to these forms of inflammation is that they have an
afferent phase, in which the presence of a ‘foreign material’ is
sensed by some types of cell, and an efferent phase, in which
an inflammatory response is generated to eliminate the per-
ceived hostile intruder. The purpose of the inflammatory
response to micro-organisms is obvious, and the response is ben-
eficial and necessary to protect the integrity of the body as long
as it does not become unnecessarily destructive or long-lasting.
Inflammation caused by non-pathogenic agents can also be ben-
eficial and remove the foreign material e.g. by increasing
mucous production and increasing the number of phagocytic
cells, but it may also have negative health effects in particular
if long-lasting. Allergic inflammation is triggered by minute
amounts of innocuous foreign material, so-called allergens
from plants, insects, animals and foods, and serves no obvious
beneficial purpose, except that similar responses may protect
against certain infectious agents (parasites). Neurogenic inflam-
mation may be looked upon as an adjuct mechanism to the other
three types of inflammation. Irrespective of the cause of the
inflammation, the response involves four major events.
(i) An increased blood supply to the site of inflammation.
(ii) Increased capillary permeability caused by retraction of
endothelial cells. This permits larger molecules, not
normally capable of traversing the endothelium, to do
so and thus delivers some soluble mediators to the site
of inflammation.
(iii) Leucocyte migration from the capillaries into the sur-
rounding tissue (Fig. 1). This is promoted by release
of chemoattractants from the site of inflammation and
by the upregulation of adhesion molecules on the endo-
thelium. Once in the tissue the leucocytes move to the
site of inflammation.
(iv) Release of mediators from leucocytes at the site of
inflammation (Fig. 1). These may include lipid mediators
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(e.g. PG, leukotrienes), peptide mediators (e.g. cyto-
kines), reactive oxygen species (ROS, e.g. superoxide),
amino acid derivatives (e.g. histamine) and enzymes
(e.g. matrix proteases) depending upon the cell type
involved, the nature of the inflammatory stimulus, the
anatomical site involved and the stage during the inflam-
matory response. These mediators normally would play a
role in host defence, but when produced inappropriately or
in an unregulated fashion, they can cause damage to host
tissues, leading to disease. Several of these mediators may
act to amplify the inflammatory process acting, for
example, as chemoattractants. Some of the inflammatory
mediators may escape the inflammatory site into the circu-
lation and from there they can exert systemic effects. For
example, the cytokine IL-6 induces hepatic synthesis of
the acute phase protein C-reactive protein (CRP), while
the cytokine TNF-a elicits metabolic effects within
skeletal muscle, adipose tissue and bone.
Characteristics of inflammatory conditions afflicting
specific organ systems
Gut: celiac disease
Normal function of mucosal immunity. The gastrointestinal
mucosa is an interface for communication between the
individual and the external environment. The large mucosal
surface (300–400 m2 in an adult human) is adapted with
specialised structures for the chemical and immunological rec-
ognition of substances and organisms passing through the
tract. Intestinal epithelial cells play a crucial role in detecting
foreign substances and mediating host innate and adaptive
mucosal immune responses. Activation of innate host defence
mechanisms is based on the rapid recognition of conserved
molecular patterns in microbes by preformed receptors, toll-
like receptors, mainly expressed in the cell membrane and
nucleotide-binding oligomerisation domain (NOD)-family
(also known as caspase recruitment domain-family) receptors
in the cytosol(1). In response to invading bacteria, the signals
converge to transcription factors (NF-kB) and others), which
initiate the transcription of genes responsible for the synthesis
of proinflammatory proteins(2). Intestinal epithelial cells also
express human leucocyte antigen (HLA) class II molecules,
suggesting that they can function as antigen-presenting
cells(3). On the other hand, non-pathogenic bacteria and inno-
cuous food antigens may elicit other types of cytokine
responses that are transmitted to underlying immunocompe-
tent cells(4). Normally, responses to non-pathogenic bacteria
involve regulatory cytokines such as transforming growth
factor (TGF)-b or IL-10, and are related with the induction
of regulatory pathways of the immune system(5,6). Acquired
immune responses develop in specialised lymphoid tissues.
Gut-associated lymphoid tissue is located in three compart-
ments: organised structures (Peyer’s patches and lymphoid
follicles); the lamina propria; the surface epithelium(7). The
organised structures are the inductive sites for acquired immu-
nity. These structures are covered by follicle-associated
epithelium, which contains M-cells. These are specialised epi-
thelial cells that transport micro-organisms and other antigens
from the gut lumen into the organised lymphoid tissue.
Antigens are presented to naı¨ve T-cells by antigen-presenting
cells such as dendritic cells (DC) and macrophages. In
addition, luminal antigens may also be taken up and presented
by epithelial cells. After priming, antigen-specific T-cell
clones proliferate, but these T-cells may differentiate into
Th1, Th2 or regulatory T-cells, with different effector capa-
bilities(8). Th1 or Th2 cells have a polarised cytokine secretion
either of interferon (IFN)-g, TNF-a and IL-2 (Th1), or IL-4,
IL-5 and IL-13 (Th2). Such skewing of the adaptive
immune response depends on the presence of micro-
environmental factors, including ‘danger signals’ from
microbial products, and eventually induces pro-inflammatory
systemic-type immunity, with the potential for tissue
damage. By contrast, regulatory T-cells produce IL-10 and
Fig. 1. Generalised view of inflammation.
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TGF-b and lead to suppressive mechanisms that avoid local
and peripheral hypersensitivity to innocuous antigens in
food. Such mucosal tolerance to food antigens is an important
adaptive immune function in view of the fact that as much as a
ton of food may pass through the gut of an adult every year,
resulting in substantial exposure to antigens. Thus, in the
healthy state, the vulnerable gut mucosa exhibits virtually no
proinflammatory response to food antigens(9,10) and contains
very few hyperactivated T-cells.
Definition and description of celiac disease. Celiac dis-
ease is an immune-mediated disorder that affects primarily
the small intestinal mucosa. The disease is triggered by the
ingestion of gluten in genetically susceptible individuals.
Strictly speaking, gluten is a protein component in wheat,
but the term is collectively applied to disease-activating pro-
teins in wheat, rye and barley. Celiac disease is characterised
by chronic inflammation of the small intestinal mucosa that
may result in atrophy of intestinal villi. The progressive
destruction of the small intestinal mucosa causes malabsorp-
tion, and a variety of clinical manifestations, including diar-
rhoea, abdominal pain, vitamin and mineral deficiencies,
iron-deficiency anaemia, osteoporosis, growth delay, skin
lesions, neurological disorders, etc. Diagnosis of the disease
requires examination of biopsies of small intestinal
mucosa(11). The Marsh classification(12) has been adopted to
describe the progression of the abnormalities in the
mucosa, from early stages with normal architecture and a
lymphocytic infiltration of the villus epithelial layer up to
total atrophy of the villi caused by chronic inflammation.
A number of serologic tests are available commercially for
identifying individuals who require an intestinal biopsy
examination to diagnose celiac disease(13). The best markers
are the detection in serum of anti-tissue transglutaminase
IgA by ELISA, or anti-endomysial IgA by immuno-
fluorescence. Both tests appear to have equivalent diagnostic
accuracy as the tissue transglutaminase is the specific protein
that is recognised by the IgA-endomysial antibody. Anti-
gliadin antibody tests are no longer routinely recommended
because of their lower sensitivity and specificity(13). The
increasing use of serologic screening is leading to diagnosis
in milder cases. It is presently recognised that, at certain
points in time, the disease is not associated with obvious
clinical signs and symptoms. Silent celiac disease is charac-
terised by the presence of positive serologic markers
(anti-tissue transglutaminase and/or endomysial antibody) and
histological lesions on small bowel biopsy typical for celiac dis-
ease in an asymptomatic individual. In latent celiac disease,
small bowel biopsy shows only minimal changes (increased
intraepithelial lymphocyte infiltration) and anti-tissue transglu-
taminase or endomysial antibodies may be detected, but the
characteristic feature is that the subjects develop symptoms
and positive serologic and histological markers, while on a
gluten-containing diet. Latent celiac disease precedes diagnosis
of celiac disease or follows successful treatment of active dis-
ease with a gluten-free diet. Finally, active celiac disease is
characterised by intestinal and/or extraintestinal symptoms,
villus atrophy and strongly positive anti-tissue transglutaminase
and endomysial antibodies.
Epidemiology of celiac disease. Population-based esti-
mates of the incidence of confirmed celiac disease vary
from two to thirteen new cases per 100 000 person-years.
These rates have to be interpreted with caution because
many patients diagnosed as adults are likely to have had sev-
eral years of untreated celiac disease, and thus do not represent
true new cases. The recent increase in the incidence rates has
likely been due to increasing use of serologic screening lead-
ing to diagnosis in milder cases(14). Although the prevalence
of diagnosed celiac disease varies widely among different
populations, the estimates of combined undiagnosed and
diagnosed (latent, silent and active) celiac disease are remark-
ably similar, between 0·7 % and 2·0 %, in most European
and non-European white populations, including those in
Finland, Sweden, Germany, Italy, Spain, Israel, the United
States, Argentina, Australia and New Zealand(14,15). However,
celiac disease is virtually unknown in East Asian and African
populations, whereas rates close to those in Europe have been
reported from the Middle East and India(14).
Genetic background appears to be a major risk factor for
celiac disease. It is unequivocal that celiac disease is strongly
associated with specific HLA class II genes that map to the
DQ locus of the MHC used for cell-to-cell interaction
during the process of antigen presentation(16). The presence
of specific alleles at the HLA-DQ locus appears to be
necessary, although not sufficient, for the phenotypic
expression of disease. Thus, virtually all affected individuals
have either DQ2 (HLA-DQA1*05-DQB1*02) or DQ8
(HLADQA1*03-DQB1*0302) alleles, in comparison with
the general population in which 39·5 % have either DQ2 or
DQ8. However, only 3 % of individuals in the general popu-
lation carrying DQ2 or DQ8 will develop evidence of celiac
disease, suggesting that HLA typing could be used to identify
genetic risk, but not for defining celiac disease(16).
Environmental factors also play a major role. It is well
established that celiac disease is strictly dependent on
exposure to wheat gluten and related proteins in rye and
barley. Thus, these cereal proteins are necessary causal factors
both to initiate and to maintain the disease process. On the
other hand, epidemiological studies have shown that breast-
feeding is a protective factor. Introduction of gluten-contain-
ing foods while the infant is still breast-feeding reduces the
risk for celiac disease(17). The age of the infant at introduction
of gluten-containing foods does not seem to be an independent
risk factor, but it is well established that introduction of
gluten-containing foods in large amounts, as compared with
small or medium amounts, increases the risk for celiac disease.
Infectious episodes affecting the gut mucosal barrier could
potentially contribute to the development of celiac disease in
genetically susceptible individuals(17).
Description of the pathophysiological mechanisms involved
in celiac disease. HLA class II molecules are expressed on
the surface of antigen-presenting cells where they can bind
and subsequently present ‘foreign’ peptides encountered in
the extracellular environment to populations of naı¨ve
T-helper lymphocytes that recognise the DQ2- or DQ8–
peptide complex. In the case of celiac disease, glutamine resi-
dues that remain in glutamine/proline-rich peptides following
the intestinal digestion of ‘gluten’ are converted by tissue
transglutaminase to negatively charged glutamic acid that
binds to DQ2 or DQ8 molecules on antigen-presenting
cells(18). The DQ–‘gluten’ peptide complexes activate DQ2
or DQ8 restricted T-helper cells, respectively, that proliferate
and produce mainly Th1-type cytokines, particularly IFN-g.
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Of note, such gluten-activated Th1 cells were isolated from
the small intestinal mucosa of patients with celiac disease,
but they are not found in the intestinal mucosa of individuals
without celiac disease, who also have the relevant disease-
associated DQ2 or DQ8 HLA class II molecules(18). Secretion
of Th1 cytokines such as IFN-g and TNF-a activates the
release of enzymes such as matrix metalloproteinases that
can damage the intestinal mucosa, with a loss of villus struc-
ture(18). These cytokines increase epithelial permeability and
proinflammatory cytokine production, which in turn will
increase the passage of gluten peptides and peptide binding
to DQ2 and DQ8 molecules on antigen-presenting cells, lead-
ing to a chronic feedback of the inflammatory process as long
as gluten peptides are present in the intestinal lumen.
A strict gluten-free diet for life is the only accepted treat-
ment for celiac disease(19). Successful outcomes are highly
dependent on compliance to such a diet. Advanced celiac
disease may not respond to a gluten-free diet, and these refrac-
tory cases are being treated with immunosuppressant drugs,
including azathioprine and anti-TNF therapies with variable
results (Fig. 2).
Gut: inflammatory bowel diseases
Definition and description of inflammatory bowel diseases.
Ulcerative colitis (UC) and Crohn’s disease (CD) are the
two main forms of inflammatory bowel disease (IBD). UC
and CD are both acute and chronic disabling inflammatory
illnesses, whose aetiologies are unknown. Present opinion
holds that IBD are multifactorial conditions, in which they
involve both genetic and environmental components, with
the final outcome being determined by an aberrant immune
response to normal commensal microbiota in individuals
who have a weakened epithelial barrier(20 – 22). IBD is incur-
able, but typical maintenance treatments involve the use of
immunosuppressant and anti-inflammatory drugs, antibiotics
and surgery. An important factor differentiating CD from
UC is that it can affect any part of the gastrointestinal tract,
not just the large bowel as in UC. Whereas CD is character-
ised by patchy, transmural inflammation with inflammatory
processes occurring deep in the tissues, the inflammatory
response in UC is primarily located in the colonic mucosa
and submucosa resulting in severe tissue damage, ulceration
and haemorrhage(23). In both forms of IBD, large infiltrates
of neutrophils can be seen in the inflamed tissues, together
with the presence of microabscesses in the lamina propria.
The main clinical feature of UC is bloody diarrhoea; other
symptoms such as colicky abdominal pain and an urgency to
defaecate may also be present, whereas in CD the symptoms
can be more heterogenous and include diarrhoea, abdominal
pain, weight loss and malaise(23). Both CD and UC are associ-
ated with a 5-fold increased risk of developing colon cancer.
Epidemiology of inflammatory bowel diseases. Up to two
million people are affected by IBD globally, with the disease
being mainly associated with industrialised countries in the
northern hemisphere. The incidence of CD is increasing in
the UK and is about five to ten per 100 000 per annum, with
a prevalence of 50–100 per 100 000, although this is believed
to be an underestimate(23). Overall, the incidence and preva-
lence of UC is approximately twice that of CD. IBD usually
starts early in life with the greatest onset being in young
adults aged between 15 and 25 years, but it can affect
people of any age, with 15 % of people aged over 60 years
at diagnosis.
Although a genetic component is known to be involved in
IBD, with both CD and UC sharing some susceptibility
genes, there is stronger evidence for a genetic link in
CD(21,22). In CD, a 44 % concordance exists between monozy-
gotic twins, and a 4 % concordance between dizygotic twins.
Between 4·5 and 16·6 % of CD patients have the disease
already in the family, suggesting a polygenetic inheritance.
A mutation in the NOD2/caspase recruitment domain-15
(called IBD-1) gene on chromosome 16 has been found in
30 % of patients with CD(24). NOD2 is a cytoplasmic receptor
Fig. 2. Generalised scheme for the development of celiac disease.
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for muramyl peptide found in bacterial cell walls, which may
result in CD patients with this mutation having a reduced
ability to clear invasive bacteria. A higher incidence of UC
has been found in Jewish than in non-Jewish families, and
Ashkenazi Jews born in the West have been found to have a
higher incidence of CD than those born in Israel or non-
Ashkenazi Jews. Largely uncategorised environmental factors
are thought to predispose towards IBD. However, the change
to a more Western-style diet has been suggested as a link in
IBD development. Smokers are more likely to develop CD
and have more aggressive disease, with more severe relapses
than non-smoking CD patients, although smoking has been
shown to be protective in UC. Physiological stress, particu-
larly long-term stress, may also be a precipitating factor in
IBD. Stress can also bring about relapses in animal models
of colitis and cotton-top tamarinds spontaneously develop
colitis when kept in long-term captivity. Childhood illnesses
and not being breast-fed are also thought to incur increased
risk of developing IBD; however, appendectomy in early
life can prevent the development of UC.
Description of the pathophysiological mechanisms involved
in inflammatory bowel diseases. There is considerable
evidence for microbial involvement in IBD. For example,
while germ-free animals do not manifest an inflammatory
response, knock-out or transgenic mice with genetic suscepti-
bilities to IBD only acquire characteristic lesions when repo-
pulated with normal commensal bacteria(25). Human studies
have shown that UC patients have increased levels of mucosal
IgG against the normal colonic microflora, as well as
increased antibody production against strictly anaerobic bac-
teria. UC also starts in the area of the gut with the highest con-
centration of micro-organisms. A number of different bacteria
have been implicated in IBD in human subjects and animals,
in various studies, but none have been definitively shown to
be aetiologic agents in human subjects. The role of mucosal
bacteria may be important due to their ability to interact
more directly with the host immune system(26,27). Neverthe-
less, CD patients have been shown to have higher numbers
of bacteroides and lower numbers of bifidobacteria in
faecal(28) and mucosal samples, while higher numbers of
peptostreptococci and lower numbers of bifidobacteria have
been found on the mucosa in patients with UC(29). Low num-
bers of bifidobacteria may be of significance in IBD because
some species exhibit strong immunomodulatory properties(30).
This dysbiosis in mucosal bacterial populations in IBD, with
the loss of beneficial commensal species, and perhaps a
switch to a more pro-inflammatory phenotype, may explain
why probiotic bacteria have been shown to be useful, in
some cases, in the treatment of some forms of IBD, such as
UC and pouchitis(27,29,31).
In IBD, the interaction between the mucosal immune
system and the commensal microflora in the gut is disturbed
and dysregulation of the immune system occurs. The T-cell
response profiles associated with UC and CD are different in
that a Th1 pattern of cytokine formation develops in CD
with increased production of TNF-a, IFN-g, IL-12, IL-6 and
IL-1b, whereas UC more resembles a modified Th2 profile,
where cytokines including IL-5 and IL-10 are upregulated,
although IL-4 is not(21). In addition to this change in cytokine
profile, intestinal B lymphocytes produce large amounts of
IgG. TNF-a is expressed in the intestinal mucosa of patients
with IBD and triggers inflammation via an NF-kB-dependent
signalling cascade. Most of the pro-inflammatory responses
in IBD are transcriptionally regulated by NF-kB and many
of the cytokines involved act on signal transducers and activa-
tors of transcription (STAT) family(32). IL-12 can act on
CD4 þ T-cells to induce differentiation into Th1 effector
cells and activate the signalling proteins STAT-3 and STAT-4,
which in turn leads to the production of IFN-g. Animal studies
have shown that STAT-4-deficient mice have impaired IFN-g
production, and do not develop colitis, whereas mice over-
expressing STAT-4 have diffuse infiltration of IFN-g and
develop gut inflammation. STAT-3 signalling has been
found in UC and CD where it has been shown to be confined
to areas of active inflammation, infiltrating macrophages and
T-cells. STAT-3 induces transcription of the pro-inflammatory
cytokine IL-6, which can increase resistance of T-cells to
apoptosis lengthening the chronicity of CD, due to the
accumulation of active T-cells. Increased numbers of blood
mononuclear cells have also been found in IBD, which may
lead to extraintestinal manifestations, while the production
of free radicals from macrophages contributes to cellular
damage. Other factors implicated in CD include generation
of matrix metalloproteinases, such as collagenases and
stromelysins, which can degrade extracellular matrices,
cause ulceration and result in tissue destruction(22,33). High
levels of extracellular matrix metalloproteases, which can be
upregulated by pro-inflammatory cytokines, have been
shown in areas of tissue injury and foci of ulceration in CD
patients. Group II phospholipase in serum and colonic
mucosa has also been shown to be increased in patients with
CD, which can be inhibited by steroids and anti-inflammatory
drugs. Corticosteroids are the main therapy used for treatment
of active IBD, to downregulate the immune response, and
allow the mucosa to heal. More recently, therapies involving
the use of monoclonal antibodies such as Inflixamab against
TNF-a have been found to be effective in inducing remission
in CD.
Lungs: airways and the allergic inflammation
Normal functioning of the airways. The airways bring air
into the alveoli of the lungs, where air and blood are separated
only by the alveolar membrane that is about 0·001 mm thick.
The turbulence of the air passing through the upper airways
is such that most particles larger than 2mm in diameter are
caught on the mucosal surface in the nasal cavity. This is ben-
eficial with regard to starting an immune response against
foreign material, because the back of the nasal cavity and
the upper pharynx are rich in immune cells and lymphoid
tissue. The trachea splits into two main bronchi that continue
to branch out into bronchi and bronchioli, to end in the so-
called alveolar sacs and alveoli. Alveoli have a good blood
supply and are extremely thin-walled to allow gas exchange
between blood and air. From the alveoli, the anatomical struc-
ture of the airways gradually changes towards the bronchi.
The basic components are the epithelium that covers the
inside of the airway tubes, and under the epithelium,
the submucosa and then a layer with smooth muscle that
can contract and thereby narrow the airways. In certain
areas, the epithelial surface against the airway lumen has
fine hair-like structures called cilia, which have a contractile
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apparatus and a synchronised beat so that mucus and particles
will be moved up towards the larger airways and the larynx
(‘the mucociliary escalator’).
Normal function of inflammatory responses to maintain
homeostasis in the airways. The alveolar membrane
(140 m2 surface area) is protected by three major, integrated
defence systems along the airways. Firstly, the anatomy of
the airways provides ‘mechanical’ defence, conditioning and
cleaning the air as it passes through the nose. The mucociliary
escalator helps remove particulate material. Secondly, the
inflammatory response mediated by several cell types results
in a rapid capacity to eliminate intruding microbes as well
as foreign material and debris, but may become long-lasting
if the material is not properly removed (in this case lung dis-
ease may result). Finally, the specific immune response is
highly effective at eliminating microbes and other foreign
material. The human lung is exposed daily to between
10 000 and 20 000 litres of ambient air containing large num-
bers of particles and gases that may cause oxidative stress
and inflammation. Not surprisingly, the lungs have several
systems to counter oxidative stress(34).
Description of inflammatory airway and lung diseases:
rhinoconjunctivitis, asthma and chronic obstructive pulmon-
ary disease. The main diseases of the airways to be addressed
are allergic rhinoconjunctivitis, allergic asthma and chronic
obstructive pulmonary disease (COPD). These three are usually
described as separate entities, but it is important to realise that
there is a strong link between allergic rhinoconjunctivitis and
asthma, and that asthma and COPD may be part of a continous
spectrum of disease. At the one end of this spectrum would be
allergic asthma with near-complete reversibility of bronchial
obstruction and little inflammatory change and at the other
end COPD with nearly no reversibility of airflow limitation,
and pronounced inflammation and destruction of lung tissue.
If asthma and COPD are considered as separate diseases, then
many patients present components of both diseases to varying
degrees. These components of airway disease include signs
like variable airflow limitation, airway hyper-responsiveness,
chronic airflow limitation and airway inflammation with differ-
ent characteristics, as well as bronchiectasis and emphysema.
Symptoms include chest tightness, wheezing, dyspnoea, cough
and sputum and are all non-specific, since they can result from
several disease components. Measures of lung function and
inflammation are necessary to be certain as to which condition
the symptoms are associated with(35). Thus, many patients
with COPD and asthma can be readily distinguished from
one another, but many patients also have features of both
disorders(36).
Allergic rhinoconjunctivitis is a fairly ‘pure’ allergic disease,
in which the classical anti-allergen IgE-mediated release of
histamine and other mediators from mast cells triggers the
classical symptoms and signs of itching, sneezing, oedema,
influx of eosinophils and watery mucous production.
In contrast to allergic asthma, in rhinitis, there is no smooth
muscle constriction narrowing the airways (narrowing is
caused by swelling of the mucosa), and no significant tissue
destruction. Subjects with allergic rhinoconjunctivitis are
often found to have bronchial hyper-reactivity, and may later
develop asthma.
Asthma is considered a chronic inflammatory disease of
the lungs. Asthma is traditionally classified into allergic and
non-allergic asthma. Allergic asthma is considered to be the
most common form of asthma in children, while in adults
asthma without known allergen triggers is more common.
However, the distinction depends on the demonstration of trig-
gering allergens, and is, therefore, somewhat unclear. It may
be argued that asthma and allergy at least sometimes may
be parallel but separate conditions (e.g. ‘non-allergic’
asthma in an individual that also has allergies). With both
types of asthma, various ‘non-specific’ irritants may aggravate
asthma and trigger an asthmatic attack, and the allergen-
triggered allergic inflammation can be looked upon as one
of several such asthmagenic stimuli. Asthma has chest tight-
ness, wheeze, cough and dyspnoea as prominent symptoms,
and is functionally characterised as reversible bronchial
obstruction, caused by contraction of the smooth muscle
layer in the mucosa of the bronchi, by mucous production,
mucosal oedema and mucosal inflammation. Airway hyper-
responsiveness (oversensitivity and overreactivity to stimuli)
is typically present in asthma, but is not an obligatory feature.
Similarly, bronchial hyper-responsiveness is often found in
individuals without manifest asthma. A prominent cell in
the asthmatic inflammation is the eosinophil, together with
lymphocytes. Granulocytes other than eosinophils may be pre-
sent to varying degrees. The inflammation may lead to
destruction and shedding of the epithelial cell layer. Over
time, structural changes take place in asthma, so-called remo-
delling, inflammation will become permanent and more
severe, and reversibility of the airways obstruction will
become less complete. Chronic severe asthma may thus
show features of COPD.
The definition of COPD rests much on functional criteria,
with non-reversible or incompletely reversible airflow obstruc-
tion accompanied by shortness of breath, cough and sputum
production, and intermittent exacerbations. However, some
reversibility of airways obstruction may be present, and
bronchodilators are the basic medication used in COPD.
Underlying the symptoms are chronic lung inflammation and
progressive, often pronounced tissue destruction. In addition
to pulmonary manifestations, other organ systems may be
affected in COPD. Systemic manifestations of COPD include
weight loss, nutritional abnormalities and musculoskeletal
dysfunction(37 – 39).
Epidemiology of allergic rhinoconjunctivitis, asthma and
chronic obstructive pulmonary disease. Allergic rhinitis is
triggered by allergens, but symptoms may be increased by
air pollution. Allergic rhinitis may be constant (perennial) if
the eliciting allergen is constantly present (e.g. mite allergens),
seasonal if the allergen shows seasonal variation (e.g. in pollen
allergy in the Nordic countries) or episodic (e.g. a person
allergic to cats with low habitual exposure, who visits a
home with cats). Allergic rhinitis starts in infancy and peaks
in childhood and adolescence. Atopic individuals constitute
the group at risk. In 80 % of cases, the symptoms develop
before the age of 20 years. Severity varies from trivial symp-
toms to periodically incapacitating disease. Allergic rhinitis
may be associated with other upper-airway inflammatory
conditions(40,41). A large international study showed consider-
able variation in prevalence between countries, from 0·8 % to
14·9 % in 6- to 7-year olds, and from 1·4 to 39·7 % in 13- to
14-year olds(42). There has been a general pattern of increased
prevalence in the industrialised compared with the developing
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countries. Cross-sectional studies with similar methodology
suggest a rising prevalence(43).
Asthma severity varies from barely noticeable symptoms to
lethal exacerbations. Prevalence of asthma can vary 3-fold in
the same population depending on the diagnostic criteria used,
and prevalence data should be interpreted cautiously(44).
Atopic individuals constitute the major risk group. However,
as already mentioned, asthma is also frequently diagnosed in
non-allergic individuals. Asthma is not only common in
children but also develops in adult life. Diagnosis in small
children is uncertain. For all age groups, incidence varies
between countries from 2·7 to 4 per 1000 individuals per
year. After 25 years of age, it has been estimated at 2·1 per
1000 individuals(44). Before puberty, asthma is more
common in boys than girls, but after puberty this sex differ-
ence is reversed. Prevalence has been extensively studied in
the last 30 years, and one major study is the International
Study of Asthma and Allergies in Childhood(45,46). The pre-
sent study of nearly half a million children aged 13–14
years in 56 countries showed large variability between
countries. The highest 12-month prevalence was found in
the UK, Republic of Ireland, Australia and New Zealand
(up to 36·8 %), and the lowest in Eastern European countries,
Indonesia, China, India and Ethiopia (the lowest 1·6 %).
A number of studies have found an increasing incidence and
prevalence over the last decades(44,47). However, some fairly
recent studies have indicated that in some regions(48), but
not others(49), the increase may have levelled out.
In 1990, COPD was the twelfth leading cause of morbidity
and the sixth leading cause of death worldwide. Of all the
major diseases, COPD is the one whose burden is rising
the fastest, and it is projected to become the fifth leading
cause of disability and the third leading cause of death by
2020(50). COPD is strongly associated with cigarette
smoking, but also occurs in non-smokers, and individuals
vary greatly in their susceptibility to the effect of tobacco
smoke. COPD is markedly underdiagnosed and frequently
undermanaged, perhaps because it has been considered irre-
versible and that treatment has little to offer. However,
COPD may be partially reversible and clinical responses to
treatment do occur(51).
Description of the pathophysiological mechanisms of lung
disease, with an emphasis on inflammation
Environmental triggers. Asthma appears to be caused by
environmental factors, such as allergens, irritants and infec-
tions, in genetically predisposed individuals. Once asthma
has become manifest, essentially the same agents may trigger
worsening of the disease and precipitate serious asthmatic
attacks, as well as contribute to the development of chronic
disease. A host of triggering as well as some protective factors
are known, but the basic understanding of why and how
asthma develops is still rudimentary. A major factor contribut-
ing to the development of allergy and asthma is the so-called
Western lifestyle. This is illustrated by the 2- to 3-fold higher
prevalence of asthma in former West Germany compared with
East Germany, and Hong Kong compared with nearby cities in
China(52,53). Gradients in the prevalence of allergic disease
corresponding to social gradients are also found within indi-
vidual countries, and allergic diseases have been described
as a price paid for wealth and a high standard of living.
Environmental and lifestyle factors have changed in a broad
sense over the last decades in industrialised countries, but it
is not known which specific conditions in the more affluent,
industrialised or urbanised lifestyle drive the development of
asthma and allergy. Also, asthma is a major health problem
among the poor populations living in deprived inner city dis-
tricts and the homeless in USA, with a very high prevalence of
severe asthma, and prevalence is also high in some other
underprivileged regions e.g. in South America. Asthma there-
fore does not, in all places, fit the ‘hygiene hypothesis’ model
of more allergic disease among the ‘clean and rich’ and less
among the poor (see later).
Allergen exposure will trigger asthma once the disease has
become manifest, as will a wide array of non-specific irritants
in the occupational setting, indoor environmental factors (e.g.
second-hand tobacco smoke, strong odours and perfume) and
outdoor air pollution factors like fine particulate matter, ozone
and oxides of nitrogen. Also, physical exercise and psycho-
logical stimuli may precipitate asthma(44).
For the causation of asthma, loss of protective environmen-
tal factors may be as important as asthma-provoking factors.
The observation that the risk of asthma is reduced with
increasing number of older siblings was explained by the
Th1–Th2 pardigm of immune responses (see later) and the
so-called hygiene hypothesis. In its original form, this
hypothesis stated that younger siblings got more infections
and got them earlier than the older siblings, and that the infec-
tions stimulated the development of Th1 immunity and coun-
teracted the development of allergy-associated Th2
responses(54). Although the focus has moved away from the
hygiene hypothesis in the original form(55 – 57), it is still con-
sidered that ‘something with micro-organisms’ is protective
in relation to asthma and allergy(58). Observations that more
or less indirectly support this include the inverse relationship
between family size and asthma(59), the protective effect of
early placement in day care settings(60), the protective effect
of exposure to farm animals(61), the protective effect of endo-
toxin exposure (allergy more than asthma)(58), the reduced
prevalence of asthma among anthroposophic Steiner school
attendants(62), the protective effect of extensive exposure to
cats and dogs(63), the association between intestinal flora and
atopic manifestations(64) and the association between early
use of antibiotics and increased incidence of allergy(65).
Other hypotheses of asthma causation include reduced intake
of antioxidants from foods like fruit and vegetables(66,67) and
an altered balance of fatty acids in the diet(68). Finally, obes-
ity(69) and physical inactivity(70) are associated with asthma
and bronchial hyper-reactivity. Whatever the explanation,
asthma must be said to represent ‘an epidemic of dysregulated
immunity’(71).
For COPD, the major known environmental trigger is
tobacco smoke. Also occupational chemicals and particulate
matter may contribute to the development of the disease, as
well as indoor and outdoor air pollution. Diet has been
reported to be a modifying factor, with fruit and vegetable
consumption having a protective effect(72).
Perpetuating factors. In allergic diseases, like allergic
rhinoconjunctivitis and allergic asthma, repeated and chronic
allergen exposure will keep the disease active and worsening.
Typically, general hypersensitivity and hyper-reactivity also
to non-specific stimuli develop. These will contribute to
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perpetuating the disease, and viral infections and environmen-
tal pollutants (e.g. tobacco smoke and diesel exhaust particu-
lates) will worsen the disease and may precipitate acute
attacks of severe asthma. Largely, the same non-specific stimuli
as seen in asthma, but in particular tobacco smoke, will contrib-
ute to perpetuating and accelerating COPD.
Mechanisms and mediators. Alveolar macrophages in the
lumen of the airways are first-line defence cells, capable not
only of engulfing foreign material to destroy it, but also of
secreting several signal molecules (cytokines) that serve to
attract and activate other cells to create inflammation. Macro-
phages can remove residual material after phagocytosis in two
ways. They can go through the bronchiolar and alveolar walls
to enter the lymphatic system carrying fluid and cells to the
numerous lymph nodes located along the trachea and bronchi,
or move out along the airways helped by the mucociliary esca-
lator mentioned earlier, to be swallowed into the stomach or
spat out. Particulate matter that is not dissolved may remain
in the lymph nodes for a long time.
Epithelial cells are themselves active participants in
immunoregulation and inflammation by secreting a number
of inflammatory and immunoregulatory molecules. Further-
more, specialised cells (goblet cells) secrete protective
mucus to cover the epithelial surface, and so-called type 2
cells secrete a family of molecules collectively referred to
as surfactant. The surfactant has a number of beneficial
functions, among others to regulate immune responses and
inflammation(73).
In the submucosa, various cells of the specific and non-
specific immune systems can be found; among them, mast
cells are important also in allergic reactions. The blood
vessels bring various immune cells to the lung submucosa
and epithelium. These include various subgroups of T and B
lymphocytes and natural killer cells, monocytes, neutrophils,
eosinophils and other cells. These various cells, in addition
to performing defence tasks by cell-to-cell contact, carry
with them or produce on-site two groups of molecules,
signal molecules and defence molecules (with somewhat over-
lapping functions). Signal molecules more or less specifically
regulate functions in other cells. For example, CD4 þ T
lymphocytes can secrete the cytokines IL-13, IL-4 and IL-9
to stimulate mucous production by epithelial cells, IL-13
and IL-9 to stimulate bronchial muscle contraction, IL-4 and
IL-13 to stimulate antibody production by B lymphocytes,
IL-3, IL-4, IL-5, IL-9, IL-13 and granulocyte–macrophage
colony stimulating factor to attract and activate various
other cells (sometimes in a very specific way), and IL-3,
IL-4, IL-9 and IL-13 to stimulate the development of other
cells. Accumulation and activation of cells is an important
feature of the inflammatory response, and the cytokines
mentioned will more or less contribute to such a response.
Some other cytokines are particularly important for inflam-
mation, like TNF-a, IL-6, and IL-8 and IL-17, while IL-10
tends to downregulate inflammation as well as immune
responses – an important function to protect against self-
destruction. Other defence molecules are designed to directly
destroy the intruders: lysozyme; lactoferrin; complement; a-1
antitrypsin; cationic proteins; lysophospholipases; catalases;
non-specific esterases; others. The various granulocytes and
the mast cells have in their cytoplasm granules containing pre-
formed mediators that are released in the ‘combat’ situation.
At the heart of the allergic reaction is the interaction
between IgE molecules bound to specific receptors on the
membrane of mast cells and their corresponding allergens.
When the IgE molecules are cross-linked by allergen, the
mast cell is triggered to release the potent inflammatory
mediators contained in its cytoplasmic granules, and the aller-
gic inflammatory response develops. This response has two
phases, an early virtually immediate reaction and a late
response developing after some 6 to 8 h. Mast cells are the
key cells in the early response, while eosinophils are the pre-
dominant cell in the late response. Eosinophils are thought to
play a central role in allergic rhinitis as well as asthma(41,74).
Asthma historically changed from being looked upon as a
disease of the smooth musculature of the bronchi to being a
Th2-dominated chronic inflammatory disease, with the eosino-
phil as the typical infiltrating cell. Other cells that regulate
Th2 responses, asthma and allergy are NKT cells(75), and
the various types of regulatory T-cells (Treg cells) that have
the capacity to inhibit the effector function of Th2 and Th1
cells(76). Increased levels of the Th2 cytokines IL-4, IL-5,
IL-9 and IL-13 have been demonstrated in the asthmatic
airway(77). The Th2-driven inflammation has two arms, one
via B-cells activated by IL-4 to produce IgE, which triggers
the mast cell-mediated allergic inflammation, and the other
via IL-4-, but mainly via IL-13-mediated direct effects on epi-
thelium and bronchial smooth muscle(78). However, whereas
the Th1/Th2 concept revolutionised immunological thinking
when first proposed in 1987, it has been challenged over the
past several years for several reasons(56,79). Both Th1 and
Th2 cells are pro-inflammatory, and Th1 cells do not always
downregulate Th2 cells, but may instead exacerbate Th2-
mediated diseases(80 – 82). It is of interest that the Th1 cytokine
IFN-g, now considered an aggravating factor in severe asthma,
is also considered to be important in COPD(83). Recently,
TNF-a has also been reported to play an important role in
severe asthma(84). That Th1 cells play a role in asthma
development is also illustrated by the finding that the Th1
transcription factor T-bet controls features of asthma. In the
absence of T-bet (e.g. in T-bet-deficient mice), airway remo-
delling and airway hyper-reactivity develop spontaneously(85).
Additionally, it has been demonstrated that different asth-
matic individuals display different ‘individualised’ cytokine
patterns, caused probably both by different genetic factors
and by differences in environmental exposure(82). Neural
mechanisms are central in the asthmatic inflammation(86,87),
but may also have a capacity to downregulate inflammation
as has been shown in gastrointestinal inflammation(88).
A number of genes have been implicated in asthma, e.g.
ADAM33(89). It is estimated that more than a dozen poly-
morphic genes regulate features of asthma like the inflamma-
tory response, IgE synthesis, cytokine and chemokine
production, airway remodelling and airway function(90).
On the molecular level, oxidative stress appears to play an
important role in asthma(91,92), and the endogenous antioxidant
capacity of the lungs has been found to be defective in asth-
matic patients(93). Oxidative stress is caused by ROS. The
inflammatory cells recruited into the asthmatic airways have
a capacity to produce ROS as part of normal antimicrobial
defence. Also, exogenous factors precipitating asthma, not
only ozone and oxides of nitrogen, but also fine particulate
matter, appear to cause oxidative stress(94,95). In animal
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models, factors that inhibit increased ROS generation have
been found to reduce inflammation and hyper-reactivity, two
important components of asthma(96).
While irreversible airflow limitation is a functional hallmark
of COPD, the lesion is histopathologically characterised by
inflammation and tissue destruction. Dominating inflammatory
cells are neutrophils, macrophages and CD8 þ -T lymphocytes
and IFN-g is an important cytokine(83). Oxidative stress appears
to be important in the inflammation and tissue damage in
COPD. Environmental agents linked to COPD, like tobacco
smoke and particulate matter, induce oxidative stress and
inflammation. Increased levels of markers of oxidative stress
have been found in exhaled breath condensates of COPD
patients(97 – 99), and in a mouse model of tobacco smoke-
induced COPD tissue, damage due to oxidative stress was
observed. Corticosteroid resistance in COPD has also been
related to oxidative stress. An imbalance between protease
and anti-protease enzymes is thought to be of importance for
the development of the emphysema component of COPD(100),
and this is supported by findings in experimental models(101).
Joints: rheumatoid arthritis
Normal function of inflammatory processes to maintain
homeostasis. Controlled inflammation as a result of various
triggers is likely to occur in normal joints. Possible triggers
are local mechanical stress and transient infection. Local
mechanical stress leads to induction of cellular stress proteins,
which can be targeted by stress protein-specific regulatory
T-cells(102). Besides genetic factors and infection, there is
some conflicting data on failing T-cell regulation as a critical
factor in the aetiology of rheumatoid arthritis (RA)(103).
Definition and description of rheumatoid arthritis. RA is a
common autoimmune disease characterised by chronic inflam-
mation of the synovium of diarthrodial joints(104). It can lead
to long-term joint damage, resulting in chronic pain, loss of
function and disability. Primarily, the small joints of the extre-
mities are affected, but as the disease progresses joints become
involved. The chronic inflammatory process changes the cellu-
lar composition (cellular infiltration) and the gene expression
profile of the synovial membrane, resulting in hyperplasia of
the synovial membrane, which causes structural damage in
cartilage, bone and ligaments. Extra-articular disease affecting
a variety of organs is a significant factor in morbidity and mor-
tality of RA(105). The severity of RA encompasses a wide
spectrum, ranging from self-limiting disease to chronic pro-
gressive disease, causing varying degrees of joint destruction
and extra-articular organ involvement.
Epidemiology of rheumatoid arthritis. RA occurs in
0·5–1·0 % of the population worldwide(106). RA is about two
to three times more common in women than men. No
increased incidence of RA has been noted over recent decades.
In fact, decreases were documented, although this might have
been artificially caused by a changed clinical classification of
diseases previously characterised as RA(107). Juvenile idio-
pathic arthritis (JIA) is one of the most common autoimmune
diseases in childhood(108). Although JIA has strong histopatho-
logical similarities to RA, it forms a separate clinical entity.
Whereas untreated RA generally is progressive, JIA consists
of different subtypes with striking differences in both severity
and outcome. One subtype is persistent oligoarticular JIA,
characterised by a remitting and often spontaneously self-
limiting course. As a result of this, persistent oligoarticular
JIA is unique among all autoimmune diseases. The self-
limitation of an autoimmune process is often seen in
experimental animal models but hardly ever in human subjects
and seems to suggest the active involvement of immuno-
regulatory processes, such as regulatory T-cells. Indeed,
the frequency of CD4 þ CD25 þ regulatory T-cells in the
peripheral blood and in the synovial fluid of JIA patients
has been found to correlate with the clinical course of the
disease(109,110). Neither hygienic nor unhygienic living con-
ditions are associated with the risk of developing juvenile
RA(111). Although the causes of RA remain elusive, the gen-
eral consensus is that factors contributing to its occurrence
and course (clinical heterogeneity) are probably both genetic
and environmental. The main risk factors for the disease
include genetic susceptibility, sex and age, smoking and infec-
tious agents. In addition, hormonal, dietary, socio-economic
and ethnic factors seem to contribute(112). For RA, the main
predisposing genetic factor is HLA-DR4. HLA-DR4 predis-
poses for a more severe progressive disease course. Besides
HLA-DR4, other genetic factors have recently been discov-
ered in RA, such as the genetic polymorphisms in the
lymphoid protein tyrosine phosphatase (LYP), associated
with both type 1 diabetes and RA(113). As LYP is responsible
for the tuning of T-cell activation, genetic variation of LYP
will lead to variation in overall lymphocyte reactivity. The
presence of anti-cyclic citrullinated peptides (CCP) antibodies
(see later) seems to be an indicator for a higher grade of joint
destruction and disease persistence. Smoking was found to be
a risk factor for the development of anti-CCP antibodies.
Anti-CCP positive RA may be a distinct disease entity that
can react differently to treatment(114).
Pathophysiological mechanisms of rheumatoid arthritis.
RA involves many elements of the immune response. The
synovium (or synovial membrane) is normally a relatively
acellular structure consisting of one or two layers of
synoviocytes. In RA, the synovium becomes hypertrophic
and oedematous. Angioneogenesis, recruitment of inflamma-
tory cells due to production of chemokines, local retention
and cell proliferation contribute to the accumulation of cells
in the inflamed synovium. Locally expressed degradative
enzymes digest extracellular matrix and destroy articular
structures(115). The synovial membrane that extends to the
cartilage and bone is known as pannus. It actively invades
and destroys the periarticular bone and cartilage at the
margin between synovium and bone. T-cells are actively
involved in the pathogenesis of RA. Activated T-cells that
are abundantly present in the inflamed joints of RA patients
can stimulate other cells (e.g. B-cells, macrophages and
fibroblast-like synoviocytes)(116). These T-cells are found to
participate in the complex network of cell- and mediator-
driven events leading to inflammation and joint destruction.
B-cells play several critical roles in the pathogenesis of RA.
They are the source of autoantibodies being produced in RA
and contribute to immune complex formation (rheumatoid fac-
tors reactive with the constant region of their autologous IgG
molecules) and complement activation in the joints(117).
Multiple other autoantibodies have been found in RA, with
recent interest focused on those directed at CCP(118).
Antibodies that are directed to citrullinated protein(119)
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detect CCP in many different proteins and are present in about
80 % of the RA patients. Several lines of evidence suggest that
citrullinated antigens have direct involvement in the rheumatoid
disease process. Anti-CCP antibodies precede the clinical
development of synovitis by many years. B-cells are also very
efficient antigen-presenting cells, and can contribute to T-cell
activation. The important role of B-cells in the disease aetiology
is supported by the recent success of B-cell depletion therapy
using rituximab(120). The major effector cells in the pathogen-
esis of arthritis are synovial macrophages and fibroblasts.
Activated macrophages are critical in RA, not only due to
macrophage-derived cytokines (in particular TNF-a and IL-1)
in the synovial compartments(121), but also because of their
localisation at strategic sites within the destructive pannus
tissue. The variety and extent of macrophage-derived cytokines
in RA and their widespread effect indicate that macrophages
are local and systemic amplifiers of disease severity and
perpetuation(122). Among the many cell types present in the
rheumatoid joint, the fibroblast-like synovial cell is prominent.
It is now accepted that these cells are directly responsible for car-
tilage destruction, and also drive inflammation(123). There is evi-
dence for proliferation and expression of inflammatory cytokines
and chemokines by fibroblast-like synovial cells in inflamed
synovia. Various studies have shown the presence and activity
of regulatory T-cells in RA, both in peripheral blood and in the
synovial compartment during active disease(103,109). Although
in one of the RA studies anti-TNF interventions were shown to
restore a compromised activity of regulatory T-cells(124), it
seems that impaired T-cell regulation is a more prominent
feature of multiple sclerosis and type 1 diabetes than RA.
Skin: atopic eczema and psoriasis
Atopic eczema (also called atopic dermatitis) and psoriasis are
among the commonest inflammatory skin diseases. Both
involve interactions between the immune system and the skin.
Although broad acting immunosuppressive therapies are
effective against both, very different pathogenetic mechanisms
are involved.
Atopic eczema. Fifteen per cent of children will have
eczema at some time during the first 12 years of their
life(125). The clinical manifestations usually appear within
the first year of life and often within a few weeks of birth.
The rash of eczema is characteristically distributed (flexures)
over ill-defined areas of intensely itchy redness containing
an infiltrate of T lymphocytes and eosinophils. There is a
clear genetic predisposition but expression of the phenotype
is determined by environmental factors (among those
suggested are lack of bacterial exposure providing an
immune stimulus, intra-uterine exposure to allergens, poor
fetal nutritional status). A major component in the pathogen-
esis of atopic eczema is the involvement of the immune
system through a combination of immediate type (IgE-
mediated) and T-cell-mediated immune hypersensitivities to
environmental aeroallergens and to food allergens. Although
the different types of hypersensitivity are demonstrable by
prick test, intradermal injection or epicutaneous patch test
challenge with a range of allergens, proving that the causal
relevance of specific allergies is difficult and unreliable. The
main effective therapies for atopic dermatis include topical
steroids and systemic immuno-suppressives.
A fundamental component of the atopic state appears to be a
dysregulation of the immune system such that T lymphocytes
responding to atopic allergens differentiate towards the Th2
phenotype(126,127). This may represent a failure of maturation
of the fetal immune system, which is maintained during preg-
nancy with a bias towards Th2 responses(128). Signals from
DC are thought to determine the differentiation pathway of Th
cells. Microbial components including lipopolysaccharides sig-
nalling through innate receptors such as toll-like receptors are
critical in this, as reflected by the hygiene hypothesis(54,129 – 131).
This proposes that early life exposure to microbes accelerates
the maturation of the immune system away from the fetal Th2
bias and towards the adult Th1-biased differentiation pathway.
Monocytes from atopic eczema sufferers release increased
quantities of PGE2, which can drive T-cell differentiation
towards the Th2 phenotype(132,133).
Psoriasis. Two to three per cent of the population suffer
from psoriasis; 10–15 % of these have it severely and require
management by dermatologists. Fifty per cent of these will
have significant joint symptoms and psoriatic arthritis. There
is a genetic susceptibility and a number of genetic loci have
been identified that may contribute to this susceptibility. There
are associations with hyperlipidaemia and CHD(134,135) as well
as CD(136). Various factors are involved in the expression of
the psoriatic phenotype: streptococcal infections; psychological
stress; physical trauma to the skin. The rash of psoriasis is
characterised by plaques of red scaly skin characteristically dis-
tributed over bony prominences. The pathophysiology involves
an interaction between the immune system and the skin. There is
an infiltrate of T lymphocytes (both CD4 þ and CD8 þ ) into
the dermis, formation of clusters of neutrophils in the epidermis,
involvement of two or three layers of the epidermis in prolifer-
ation and a greatly accelerated but incomplete differentiation.
There are also proliferation and altered structure of the dermal
capillaries, which become tortuous and dilated. Activation of
the innate immune system by streptococcal products and, most
likely, as yet unidentified factors, induces release of cytokines
including IFN-a and -g. The cellular source is unclear but
could be plasmacytoid DC or other DC. This activates keratino-
cytes to proliferate and produce angiogenic factors that induce
proliferation of dermal microvessels. The fundamental abnorm-
ality has not been identified, but the central feature is a failure of
mechanisms of resolution of inflammation. The main treatment
modalities include agents that modulate both keratinocyte pro-
liferation and activation of T-cells. These include topical
agents and systemic drugs. While many therapies have diverse
effects on immune cells, cytokine production and/or cellular
proliferation, it is unclear what the critical therapeutic
target is. Retinoids, vitamin D analogues and glucocorticoids
all have significant therapeutic efficacy and have in common
action via the superfamily of ligand-activated nuclear tran-
scription factors. The possibility is that nutritional interven-
tion is suggested by the evidence of the involvement of
eicosanoid mediators in psoriasis. Thus, there are reports
that inhibition of leukotriene B4 (LTB4) with benoxaprofen
was effective against psoriasis(127,138).
The vascular wall: CVD
Medium-sized arteries, such as the coronary vessels, consist of
three compartments termed the intima, media and adventitia,
P. C. Calder et al.S10
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509377867
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:35:15, subject to the Cambridge Core terms of use, available at
respectively. The intima is lined by a single continuous
layer of endothelial cells. The endothelium forms the
interface between the constituents of blood and the artery
wall. Collectively, the cells of the endothelium have a mass of
more than a kilogram and a surface area equivalent to that of
a football pitch. Endothelial cells differ in their properties at
different anatomical sites in the vascular tree. Such differences
include variations in permeability and cytokine expression.
Endothelial heterogeneity may be partially responsible for the
characteristic regional distribution of atherosclerotic lesions
described in human post-mortem studies. The endothelium
appears to play a critical role in the regulation of vascular
tone, and inhibiting leucocyte adhesion and platelet aggre-
gation, through its release of mediators such as NO and
prostacyclin(139). NO is derived from L-arginine through the
action of the constitutive form of the enzyme, endothelial NO
synthase. It inhibits platelet aggregation and adhesion, modu-
lates smooth muscle cell proliferation, attenuates the generation
of endothelin and reduces leucocyte adhesion to the endo-
thelium. The intima and media are separated from each other
by a thin layer of elastic tissue called the internal elastic laminar.
The media is composed of spirally arranged smooth muscle cells
responsible for the generation of tone within the artery and
determining the luminal diameter.
Atherogenesis. Atherosclerosis, or ‘hardening of arteries’
is the major cause of CVD. It is most often due to the for-
mation of atheroma. Endothelial dysfunction is thought to
presage atherosclerosis, and is characterised by altered endo-
thelial function, enhanced adhesion molecule expression,
increased leucocyte adhesion and impaired endothelium-
dependent vasodilator responses(140 – 143). Although the endo-
thelium appears to continue to elaborate NO, its biological
activity appears to be compromised in the early phases of
atherogenesis(144). The latter is likely to be due in part to
the interaction of NO with other molecular species such as
the superoxide radical. These interactions neutralise the
protective effects of NO and generate products, such as perox-
ynitrite that may be cytotoxic and pro-inflammatory. These
changes in the properties of the endothelium have given rise
to the concept of endothelial dysfunction. Endothelial dys-
function is associated with enhanced thrombosis and impaired
fibrinolysis, and a number of risk factors appear to contribute
to endothelial injury, including smoking, hypertension and
hyperlipidaemia. The emergence of the ‘lipid oxidation’
hypothesis(145) provided yet another mechanism of endothelial
injury, and an explanation for the formation of lipid-laden,
macrophage-derived foam cells. Uptake of cholesterol by
cells is normally mediated by the LDL receptor, and in the
presence of high cellular levels of cholesterol, the LDL recep-
tor is downregulated, limiting cholesterol accumulation. How-
ever, the uptake of oxidatively modified LDL is mediated by
‘scavenger receptors’ and this mechanism is not regulated
by cellular cholesterol content. The putative protective effect
of antioxidants, such as vitamin E, that inhibit LDL oxidation
is explained by this hypothesis, although it is important to note
that these effects remain contentious(146,147).
Leucocytes become attached to the dysfunctional endo-
thelium and subsequently accumulate within the subendothe-
lial space(148,149). Macrophages are converted to lipid-laden
foam cells within the artery wall, giving rise to a lesion
termed the fatty streak. The initial adhesion event is mediated
by pairs of adhesion molecules. The endothelial adhesion
molecules have been shown to be upregulated early in
atherogenesis.
The progression of the atherosclerotic plaque is complex
process, and in its early stages of development may be
reversed(150,151). The conversion of the fatty streak into a
fibrous plaque necessitates the recruitment and proliferation
of vascular smooth muscle cells(152). This process is driven
by the synergistic interplay of several growth factors.
Fatal myocardial infarction is usually associated with
thrombi and plaque fissuring. Unstable plaques are thought to
be particularly prone to fissuring, and these are characterised
by a large lipid pool, thin fibrous cap and large numbers of
inflammatory cells(153). Activated macrophages within the
plaque are a rich source of matrix metalloproteinases that
have the ability to degrade extracellular matrix(154). They there-
fore have the potential to destabilise the plaque, leading to
localised regions of de-endothelialisation that may subsequently
lead to focal thrombosis and plaque rupture. In the later stages of
its evolution, a plaque may be stabilised. Although such lesions
may be sufficiently prominent to cause luminal narrowing, and
hence angina, or claudication, they are less likely to rupture,
and are therefore considered relatively safe.
The role of chronic inflammation in atherogenesis.
Atherosclerosis bears many hallmarks of a chronic inflamma-
tory disease, and every stage of its evolution is characterised
by monocyte/macrophage and T-lymphocyte infiltration(155).
The possible stimuli to this inflammatory process include oxi-
dised LDL, homocysteine, free radicals generated from ciga-
rette smoking, and infectious micro-organisms, such as
Chlamydia pneumoniae. The T-cell infiltrates are predomi-
nantly CD4 þ cells and clones derived from human lesions
have been found to react to antigens derived from oxidised
LDL, heat-shock proteins and micro-organisms(156). The cyto-
kine milieu within atherosclerotic lesions is thought to pro-
mote a Th1-dominated response associated with macrophage
activation and the elaboration of IFN-g and IL-1b(156).
Hence, if the original insult is not adequately neutralised,
inflammation may persist, causing the local and systemic
release of growth factors and cytokines. These can, in turn,
lead to intimal thickening by stimulating smooth muscle cell
migration, proliferation and extracellular matrix elaboration.
Inflammatory biomarkers and atherosclerosis. There has
been an increasing interest in the use of inflammatory markers
to estimate the risks of acute events in patients with estab-
lished coronary disease. In part, the predictive value of these
markers may be related to their ability to identify patients
with vulnerable plaques, which are rich in activated leuco-
cytes. CRP, IL-6 and circulating leucocyte count are elevated
in patients with myocardial infarction(157). There have also
been reports of a positive relationship between serum CRP and
subclinical atherosclerosis(158), although analysis may be con-
founded because risk factors such as smoking habit, indices of
adiposity, blood pressure, TAG and HDL are also associated
with CRP concentrations. Adipose tissue may be an additional
source of inflammatory cytokines that could stimulate CRP pro-
duction(159). Other inflammatory conditions, such as RA and
systemic lupus erythematosus, are associated with impaired
endothelial function and increased coronary risk(160,161).
Epidemiology of CVD. The Framingham Heart and Seven
Countries Studies were key to identifying cigarette smoking,
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high serum cholesterol, physical inactivity, high blood press-
ure, the menopause and psychological factors as contributors
to coronary disease. The importance of multiple, low-level
risk factors has become clearly evident(162). Death rates
from CVD have been falling in many developed countries,
including most countries of Western Europe, since the early
1970s(163 – 166) and much of this reduction appears to be due
to successful implementation of primary intervention due to
dietary change, statin treatment, antihypertensive treatment
and fall in smoking habit. The rate of reduction in CVD mor-
tality differs among countries. For example, the fall in the UK
is slower than that in Australia, Canada and Sweden.
However, death rates from CVD have risen rapidly in many
Eastern European countries. Poland is an exception to this
because rates have fallen in association with a fall in the preva-
lence of smoking, reduced saturated fat and increased PUFA
and fruit consumption(167). Besides national differences, there
are very marked regional differences within countries(166,168),
which may reflect socio-economic differences. The incidence
of CHD varies with race and ethnicity(169). In the USA, black
men and women have a higher risk of CHD than white men
and women, respectively, while Hispanic groups have lower
CHD rates. South Asians living in the UK have approximately
50 % higher rates of premature CHD death, and the difference
is widening as rates do not appear to be falling as fast among
this group as for the UK as a whole. This may relate to a
higher prevalence of diabetes in this group.
Interventions. The landmark statin trials have demon-
strated that cholesterol lowering reduces cardiovascular
mortality and morbidity(170). The early benefits observed in
some of the primary prevention trials have suggested that
statins may be exerting effects other than those attributable
to cholesterol lowering alone, so-called ‘pleiotropic effects’
including effects on inflammation, although this remains a
matter of considerable debate. The role of low-dose aspirin
treatment in the prevention of coronary disease is also well
supported by trial data(171). However, the mechanism for the
protective effect may relate to the anti-platelet effects of
aspirin, rather than an effect on inflammation. Although
trials of antibiotic treatment have generally not shown a
benefit in preventing coronary disease(172), it has been
argued that diet regimens used to date may not eliminate the
carriage of organisms by peripheral monocytes. There have
been few studies describing the effects of dietary constituents
on inflammation in healthy subjects or patients with CHD.
Fish oil supplements, providing very long-chain n-3 PUFA
(VLC n-3 PUFA) alter the composition of inflammatory
cells resulting in decreased production of inflammatory eicosa-
noids and cytokines(173), alter cellular composition of human
plaques, making them appear more stable(174), and reduce
mortality from sudden death in secondary prevention(175,176).
Meta-analyses support lowered cardiovascular mortality with
increased VLC n-3 PUFA intake(177,178).
Adipose tissue: obesity
Adipose-derived mediators. The prevalence of obesity
(defined as a BMI .30 kg/m2) is rising throughout the
world, and obesity is occurring at a younger age. In the US
and most Western countries, obesity has an incidence rate
above 20 %. This is a major public health issue because of
the direct effect of obesity on the risk of developing type 2
diabetes, CVD, hypertension, stroke, abnormal blood lipids,
arthritis, asthma and cancer(179). Until very recently, the role
of adipose tissue has been thought to be passive and adipo-
cytes were considered as little more than fat stores. However,
it is now clear that this is far from the case and that adipose
tissue is an important endocrine organ(180). There is increased
understanding that, depending on the nutritional state, the pro-
file of hormones released from adipocytes can change from
being beneficial to being detrimental(181). The adipocyte
plays a major role in the inflammatory response and
releases a cocktail of inflammatory mediators and signalling
molecules(182,183).
Four findings ignited the interest in the adipocyte as an
endocrine organ. Firstly, the discovery of leptin in 1995 chan-
ged the way the adipocyte was viewed; the discovery that
leptin has a role in signalling the status of adipose tissue to
the brain was the first description of a feedback loop involved
in body weight control(182). Although its role in human
subjects is more complicated, the importance of leptin as a
hormone involved in energy balance has been exemplified
by the case studies of families with leptin deficiency; the chil-
dren are obese and lose weight with leptin therapy(183). As
human subjects gain weight, they seem to develop leptin
resistance. This may be mediated by suppressor of cytokine
signalling, which increases in the hypothalamus in tandem
with leptin. This blocks the central effect of leptin(184).
Leptin has important effects on peripheral metabolism,
which have been demonstrated through lipodystrophy
models. Leptin has been shown to have a role to play in insu-
lin sensitivity and TAG clearance from the circulation. This
observation in evolutionary terms may have allowed weight
gain in times of plenty without gross metabolic change.
Secondly, the discovery that adipocytes release TNF-a also
changed the view of adipocytes(185). In fact, mRNA
expression studies show that adipocytes can synthesise TNF-a
and several other cytokines, notably IL-1b and IL-6 among
an ever-increasing list. Circulating TNF-a and IL-6 concen-
trations are mildly elevated in obesity. Most studies suggest
increased TNF-a mRNA expression or secretion in vitro in
adipose tissue from obese subjects. The factors regulating
cytokine release within adipose tissue appear to include not
only typical inflammatory stimuli such as lipopolysaccaride,
but also the size of the fat cells per se and catecholamines.
The effects of cytokines within adipose tissue include some
actions that might be characterised as metabolic. TNF-a and
IL-6 inhibit lipoprotein lipase, and TNF-a additionally stimu-
lates hormone-sensitive lipase. TNF-a also downregulates
insulin-stimulated glucose uptake via effects on GLUT-4,
insulin receptor autophosphorylation and insulin receptor sub-
strate-1. All these effects will oppose lipid accumulation
within adipocyte(186). Other effects appear more trophic, and
include the induction of apoptosis, regulation of cell size
and induction of de-differentiation (the latter involving
reduced PPAR-g). Cytokines are important stimulators and
repressors of other cytokines. In addition, cytokines appear
to modulate other regulatory systems. Examples of the latter
include effects on leptin secretion (probably stimulation fol-
lowed by inhibition) and reduction in b3-adrenoceptor
expression. There seems to be no clear agreement as to
which cytokines derived from adipose tissue act as remote
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regulators, i.e. hormones. Leptin, which is structurally a cyto-
kine, is also a hormone. IL-6 appears to be released systemi-
cally by adipose tissue, but TNF-a is probably not. Both leptin
and IL-6 appear to act on the hypothalamus, IL-6 acts on the
liver, while leptin may have actions on the pancreas(186).
Thirdly, the discovery of adiponectin, a protein which is
specifically and very highly expressed in adipose tissue(187).
This hormone enhances insulin sensitivity in muscle and
liver and increases fatty acid oxidation in several tissues,
including muscle fibres. It also decreases serum fatty acid, glu-
cose and TAG concentrations: if normal, lean mice are given
injections of adiponectin in conjunction with a meal high in fat
and sugar, the normal postprandial increases in plasma glucose
and TAG concentrations are smaller as the result of an
increased rate of clearance from the blood rather than a
reduced rate of absorption from the gut. By contrast, if insu-
lin-resistant mice are treated with physiologic concentrations
of adiponectin, glucose tolerance is improved and insulin
resistance is reduced. In human subjects, plasma adiponectin
concentrations fall with increasing obesity and this effect
is greater in men than women. Reduced adiponectin
concentrations correlate with insulin resistance and
hyperinsulinaemia. In addition, several polymorphisms of
the adiponectin gene (APM1, mapped to chromosome 3q27)
have been identified that are associated with reduced plasma
adiponectin concentration and that increase the risk of type
2 diabetes, insulin resistance or the metabolic syndrome.
Interestingly, adiponectin appears to be implicated in the
development of atherosclerosis. Adiponectin concentrations
are reduced in patients with CHD, and adiponectin inhibits
TNF-a-induced expression of adhesion molecules and the
transformation of macrophages to foam cells, both of which
are key components of atherogenesis. In mice deficient in
apo E (and thus susceptible to atherosclerosis), treatment
with human adiponectin inhibits lesion formation in the
aortic sinus by 30 % compared with that in untreated control
animals(181,184). The central importance of adiponectin is
exemplified by the observation that it inhibits NF-kB and
reduces the proinflammatory pathway.
Fourth is the observation that adipose tissue is not homo-
geneous. Macrophage numbers in adipose tissue increase with
obesity, where they apparently function to scavenge moribund
adipocytes, which increase dramatically with obesity. Macro-
phages are responsible for most of the cytokine production in
adipose tissue, especially in obesity. In fact, adipose tissue
macrophages are responsible for perhaps as much as 50 % of
adipose tissue TNF-a production(184). In obesity, adipose
tissue contains an increased number of resident macrophages
so that, in some circumstances, macrophages can constitute
up to 40 % of the cell population within an adipose tissue depot.
An integrated view of inflammation and obesity. The
issues surrounding weight gain and inflammation cannot be
seen in isolation, but need to be viewed alongside theories
about variation in adipocyte differentiation, appetite regulation
and control of appetite. Recent evidence has suggested that the
formation of hypertrophic fat cells in environments of energy
excess may be due to a genetically determined differentiation
limit of stem cells to adipocytes or metabolic feedback con-
trolling differentiation or more likely a mixture of the two.
If there are limited numbers of adipocytes in an environment
of energy excess, this will cause excessive lipid filling in the
adipocyte and lead to hypertrophic adipocytes that are pro-
inflammatory. The key issue at the beginning of the inflamma-
tory process seems to be an excess energy intake. Many of the
processes that follow excess energy intake may acutely be an
advantage, but an environment of chronic excess energy intake
and decreased energy output will work against human health.
As the adipocyte stores TAG, there seems to be an increase in
cytokine release. Of particular importance is the suppression
of adiponectin and the increase in TNF-a. It is possible that
TNF-a can decrease proliferation and differentiation of adipo-
cytes. The control mechanisms for adipocyte proliferation and
differentiation are complex, but examination of the transcrip-
tional and extracellular signals necessary for stem cell differ-
entiation into a preadipocyte, and from the preadipocyte into a
mature fat cell, is being elucidated. Regulation of adipocyte
proliferation and differentiation involves growth arrest and
the coordinate activation/inactivation of nuclear transcription
factors that regulate the expression of genes necessary for
lipid storage and insulin sensitivity. ADD/SREB-1, C/EBP-a,
-b and -d and PPAR-g are a few of the transcription factors
known to be involved. These transcription factors are
regulated in response to extracellular signals, such as PG,
cytokines, and hormones including corticosteroids and
insulin(188). Defects in any one of these steps are potentially
important in the failure of proliferation or differentiation of
adipocytes. This will limit the number of adipocytes coping
with the excess energy intake. This will have several effects.
(i) Effects on recruitement of monocytes into adipose
tissue. As the lipid content of adipose tissue increases,
the adipocytes increase leptin output and this has
the effect of increasing expression of adhesion mol-
ecules such as ICAM-1 and platelet-endothelial cell
adhesion molecule-1 in endothelial cells inducing
adhesion and transmigration of monocyte/macrophages.
The transmigration of macrophages is further
enhanced by monocyte chemoattractant protein-1.
The result is a tissue that produces the low-grade sys-
temic inflammation seen in obesity(189).
(ii) Effects on apoptosis and TNF-a. In mature white adipo-
cytes, TNF-a is reported to regulate cell size, the sug-
gestion being that as the cells get bigger they produce
more TNF-a, which in turn initiates changes to limit
adipocyte size or to induce apoptosis. This is possibly
coupled with increasing local hypoxia. The net result
is recruitment of greater numbers of macrophages that
surround the apoptotic cell(186,189).
(iii) Autocrine effects on adipokines. The increase in TNF-a
has been shown to have several autocrine effects includ-
ing reduced expression of the GLUT4 glucose transpor-
ter, increased hormone-sensitive lipase activity leading
to increased lipolysis, decreased lipoprotein lipase
activity, reduced insulin signalling and decreased
C/EBP and PPAR-g activity, so creating an insulin
insensitive adipocyte with a high output of NEFA(186).
(iv) Effects on peripheral tissue. From the earlier adipocyte
hypertrophy, increased insulin resistance and increased
fatty acid output result and excess dietary fat may be
shunted to the liver, skeletal muscle and the b-cell.
Importantly, if fat oxidation cannot be increased to
compensate for the increased influx of lipid within
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these tissues, then intracellular accumulation of lipids
will occur. The oxidation of fat is mediated by activat-
ing AMP-activated protein kinase (AMPK). It is known
that adiponectin activates AMPK as does leptin. So, in
normal physiology, leptin and adiponectin signal trans-
duction involves the phosphorylation of STAT path-
ways, but how this translates into the observed
changes in lipid metabolism is not clear. One likely
mechanism is via increased phosphorylation activation
of AMPK, which phosphorylates acetyl CoA carboxy-
lase and malonyl CoA decarboxylase. Phosphorylation
inactivates carboxylase, but activates malonyl CoA dec-
arboxylase. Because carboxylase catalyses malonyl
CoA formation, and malonyl CoA decarboxylase cata-
lyses its decarboxylation, the net effect of AMPK acti-
vation on these target enzymes is to lower malonyl
CoA concentration. Malonyl CoA is the first committed
step in lipogenesis and a powerful inhibitor of carnitine
palmityl transferase-1-mediated fatty acid oxidation.
The combination of an increase in fatty acid oxidation
and a decrease in fatty acid synthesis could account
for the reduction in the lipid content of a cell. At present,
however, we do not understand how leptin activates
AMPK. In the inflammatory state there is low adiponec-
tin and leptin resistance and therefore low activity of
AMPK, and reduced oxidation of fat and the storage
of TAG in cells. It is likely that it is products generated
from TAG such as unoxidised palmitoyl-CoA that lead
to insulin resistance and cell apotosis. Also diacylgly-
cerol has been shown to have effects on protein kinase
C; this can in turn affect the insulin signal by causing
serine phosphorylation rather than tyrosine phosphoryl-
ation on IRS-1 so reducing the insulin signal. This
theory is supported by the recent observation that there
is a direct relationship between hepatocyte and myocyte
lipid content and insulin sensitivity. Interestingly, IL-6
can also affect steroid hormone conversion, changing
the balance of sex hormones, which is well known to
regulate adipose tissue distribution(190 – 192).
The release of other cytokines (e.g. plasminogen activation
inhibitor 1 (PAI-1)) from the adipocyte can have dramatic
effects on risk of disease. There is evidence for an associ-
ation between increased PAI-1 levels and myocardial
infarction. Interestingly, PAI-1 has been shown to predict
myocardial events in univariate analysis, but the predictive
power was not affected by adjustement for inflammatory par-
ameters and disappeared after adjustment for BMI, TAG and
HDL cholesterol. This suggests that the metabolic syndrome
is a precursor to high plasma PAI-1 levels in patients prone
to atherosclerosis(193).
Effect of weight loss on inflammatory markers. The induc-
tion of a negative energy balance has profound effects on
inflammatory markers in obesity: weight loss with diet and
exercise has been shown to decrease circulating IL-6 and
TNF-a concentrations in obese subjects(194,195). Serum CRP
concentration fell 4 months after bariatric surgery but
remained significantly elevated relative to non-obese con-
trols(196). Very recently, there has been a description of a
fall in proinflammatory cytokines and macrophage numbers
in white adipose tissue following weight loss(195). A recent
study on obese children has demonstrated falls in plasma
TNF-a and CRP concentrations with weight loss(197).
Interestingly, liposuction has very little effect on inflammatory
markers(198). The success of lifestyle intervention has been
demonstrated with the American and Finnish Diabetes
Prevention trials, which both show long-term benefit in
decreasing the risk of type 2 diabetes(199,200).
Common features of inflammatory processes that may be
suitable targets for nutritional intervention
Although inflammation-induced tissue damage occurs in an
organ-specific manner (gut, lungs, joints, skin, blood vessel
wall, adipose tissue) in different diseases or conditions, there
is some commonality among the responses seen in the differ-
ent organs (summarised in Table 1). In general, the inflamma-
tory response observed is normal but it occurs in the wrong
context, which relates to inappropriate barrier function (epi-
thelial or endothelial), inappropriate triggering (i.e. a response
to a normally benign stimulus equivalent to a loss of toler-
ance), lack of downregulation to control the response and
tissue destruction with a loss of function. In some cases, the
inflammation is the result of tissue damage caused by
endogenous molecules such as necrotic cell debris or oxidised
LDL. In other cases, it is the result of exogenous triggers such
as allergens or microbes. The involvement of different triggers
is also reflected in the distinct associations with polymorph-
isms in receptors involved in ‘pattern’ recognition such as
NOD2 in CD or with other molecules involved in specific
adaptive immune responses such as HLA-DR subtypes in
UC and RA (Table 1). However, although trigger, localisation
and resulting clinical symptoms are different, many of the
processes, cells and molecules involved in the actual inflam-
matory response are remarkably similar (Table 1). Most, if
not all, of the chronic inflammatory diseases considered here
are characterised by overproduction of cytokines (TNF-a,
IL-1b, IL-6, IFN-g), chemokines (IL-8, MCP-1), eicosanoids
(PGE2, four-series LTs) and matrix metalloproteinases. Elev-
ated levels of these mediators act to amplify the inflammatory
process (e.g. by attracting further inflammatory cells to the
site) and contribute to tissue destruction and to the clinical
symptoms observed. Many of these mediators are positively
regulated through NF-kB (Fig. 3) and some are negatively
regulated through PPAR and liver X receptors. Entry of
inflammatory cells to sites of inflammatory activity is facili-
tated by upregulation of adhesion molecules on the endo-
thelium, a process that is promoted by inflammatory
cytokines and by a range of inflammatory triggers, frequently
acting through NF-kB. The continuous process of tissue
injury, healing and repair, due to the release of cytokines, che-
mokines and growth factors by infiltrating inflammatory cells
as well as resident tissue cells, results in tissue remodelling.
Local structural cells, such as fibroblasts, epithelial cells and
smooth muscle cells can play a role in amplification of the
inflammatory response and to a large extent determine the
clinical appearance of the disease.
It is noteworthy that in many cases, at some point, the tissue
damage appears to result in a loss of barrier function and
exposure of hitherto sequestered antigens of either the host
or of its microbiota. This can result in a loss of tolerance
and sustained specific responses to such antigens. This can
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Table 1. Summary of the disease states discussed and an overview of their key inflammatory components
Coeliac disease
Crohn’s
disease Ulcerative colitis COPD Asthma
Atopic
dermatitis
(atopic
eczema) Psoriasis
Rheumatoid
arthritis Atherosclerosis Obesity
Organ
affected
Small intestine Entire gastro-
intestinal
tract
Colon and
rectum
Lungs Lungs Skin Skin Joints Vascular wall Adipose tissue
Predisposing
genetic
factors
HLA-DQ2,
HLA-DQ8
NOD2; IBD
locus
IBD locus;
MUC-3; HLA-
DR subtypes?
ADAM33; Th2
gene cluster
Filaggrin PSORS1 HLA-DR4
subtypes
Several incl.
ApoE4
Several
suggested
Triggering
factor(s)
Gluten peptides Commensal
gut
microbes
Commensal gut
microbes
Smoking;
irritants
Allergens;
irritants
Allergens;
irritants
Skin
streptococci
Not known Endothelial injury;
oxidised LDL
Energy intake
in excess of
expenditure
Antigen(s)
involved
Gluten peptides Bacterial
antigens
Bacterial
antigens
Allergens Airborne
allergens;
Hom s 4
Streptococci Proteoglycans;
filaggrin
Micro-organisms
Clinical
features
Villus atrophy;
malabsorption
Gut ulceration;
diarrhoea;
abdominal
pain; weight
loss;
malaise
Gut ulceration;
bloody
diarrhoea;
abdominal
pain; urgency
to defecate
Lung damage;
breathleness
Wheeze;
mucus;
breathleness
Itchy, dry skin Dry skin Joint swelling,
pain and
erosion
Plaque formation
– ultimately MI,
stroke, etc.,
due to plaque
rupture
Weight gain;
insulin
resistance
Cells
involved
Intraepithelial
lymphocytes;
epithelial cells;
gluten-specific
Th1 cells
Th1 cells Th1 and Th2
cells (Th2
dominant);
PMNs
PMNs Th2 cells;
mast cells;
eosinophils
Th1 and Th2
cells (Th2
dominant);
mast cells;
eosinophils
Th1 cells; NK
cells; PMNs;
keratino-
cytes
Th1 cells;
fibroblasts;
B-cells
Macrophages;
T-cells; plate-
lets; endothelial
cells
Adipocytes;
macro-
phages
Mediators
involved
IL-15, IFN-g,
TNF-a
IL-12, TNF-a,
IL-6, PG,
MMP
TNF-a, IL-5,
IL-13, PG
MMPs IL-5, IL-13,
TNF-a,
cysLTs
Th1 and Th2
type
cytokines,
cysLTs,
allergen-
specific IgE
Th1 type cyto-
kines, LTB4,
angiogenic
factors
TNF-a, IL-1,
IL-6, IL-17,
PG, LTB4,
MMP
MCP-1 in plaque
formation;
MMP in plaque
rupture
MCP-1
Biomarkers Mucosal
architecture;
anti-gliadin
antibodies;
transglutaminase
Mucosal
architecture;
endoscopic
scores;
faecal cal-
protectin;
clinical score
(CDAI); CRP
Mucosal
architecture;
endoscopic
scores; faecal
calprotectin;
clinical score
(CAI); CRP
Non-reversible
impaired
lung function
(low FEV1)
Impaired but
reversible
lung function
Clinical score Clinical score;
CRP
Rheumatoid
factor;
autoanti-
bodies;
X-ray; clinical
signs; CRP
Angiography;
plasma lipids;
CRP; soluble
adhesion
molecules;
vessel wall
thickening (e.g.
intima–media
thickness);
Body weight;
BMI; waist–
hip ratio;
body fatness
COPD, chronic obstructive pulmonary disease; HLA, human leucocyte antigen; NOD, nucleotide-binding oligomerisation domain; IBD, inflammatory bowel disease; Th, helper T-cell; PMN, polymorphonuclear cells; IFN, interferon;
MMP, matrix metalloproteinase; cysLT, cysteinyl leukotriene; LT, leukotriene; MCP, monocyte chemoattractant protein; CDAI, Crohn’s disease activity index; CRP, C-reactive protein; CAI, colitis activity index; FEV1, forced expiratory
volume at 1 s.
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involve quite distinct antigens such as the gut microflora in
CD and UC, fillagrin in eczema, and cartilage in RA. In all
these cases, these responses seem to result from loss of barrier
function and once initiated help to sustain the chronic inflam-
matory condition.
Why resolution of inflammation is absent or abnormal in so
many pathophysiological processes remains largely unknown,
although there are a number of mechanisms that may be
considered.
(i) Persistent insult (i.e. chronic infection or continued
exposure to initiating allergens) provides continued
pro-inflammatory stimuli.
(ii) The inflammatory response results in tissue damage and
loss of barrier function resulting in exposure of seques-
tered antigens and loss of tolerance to autoantigens or
components of the microbiota, which then provide a
trigger to drive prolonged inflammation.
(iii) Local (over)production of survival factors such as IL-5,
granulocyte–macrophage colony stimulating factor and
IL-1b results in prolonged survival and activity of
granulocytes.
(iv) Defective or reduced phagocytosis impairing clearance
of cellular debris. This results in granulocyte necrosis
and the release of reactive oxygen and nitrogen species
as well as the activation of macrophages leading to
sustained production of pro-inflammatory cytokines.
(v) Deficiency in immunological negative feedback mechan-
isms, which leads to loss of inflammatory control. This
could be at the level of regulatory T-cell dysfunction
(no release of anti-inflammatory cytokines), at the level
of intracellular negative feedback mechanisms in
immune cells or impaired macrophage suppresser activity
(no release of regulatory proteins).
Although the relative importance may differ, these mechan-
isms seem to contribute to most of the conditions described
here. Over time, chronic inflammation also results in a gradual
overload with reactive oxidant species, which when insuffi-
ciently countered by the gradually weakened anti-oxidative
defence systems results in a shift in redox balance. This in
turn leads to uncontrolled activation of the redox-sensitive
proinflammatory transcription factor NF-kB, continued pro-
duction of reactive oxygen and nitrogen species and supports
chronic inflammation (Fig. 4).
The foregoing considerations suggest a number of potential
targets for nutritional intervention, which are common
across the various inflammatory pathologies considered here.
Among these targets are common mediators, including
ROS, arachidonic acid-derived lipid mediators (PG, LT),
chemokines (IL-8, MCP-1), inflammatory cytokines (TNF-a,
IL-1, IL-6, IFN-g, etc.) and matrix metalloproteinases, and
common intracellular signalling factors including the transcrip-
tion factors NF-kB and PPAR-g and their upstream regulators.
Nutrition and inflammatory processes
Fatty acids
Description, sources, normal intakes and roles. The general
structure of a fatty acid is a hydocarbon (acyl) chain of varying
Fig. 3. NF-kB signalling pathway.
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length with a carboxyl group at one end and a methyl group at
the other. The carboxyl group is reactive and readily forms ester
links with alcohol groups for example those on glycerol or
cholesterol. The most abundant fatty acids have straight
chains of an even number of carbon atoms. Fatty acids contain-
ing double bonds are referred to as unsaturated fatty acids; a
fatty acid containing two or more double bonds is called a
PUFA. Most common unsaturated fatty acids contain cis
rather than trans double bonds. However, trans double bonds
do occur in ruminant fats (e.g. cow’s milk), in plant lipids
and in some seed oils. In some PUFA, the double bonds are
not separated by a methylene (ZCH2Z) group, but are conju-
gated. The systematic name for a fatty acid is derived from the
number of carbon atoms in the acyl chain, the number of double
bonds, the position of the double bonds (counting the carboxyl
carbon as carbon 1) and their configuration (cis or trans). An
alternative shorthand notation for fatty acids is frequently
used. This relies upon identifying the number of carbon
atoms in the chain, the number of double bonds and the position
of the double bond closest to the methyl terminus of the acyl
chain (the methyl carbon is known as the n-carbon). Thus, cis
9, cis 12-octadecadienoic acid is notated as 18 : 2n-6. In
addition to these nomenclatures, fatty acids are often described
by a common name(201). Human subjects cannot synthesise the
simplest n-6 and n-3 PUFA (linoleic acid (18 : 2n-6) and a-lino-
lenic acid (18 : 3n-3)) and so these are regarded as essential
fatty acids.
Fatty acids in fats, oils and foodstuffs are mainly esterified
to glycerol, as TAG, although some are present as esterified
components of phospholipids, glycolipids and other lipids.
With regard to inflammatory processes, most attention has
been paid to the effects of n?6 and n-3 PUFA(173,202), although
other fatty acid classes including saturated and trans fatty
acids may also influence inflammatory processes. Important
dietary sources of the n-6 PUFA linoleic acid include
vegetable oils (e.g. maize, sunflower, safflower and soyabean
oils) and products made from those oils (e.g. margarines).
Oils like soyabean also contain a-linolenic acid; other good
sources of this fatty acid include some nuts, flaxseeds and flax-
seed (linseed) oil. Some seed oils contain moderate to high
proportions of relatively unusual fatty acids (e.g. g-linolenic
acid (18 : 3n-6) in borage (starflower) and evening primrose
oils). Meat is an important source of the VLC n-6 fatty acid,
arachidonic acid (20 : 4n-6). Fish can be classified into lean
fish that store lipid as TAG in the liver (e.g. cod) or ‘fatty’
(‘oily’) fish that store lipid as TAG in the flesh (e.g. mackerel,
herring, salmon, tuna, sardines). The oil obtained from fatty
fish flesh or lean fish livers is termed ‘fish oil’ and it has the
distinctive characteristic of being rich in the VLC n-3 PUFA
eicosapentaenoic acid (EPA; 20 : 5n-3) and DHA (22 : 6n-3).
There are large differences in fat intake among countries
with average intakes among adults varying from ,20 g/d in
some developing countries to .100 g/d in some developed
countries. The mix of fatty acids consumed also varies in
accordance with the fatty acid compositions of the fats and
oils used in food preparation and of the foodstuffs eaten. Aver-
age fat consumption has changed over time and continues to
do so. In many developing countries fat intake is increasing,
while in developed countries fat intake has tended to decline
over the last 40 years or so.
The type of fat consumed has also changed over time,
meaning that the fatty acid composition of the human diet
has changed. The latest figures for the UK indicate that
adult males consume an average of 85 g fat/d and adult
females 60 g/d (both approx. 35 % of dietary energy). The
main PUFA in the diet is linoleic acid followed by a-linolenic
acid. On average, adult men in the UK consume about 12 and
1·9 g linoleic and a-linolenic acids, respectively, per day.
Adult women in the UK consume about 8·7 and 1·4 g linoleic
and a-linolenic acids, respectively, per day. Hulshof et al. (203)
Fig. 4. Representation of the interaction between oxidant stress and inflammation. IkB, inhibitory subunit of NF-kB; IL, interleukin; NF-kB, nuclear factor k B;
PG, prostaglandin; TNF, tumor necrosis factor.
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provided details of intakes of fatty acids among 14 Western
European countries, while Burdge & Calder(204) included
some data from North America and Australia. Longer-chain
PUFA are consumed in lower amounts than linoleic and
a-linolenic acids. Estimates of the intake of arachidonic acid
in Western populations vary between 50 and 300 mg/d for
adults(201). In the absence of fatty fish or fish oil consumption,
a-linolenic acid is by far the principal dietary n-3 PUFA.
Average intake of the VLC n-3 PUFA in the UK and in
other Western countries where oily fish consumption is not
the norm is estimated at ,250 mg per day(201).
Fatty acids are transported in the bloodstream largely in
esterified form as components of lipoproteins, although albu-
min-bound NEFA also circulate(205). Fatty acids have many
diverse functions in cells; their principal roles are as energy
sources and as membrane constituents(201). Many types of
fatty acid can fill these roles. Certain fatty acids have
additional, specific roles: arachidonic, dihomo-g-linolenic
(20 : 3n-6) and EPAs act as precursors for eicosanoid syn-
thesis; myristic and palmitic acids may be covalently attached
to certain proteins and this is believed to play an important
role in the functioning of these proteins; fatty acids are able
to influence intracellular signalling processes; fatty acids are
able to influence transcription factor activity and gene
expression. Through these different actions, fatty acids are
able to influence cellular functions and so affect physiological
responses, including inflammation.
Effects on inflammatory processes and mechanisms of action
Arachidonic acid, arachidonic acid-derived eicosanoids and
inflammation. The key link between fatty acids and inflam-
mation is that eicosanoids that act as mediators and regulators
of inflammation are generated from 20-carbon PUFA. Because
inflammatory cells typically contain a high proportion of the
n-6 PUFA arachidonic acid and low proportions of other 20-
carbon PUFA, arachidonic acid is usually the major substrate
for eicosanoid synthesis. Eicosanoids, which include PG,
thromboxanes, LT and other oxidised derivatives, are gener-
ated from arachidonic acid by reactions catalysed by cyclo-
oxygenase (COX) and lipoxygenase (LOX) enzymes (Fig. 5).
There are at least two COX enzymes and several LOX
enzymes that are expressed in different cell types, according
to different conditions and which between them produce a
range of mediators involved in modulating the intensity and
duration of inflammatory responses(206,207). These mediators
have cell- and stimulus-specific sources and frequently have
opposing effects. Thus, the overall physiological (or pathophy-
siological) outcome will depend upon the cells present, the
nature of the stimulus, the timing of eicosanoid generation,
the concentrations of different eicosanoids generated and the
sensitivity of target cells and tissues to the eicosanoids
generated.
The amount of arachidonic acid in inflammatory cells can
be increased by including it in the diet(173) and may also be
influenced by the dietary intake of its precursor, linoleic
Fig. 5. Eicosanoid biosynthesis from arachidonic acid. COX, cyclo-oxygenase; HETE, hydroxyeicosatetraenoic acid; HPETE, hydroperoxyeicosatetraenoic acid;
LOX, lipoxygenase; LT, leukotriene; PG, prostaglandin; TX, thromboxane.
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acid, although the range of linoleic acid intake over which this
relationship occurs has not been defined for human subjects.
The role of arachidonic acid as a precursor for the synthesis
of eicosanoids indicates the potential for dietary n-6 PUFA
(linoleic or arachidonic acids) to influence inflammatory pro-
cesses. However, this has been little investigated in human set-
tings. Supplementation of the diet of healthy young male
subjects with 1·5 g arachidonic acid/d for 7 weeks resulted
in a marked increase in the production of PGE2 and LTB4
by endotoxin-stimulated mononuclear cells(208). However,
production of TNF-a, IL-1b and IL-6 by the latter was not
significantly altered. Thus, increased arachidonic acid intake
may result in changes indicative of selectively increased
inflammation or inflammatory responses in human subjects.
Supplementation of the diet of healthy elderly subjects with
arachidonic acid (0·7 g/d in addition to a habitual intake of
about 0·15 g/d) for 12 weeks did not affect endotoxin-
stimulated production of TNF-a, IL-1b or IL-6 by mononuclear
cells, did not alter superoxide production by neutrophils or
monocytes and did not alter plasma-soluble adhesion molecule
concentrations(209).
Very long-chain n-3 PUFA and inflammatory eicosanoid
production. Increased consumption VLC n-3 PUFA such
as EPA and DHA, usually given as fish oil in experimemtal
settings, results in increased proportions of those fatty acids
in inflammatory cell phospholipids (see Calder(173) for refer-
ences). This occurs in a dose–response fashion and is partly
at the expense of arachidonic acid(210,211). Since there is less
substrate available for the synthesis of eicosanoids from
arachidonic acid, fish oil supplementation of the human diet
has been shown to result in decreased production of these
mediators by inflammatory cells(173). Although most studies
have used fish oil, Kelley et al. (212) demonstrated that 6 g
DHA/d resulted in decreased production of PGE2 and LTB4
by endotoxin-stimulated mononuclear cells.
EPA is also able to act as a substrate for both COX and
5-LOX, giving rise to eicosanoids with a slightly different
structure to those formed from arachidonic acid. Thus, fish
oil supplementation of the human diet has been shown to
result in increased production of alternative eicosanoids (see
Calder(173) for references). The functional significance of
this is that the mediators formed from EPA are believed to
be less potent than those formed from arachidonic acid (see
Calder(173) for references).
In addition to VLC n-3 PUFA modulating the generation of
eicosanoids from arachidonic acid and to EPA acting as sub-
strate for the generation of alternative eicosanoids, recent
studies have identified a novel group of mediators, termed
E- and D-series resolvins, formed from EPA and DHA,
respectively, by the sequential actions of COX-2 and LOX
enzymes, which appear to exert anti-inflammatory and inflam-
mation resolving actions (see Serhan et al. (213) and Serhan(214)
for reviews).
Anti-inflammatory effects of very long-chain n-3 PUFA
other than altered eicosanoid production. A number of diet-
ary supplementation studies that used between 3·1 and
14·4 g EPA þ DHA/d have demonstrated a time-dependent
decrease in chemotaxis of human neutrophils and monocytes
towards various chemoattractants; both the distance of cell
migration and the number of cells migrating were decreased
(see Calder(173) for references).
Cell culture and animal feeding studies report decreased
expression of some adhesion molecules on the surface of
monocytes, macrophages or endothelial cells following
exposure to VLC n-3 PUFA (see Calder(173) for references).
Supplementing the diet of healthy human subjects with fish
oil providing about 1·5 g EPA þ DHA/d resulted in a lower
level of expression of ICAM-1 on the surface of blood mono-
cytes stimulated ex vivo with IFN-g(215). Dietary fish oil pro-
viding 1·1 g EPA þ DHA/d was found to decrease circulating
levels of soluble VCAM-1 in elderly subjects(216), but it is not
clear whether this represents decreased surface expression of
VCAM-1.
Supplementation studies providing 3·1–8·4 g EPA þ DHA/
d have reported decreases in the production of ROS (superox-
ide and/or hydrogen peroxide) by stimulated human neutro-
phils and monocytes (see Calder(173) for references). A
recent study has reported the dose–response relationship
between EPA intake and decreased superoxide production
by human neutrophils and identified that cells from older sub-
jects seem to be more sensitive to EPA than those from young
subjects(211).
Cell culture studies demonstrate that EPA and DHA can inhi-
bit the production of inflammatory cytokines (TNF-a, IL-1b,
IL-6, IL-8) by monocytes and endothelial cells (see
Calder(173)). Fish oil feeding decreased ex vivo production of
TNF-a, IL-1b and IL-6 by rodent macrophages (see
Calder(173)). Supplementation of the diet of healthy human vol-
unteers with fish oil providing more than 2 g EPA þ DHA/d has
been shown to decrease production of TNF, or IL-1 or IL-6 by
mononuclear cells in some studies (see Calder(173)). Caughey
et al. (217) reported a significant inverse correlation between
the EPA content of mononuclear cells and the ability of those
cells to produce TNF-a and IL-1b in response to endotoxin.
Kelley et al. (212) showed that 6 g DHA/d for 12 weeks resulted
in decreased production of TNF-a and IL-1b by endotoxin-
stimulated mononuclear cells. Both EPA and DHA (4 g/d for
6 weeks) decreased plasma TNF-a concentrations in type 2
diabetics, although DHA was more potent(218). It should be
noted that there are also several studies that fail to show effects
of dietary long-chain n-3 PUFA on production of inflammatory
cytokines in human subjects (see Calder(173,202) for references
and discussion).
a-Linolenic acid and inflammatory processes. Increased
consumption of a-linolenic acid results in an increased content
of EPA and docosapentaenoic acid in the membranes of
inflammatory cells (see Burdge & Calder(219) for references)
in parallel with a decreased content of arachidonic acid.
This might be expected to affect inflammation. A recent
study has reported an inverse association between a-linolenic
acid intake and plasma concentrations of IL-6 and sVCAM-1
but not of CRP, soluble TNF receptor-2, SE-selectin or
sICAM-1 in samples taken from the Nurses Health Study 1
cohort(220). After adjustment for age, BMI, physical activity,
smoking status, alcohol consumption and intakes of linoleic
acid and SFA, there were significant negative associations
between a-linolenic acid intake and plasma CRP, IL-6 and
E-selectin concentrations(220). These observations would
suggest that increasing a-linolenic acid intake would result
in decreased inflammation. Caughey et al. (217) reported that
13·7 g/d a-linolenic acid for 4 weeks resulted in a decrease
in ex vivo production of PGE2, TNF-a and IL-1b by
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endotoxin-stimulated mononuclear cells by 33, 27 and 30 %,
respectively. By comparison, fish oil providing 2·7 g/d
EPA þ DHA decreased the production of these inflammatory
mediators by 55, 70 and 78 %, respectively(217). Thus, on a g/d
basis, VLC n-3 PUFA are about eight to fourteen times more
potent than a-linolenic acid with respect to this outcome in
healthy subjects. In contrast to the observations of Caughey
et al. (217), several studies using lower intakes of a-linolenic
acid (2–9·5 g/d) did not find effects on neutrophil chemotaxis,
neutrophil respiratory burst, monocyte respiratory burst,
TNF-a, IL-1b and IL-6 production by endotoxin-stimulated
mononuclear cells, all studied ex vivo, or on soluble adhesion
molecule concentrations (see Burdge & Calder(219) for refer-
ences). Furthermore, a study by Rallidis et al. (221) reported
no effect of 8 g/d a-linolenic acid on sICAM-1 or SE-selectin
concentrations and a similar decrease in sVCAM-1 concen-
tration in both a-linolenic acid and control groups. Likewise,
Bemelmans et al. (222) found no effect of 6·3 g/d a-linolenic
acid on sICAM-1 concentration at 1 and 2 years of interven-
tion. Taken together, these data suggest that increasing a-lino-
lenic acid intake to .9 g/d is required in order for marked
anti-inflammatory effects to be seen. Even then, the effects
will be much more modest than those exerted by VLC n-3
PUFA(217). However, both Rallidis et al. (223) and Bemelmans
et al. (222) did find a significant decrease in CRP concentration,
suggesting that this may be a marker that is more sensitive to
the intakes of a-linolenic acid, which do not affect soluble
adhesion molecule or cytokine concentrations or ex vivo
inflammatory cell responses. One study using a very high
intake of a-linolenic acid (approx. 17·5 g/d) reported signifi-
cant decreases in both CRP and soluble adhesion molecule
concentrations(224). Interestingly, the authors found that the
changes in these inflammatory markers were significantly
related to changes in serum concentrations of EPA or EPA
plus docosapentaenoic acid, but not of a-linolenic acid. This
suggests that the observed effects are due to the VLC n-3
PUFA rather than to a-linolenic acid per se. Thus, the likely
explanation for the lack of anti-inflammatory effect of a-lino-
lenic acid at modest and even at rather high intakes is that
there has been insufficient conversion to the more active EPA.
Mechanisms of action. It is clear that one anti-inflamma-
tory mechanism of action of VLC n-3 PUFA is antagonism
of production of inflammatory eicosanoids from arachidonic
acid coupled with the generation of less potent EPA-derived
eicosanoids and, in some conditions, anti-inflammatory resol-
vins(225). Altered eicosanoid profiles may have downstream
effects since some eicosanoids regulate production of inflam-
matory cytokines. Thus, an n-3 PUFA-induced decrease in
eicosanoid production might affect production of TNF-a,
IL-1b, IL-6, etc. However, the effects of n-3 PUFA on inflam-
matory cytokine production and on some other inflammatory
processes appear to be eicosanoid independent. One alterna-
tive candidate mechanism of action is altered activation of
transcription factors involved in inducing transcription of
inflammatory genes (e.g. NF-kB, PPAR-g; see
Calder(226,227)), which may occur as a result of altered
plasma membrane signalling processes(228 – 231).
Effects on clinical outcomes in inflammatory conditions
Inflammatory bowel diseases. Dietary fish oil shows
improvements in animal models of IBD (see Calder(173)).
Shoda et al. (232) determined that the increased incidence of
CD in Japan was significantly associated with an increase in
the ratio of n-6 to n-3 PUFA in the diet. They suggest that a
diet high in n-6 PUFA relative to n-3 PUFA somehow plays
a causal role in the disease, and that an increase in n-3
PUFA intake may be of benefit. VLC n-3 PUFA are incorpor-
ated into gut mucosal tissue of patients with IBD, who sup-
plement their diet with fish oil and there are reports that this
results in anti-inflammatory effects, such as decreased LTB4
production by neutrophils and colonic mucosa, decreased
PGE2 and TXB2 production by colonic mucosa and decreased
production of PGE2 by blood mononuclear cells (see
Calder(173) for references). Small open-label or pilot studies
reported clinical benefit of fish oil supplementation in UC
(see Calder(173)). A number of randomised, placebo-
controlled, double-blind studies of fish oil in IBD have been
reported (see Calder(173) for details). The dose of VLC n-3
PUFA used in these trials was between 2·7 and 5·6 g/d and
averaged about 4·5 g/d. Some of these trials indicate benefits
of fish oil, which include improved clinical score, improved
gut mucosal histology, improved sigmoidoscopic score,
lower rate of relapse and decreased use of corticosteroids.
One study of special note is that of Belluzzi et al. (233) in
which patients with CD in remission were randomised to
receive placebo or 2·7 g VLC n-3 PUFA/d from an enterically
coated fish oil preparation for 1 year: there was a significant
difference in the proportion of patients who relapsed over 12
months: 28 % in the fish oil group v. 69 % in the placebo
group. Reviews of trials of fish oil in IBD conclude that
there is some benefit from fish oil in IBD. A recent meta-
analysis has concluded that there may be reduction in
requirement for corticosteroids(234).
Asthma. There are epidemiologic data linking high n-6
PUFA or low n-3 PUFA consumption with childhood
asthma and allergic conditions (see Calder(173) for references).
Early exposure to VLC n-3 PUFA does appear to alter cyto-
kine production by neonatal T-cells(235,236) although the
longer-term clinical impact of this is not yet clear. Several
studies report anti-inflammatory effects of fish oil in patients
with asthma, such as decreased four-series LT production
and leucocyte chemotaxis (see Calder(173) for references).
A number of randomised, placebo-controlled, double-blind
studies of fish oil in asthma have been reported (see
Calder(173) for details). A systematic review concluded that
there was no consistent effect on forced expiratory volume
at one second, peak flow rate, asthma symptoms, asthma
medication use or bronchia hyper-reactivity(237). However,
one study in children has shown improved peak flow and
reduced asthma medication use with fish oil(238). A more
recent report covering twenty-six studies (both randomised,
placebo-controlled and others) has concluded that no definitive
conclusion can yet be drawn regarding the efficacy of VLC
n-3 fatty acid supplementation as a treatment for asthma in
children and adults(239). However, studies by Broughton
et al. (240) and Nagakura et al. (238) indicate that there may
be subgroups of asthmatic subjects who may benefit greatly
from VLC n-3 PUFA. A recent study has reported the effects
of a high level of fish oil, providing 5·2 g/d EPA þ DHA, on
sputum inflammatory cytokines and pulmonary function in
exercise-induced bronchoconstriction(68). Concentrations of
TNF-a and IL-1b in sputum supernatant were significantly
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lower in the fish oil group and this change was accompanied
with improved pulmonary function.
Chronic obstructive pulmonary disease. Two recent
studies have investigated the effects of fairly low supplemen-
tal intake of EPA þ DHA on inflammatory markers, as well as
exercise capacity, in COPD(241,242). Broekhuizen et al. (241)
reported improved exercise capacity in a cycling test but no
effect on systemic levels of IL-6 and TNF-a following
intake of a supplement containing 1·0 g/d EPA þ DHA.
Matsuyama et al. (242) measured both systemic (serum) and
sputum TNF-a and IL-8 levels in a 2-year intervention with
a supplemental intake of 0·6 g/d EPA þ DHA. The present
study also failed to find differences in serum cytokine concen-
trations, but did report decreased sputum TNF-a and IL-8
levels in the n-3 PUFA group. This effect was accompanied
by improved exercise capacity in a walk test.
Rheumatoid arthritis. Dietary fish oil shows improve-
ments in animal models of RA (see Calder(173)). Several
studies report anti-inflammatory effects of fish oil in patients
with RA, such as decreased LTB4 production by neutrophils
and monocytes, decreased IL-1 production by monocytes,
decreased plasma IL-1b concentrations, decreased serum
CRP concentrations and normalisation of the neutrophil che-
motactic response (see Calder(173) for references). A number
of randomised, placebo-controlled, double-blind studies of
fish oil in RA have been reported (see Calder(173) for details).
The dose of VLC n-3 PUFA used in these trials was between
1·6 and 7·1 g/d and averaged about 3·5 g/d. Almost all of these
trials showed some benefit of fish oil, including reduced
duration of morning stiffness, reduced number of tender or
swollen joints, reduced joint pain, reduced time to fatigue,
increased grip strength and decreased use of non-steroidal
anti-inflammatory drugs. One study reported greater efficacy
of fish oil against a background diet designed to be low in ara-
chidonic acid(243). Reviews of the trials of fish oil in RA have
concluded that there is benefit and a meta-analysis concluded
that dietary fish oil supplementation significantly reduces
tender joint count and morning stiffness(244). A recent meta-
analysis has concluded that VLC n-3 fatty acids may reduce
requirements for corticosteroids(234). Thus, there is reasonably
strong evidence that VLC n-3 PUFA have some clinical ben-
efits in RA.
Psoriasis. Intravenous fish oil led to resolution of psoria-
sis in one study(245). Dietary supplementation studies with fish
oil do not present a clear picture although some of these have
reported clinical benefit (see Ziboh(246) for a review).
UV-induced skin inflammation. In experimental studies of
skin inflammation, UV-induced dose–response curves were
generated before and after 3 months of dietary supplementation
with fish oil(247). There was a significant inhibition of the
erythemal response, reduction in PGE2 release and biochemical
analysis of skin biopsies, which showed that the VLC n-3 PUFA
were acting as a scavenger for reactive oxygen(247,248).
CVD. Substantial evidence from epidemiological and
case-control studies indicates that consumption of fish, fatty
fish and VLC n-3 PUFA reduces risk of cardiovascular mor-
tality(177,178,249,250). Secondary prevention studies using VLC
n-3 PUFA in myocardial infarction survivors have shown a
reduction in total mortality and cardiovascular mortality with
an especially potent effect on sudden death(175). This protec-
tive effect of n-3 PUFA towards sudden death was apparent
within 4 months of beginning supplementation(176). VLC n-3
PUFA have been shown to influence a number of CVD risk
factors (see Kris-Etherton et al. (249) and Calder(250) for refer-
ences), and the extent to which a reduction in inflammation
protects against the growth of the atherosclerotic plaque and
decreases the risk and severity of cardiovascular events is
not clear. However, one study suggests that VLC n-3 PUFA
might act to stabilise advanced atherosclerotic plaques,
perhaps through their anti-inflammatory effects(174).
Antioxidant vitamins (C and E, b-carotene)
Oxidative stress and inflammation. There is a strong inter-
action between oxidative stress and inflammation. The gener-
ation of oxidants (e.g. superoxide radicals, hydrogen
peroxide), for example by granulocytes exposed to bacterial
cell wall peptides or lipopolysaccharides, is part of the host
inflammatory response. Oxidants can damage components of
host cells, such as the PUFA in cell membranes. In turn, oxi-
dants and oxidised cell components, acting through transcrip-
tion factors such as NF-kB, induce production of
inflammatory eicosanoids and cytokines (Fig. 4). Thus, one
mechanism to diminish inflammatory mediator production
may be to prevent oxidative stress. This is accomplished
through enhancing antioxidant defence mechanisms. In order
to monitor antioxidant defence, individual components of
that defence can be measured (e.g. vitamin C, vitamin E, anti-
oxidant enzyme activities). Additionally, the effectiveness of
the non-enzymatic endogenous antioxidant network can be
assessed measuring total antioxidant capacity (TAC), defined
as the moles of oxidants neutralised by 1 litre of the tested
sample(251). TAC considers the cumulative action of all the
antioxidants present in the matrix (plasma, saliva, diet, etc.),
thus providing an integrated parameter rather than the
simple summary of measurable antioxidants, giving an insight
into the delicate balance between antioxidants molecules.
Endogenous TAC has been shown to be modulated by dietary
ingestion of plant food(252) and to decline in subjects affected
by CVD(253) and cancer(254). Population-based case-control
studies have shown an inverse association of the TAC of the
diet with risk of gastric cancer(255) and overall mortality(256).
Despite these promising results, evidence about the role of the
dietary or endogenous TAC and inflammation is lacking.
Recently, TAC has been shown to be inversely and indepen-
dently associated with plasma levels of CRP in 243 non-diabetic
subjects(257). This observation highlights the interrelationship
between oxidative stress and inflammation and suggests
that improving TAC by dietary means may be a fruitful
anti-inflammatory approach.
Vitamin C
Description, sources, normal intakes and roles. The term
vitamin C includes ascorbic acid (AA) and dehydroascorbic
acid, both of which exhibit anti-scorbutic activity. AA, the
enolic form of an a-ketolactone, is the functional and pri-
mary in vivo form of vitamin C. AA contains an asymmetric
carbon atom that allows two enantiomeric forms, of which
the L-form is naturally occurring. The two enolic hydrogen
atoms of AA provide the electrons for its function as a
reductant and antioxidant. The one-electron oxidation pro-
duct of AA is the ascorbyl radical. It readily dismutates to
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AA and dehydroascorbic acid, the two-electron oxidation
product. Both ascorbyl radical and dehydroascorbic acid
are readily reduced back to AA. Dehydroascorbic acid can
also be irreversibly hydrolysed to 2,3-diketo-L-gulonic acid,
which is further decarboxylated and degraded to oxalic
acid and threonic acid.
Vitamin C is essential for human subjects and a few other
mammals, including guinea pigs and monkeys, because they
are unable to synthesise AA from glucose due to lack of the
enzyme gulonolactone oxidase. The main dietary sources of
vitamin C in the typical Western diet are fruits and vegetables,
including fruit and vegetable juices, as well as potatoes. Black
currant, raw pepper, raw broccoli, kiwi, strawberries, oranges
and freshly squeezed orange juice are particularly rich in
vitamin C.
Present dietary reference intakes have been set at 90 and
75 mg/d for adult males and females, respectively(258). An
additional 35 mg/d is recommended for smokers, given the
greater metabolic turnover of vitamin C in smokers. The rec-
ommended five servings per day of fruits and vegetables
should provide at least 200 mg of vitamin C. Storage and
food processing have a major impact on vitamin C content.
There are also an increasing number of foods and drinks for-
tified with vitamin C. At usual dietary vitamin C intakes, in
the range of 30–180 mg/d, approximately 70–90 % is
absorbed, while absorption decreases to about # 50 % at
doses exceeding 1 g(259).
Maximal neutrophil concentrations with minimal urinary
losses are thought to be the best biomarkers for estimating
vitamin C requirements. Saturation of leucocytes with vitamin
C occurs at a lower intake compared with plasma(259). Mean
plasma concentrations of healthy subjects are about
65mmol/l, while scurvy occurs at plasma concentrations of
less than 10mmol/l.
Vitamin C plays an important role in mechanisms involved
in immune function and inflammatory processes, including,
for instance, free radical scavenging and protection against
lipid peroxidation. Given its high reducing power, vitamin
C is a potent water-soluble antioxidant that acts in the
aqueous phase both intra- and extracellularly. It readily sca-
venges ROS and reactive nitrogen species including
hydroxyl, peroxyl, superoxide, nitroxide radical, peroxyni-
trite, as well as singlet oxygen and hypochlorite(260).
Ascorbyl radical, the one-electron oxidation product, and
dehydroascorbic acid, the two-electron oxidation product of
vitamin C, are readily regenerated to AA by glutathione
and NADH or NADPH.
AA tissue levels are relatively high and thus ensure efficient
antioxidant protection, for instance, against ROS produced in
activated neutrophils during phagocytosis(261). AA also sca-
venges ROS in the aqueous phase before they initiate lipid
peroxidation of fatty acids in plasma and LDL(262,263). More-
over, AA enhances antioxidant protection by sparing or regen-
erating a-tocopherol and glutathione back to their active
forms(264).
In addition to its antioxidant action, vitamin C is a cofactor
for enzymes involved in the biosynthesis of collagen, carnitine
and neurotransmitters as well as corticosteroids, the micro-
somal drug-metabolising enzymes and cytochrome P-450 elec-
tron transport. It modulates iron absorption, transport and
storage. AA has also been shown to modulate PG synthesis(265).
Effects on inflammatory processes and mechanisms of
action. In infectious diseases and inflammation, ROS are
generated during neutrophil activation and phagocytosis. AA
exerts cellular protection against ROS generated by the respir-
atory burst. It neutralises hypochlorous acid, a powerful ROS
generated by myeloperoxidase in activated neutrophils and
monocytes such that inactivation of a1-proteinase inhibitor
by hypochlorous acid is inhibited and, consequently, proteo-
lytic damage is prevented at the site of inflammation(266). It
is important to note that, under normal conditions, phago-
cyte-derived ROS are neutralised without inhibiting the bac-
tericidal activity of the phagosome(267). Vitamin C also
affects antimicrobial and natural killer cell activities, lympho-
cyte proliferation, chemotaxis and delayed-type hypersensitiv-
ity. Vitamin C further enhances phagocytosis and migration of
neutrophils(268). In healthy subjects, vitamin C concentrations
are inversely correlated with CRP and 8-epi PGF2a(269,270).
Plasma 8-epi PGF2a and MCP-1 concentrations decreased sig-
nificantly during consumption of approximately 72 mg/d
vitamin C from vegetable soup(269).
An energy-dependent transport system allows for a 25- to
80-fold accumulation of AA in neutrophils, lymphocytes and
mast cells as compared with plasma levels(259,271). During
the course of infections, there is a rapid depletion of cellular
ascorbate that returns to normal after recovery. At the site of
inflammation, the ratio of oxidised to reduced ascorbate (dehy-
droascorbic acid: AA) is increased, as has been shown for the
synovial fluid of RA joints(272), and in the epithelial lining
fluid of the lung and in the plasma of patients with adult res-
piratory distress syndrome(273). Dehydroascorbic acid is the
form of vitamin C that crosses the cell membranes and is
then reduced intracellularly to AA. Reduction in vitamin C
is associated with oxidation of reduced glutathione (GSH) to
its oxidised form (GSSG).
Effects in inflammatory conditions
Inflammatory bowel diseases. Serum and leucocyte ascorbate
levels are low in adult and pediatric patients with CD, both in
active disease and in disease remission(274 – 277). Colonic biop-
sies of inflamed v. non-inflamed areas in patients with CD
showed a 35 % reduction in reduced and total AA content
and in patients with UC total AA content was reduced by
73 % and reduced AA by 41 %(278). Also, different biomarkers
of lipid peroxidation are higher(277) and decreased during sup-
plementation of vitamin C and E(279). Fish oil plus antioxidant
treatment (90 mg vitamin C, 30 mg vitamin E, 150mg retinol
equivalents as b-carotene) of patients with CD showed a sig-
nificant reduction in the production of PGE2 and IFN-g by
circulating monocytes and macrophages(280).
Lung inflammation. Evidence of AA oxidation has been
seen in adult respiratory distress syndrome(273). Adults with
mild asthma exhibit decreased AA in lung fluid and increased
GSSG concentrations which, in the presence of normal
plasma concentrations, are suggestive of oxidative stress in
the airways(281). Cross-sectional studies showed an inverse
relation between plasma vitamin C and lung inflammation(282)
and suggest that high plasma AA concentrations or vitamin C
intakes have a positive impact on lung function(283,284).
Compared with the highest quintile, serum vitamin C concen-
trations in the lowest quintile were associated with an
increased risk of asthma in children and adolescents(285).
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Low maternal vitamin C intake during pregnancy is associated
with asthma in 5-year-old children(286). Asthmatic children
showed reduced vitamin C concentrations in leucocytes
(50 %) and plasma (35 %)(287). Small clinical studies showed
that vitamin C supplements of 2 g/d exert protective effects
on airway responsiveness to viral infections and allergens(288),
but have little effect on exercise-induced asthma(289), although
one study did report attenuated exercise-induced bronchocon-
striction in patients with asthma(290).
Rheumatoid arthritis. Evidence of AA oxidation has been
seen in RA(272). An intervention study with a Mediterranean
diet, rich in antioxidant containing foods, in RA showed a
negative correlation between plasma vitamin C levels and
disease activity(291).
CVD. Vitamin C and other single vitamin supplementation
and CVD have been reviewed recently(292). Associations
between antioxidants and markers of endothelial function
(sICAM-1; flow-mediated vasodilation) and inflammation
(CRP, fibrinogen and white blood corpuscles count) were
studied in subjects recruited from the general population.
Plasma vitamin C and CRP concentrations were inversely
related(293). Recent randomised controlled trials have shown
that vitamins C plus E improved arterial stiffness and endo-
thelial function in patients with essential hypertension(294),
vitamin C decreased sPselectin concentration and vitamins
C plus E decreased sICAM-1 in patients with chronic degen-
erative aortic stenosis with or without concomitant coronary
artery disease(295).
Vitamin E
Description, sources, normal intakes and roles. Vitamin E is
an umbrella term for a number of tocopherols and tocotrienols.
They are composed of a chromanol ring and a 16-C phytyl tail,
which is saturated in the tocopherols and unsaturated in the toco-
trienols. The chromanol ring is substituted with one, two or three
methyl groups and one hydroxyl group, which exerts the antiox-
idant function. Depending on the number and positions of the
methyl groups of the chromanol ring, a- (three methyl groups
at C-5, C-7 and C-8 positions), b- (two methyl groups at C-5
and C-8 positions), g- (two methyl groups, C-5 position unsub-
stituted) and d- (one methyl group at C-8 position) forms can be
distinguished for both tocopherols and tocotrienols. These
differences in the chemical structure have an impact not only
on the hydrophobicity of the different types of tocopherols,
but also on the discrimination by the a-tocopherol-transfer pro-
tein in the liver, which recognises the fully methylated aromatic
ring of a-tocopherol(296). Consequently, a-tocopherol is incor-
porated into nascent VLDL, while g-tocopherol is metabolised
and excreted, resulting in substantially lower g- than a-toco-
pherol concentrations in plasma and tissues. The physiological
metabolites of tocopherols and tocotrienols, i.e. the carbox-
yethyl hydroxychromans (CEHC), are generated via a similar
degradation pathway that involves cytochrome P450-mediated
n-oxidation of the phytyl chain and subsequent b-chain oxi-
dation to the corresponding hydrophilic metabolites in the
absence of modification of the chromanol ring(297,298). The
hydroxyl group on the chromanol ring exerts the antioxidant
action. It can be esterified to give rise to tocopherol acetate or
succinate.
Vitamin E is widely distributed in different kinds of foods.
Dietary vitamin E mainly consists of a- and g-tocopherol.
Frequently, the major source of vitamin E is g-tocopherol,
which is present at high concentrations in plant seeds and veg-
etable oils such as maize oil and soyabean oil, as well as in
nuts such as walnuts, pecans and peanuts(299,300). Fats and
oils contributed about 20 %, vegetables 15 %, meat and fish
12·5 %, desserts 10 %, breakfast cereals 9 %, fruits 5 %,
bread and grain products 5 %, dairy products 4·5 %, mixed
main dishes 4 %, nuts and seeds 4 %, eggs 3 %, salty snacks
3 %, legumes 2 % and soups, sauces and gravies 2 % of the
total vitamin E intake among American adults(301). North
American dietary reference intakes for vitamin E have
recently been set at 15 mg/d for both men and women(258).
Vitamin E supplements further contribute to vitamin E
intake. In the Boston Nutritional Status Survey, 38 % of the
men of 60 years of age and older and 49 % of the women
were users, and 68 % and 73 %, respectively, of the male
and female users took vitamin E supplements(302). In contrast
to vitamin E in the diet, almost all supplements contain
a-tocopherol exclusively.
Vitamin E is a potent chain-breaking antioxidant that acts
mainly in the lipid phase and interrupts the chain reaction of
lipid peroxidation and, consequently, prevents the propagation
of free radical-initiated reactions(303,304). There are differences
between a- and g-tocopherols(304) and a recent review has
paid attention to g-tocopherol(305). a-Tocopherol decreases
lipid peroxidation and enhances LDL resistance to oxi-
dation(306,307). g-Tocopherol decreases the concentrations of
biomarkers of oxidative stress, including LDL oxidation,
MDA formation and superoxide anion generation and is
more potent than a-tocopherol(308,309). a-Tocopherol also
decreased the expression of the scavenger receptors SR-A
and CD36, which are important in the formation of foam
cells in the early stages of atherogenesis(310). However,
g-tocopherol cannot replace a-tocopherol in its functions in
fertility(311).
A more recently discovered mechanism of action has been
restricted to g-tocopherol and its physiological metabolite,
g-CEHC. Because of an unsubstituted position on the chroma-
nol ring, g-tocopherol traps certain reactive nitrogen species in
cell lines and unsaturated liposomes with formation of 5-nitro-
g-tocopherol(312,313).
Effects on inflammatory processes and mechanisms of
action. One of the mechanisms of action of vitamin E on
inflammatory processes is its well-known antioxidant activity,
which limits the generation of ROS as well as the perpetuation
and damaging effects of the reactions initiated by ROS, which
in turn, could activate the inflammatory process.
a-Tocopherol, especially at high doses, decreases the
release of pro-inflammatory cytokines, the chemokine IL-8
and PAI-1 and decreases adhesion of monocytes to endo-
thelium(314). Vitamin E (particularly g-tocopherol) has been
shown to decrease NF-kB activation(315). Additional effects
include inhibition of the activities of protein kinase C,
5-LOX, tyrosine kinase and COX-2(316,317). a-Tocopherol
has also been shown to decrease CRP levels(314).
g-Tocopherol and g-CEHC exert actions not shared by
a-tocopherol and a-CEHC. For instance, g-tocopherol but
not a-tocopherol inhibits PGE2 generation in cell cul-
ture(318 – 320). Furthermore, LTB4, a potent chemotactic
agent synthesised by 5-LOX of neutrophils, and TNF-a
were decreased in carrageenan-induced inflammation in
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rats and in different cell lines by g-tocopherol, but not by
a-tocopherol(319,320). g-Tocopherol decreased oxidised
LDL-mediated NF-kB acitivation in human coronary artery
endothelial cells(321). g-Tocopherol and g-CEHC, but not
a-tocopherol, inhibited COX activity in macrophages and
epithelial cells(322).
Effects in inflammatory conditions
Rheumatoid arthritis. Low antioxidant level (the lowest v.
higher tertiles of the product of molar concentrations of
a-tocopherol, b-carotene and selenium) was a risk factor for
RA over 20 years of follow-up of a case-control study(323).
In the KRN/NOD mouse, a mouse model of RA, vitamin E
(RRR a-tocopherol) prevented joint destruction as assessed
by histological analysis, but did not have an effect on clinical
features such as time of onset or disease intensity. In addition,
levels of IL-1b, the main cytokine involved in articular
destruction, were reduced, as was neutrophil activation
measured by chemiluminescence(324). In an animal model
for RA, mice fed a fish oil and additional vitamin E-enriched
diet showed significantly lower serum IL-6, TNF-a, PGE2,
TXB2 and LTB4 levels compared with the fish oil
diet alone(325). In a double-blind placebo-controlled trial
patients with RA, who received 600 mg vitamin E twice a
day, showed a significant pain reduction but no changes in
clinical and biochemical indices of inflammation(326).
CVD. Vitamin E inhibits LDL oxidation both when induced
by copper ions ex vivo (307,327) and in cell culture(328). In
addition to that vitamin E could have an effect on different
aspects of atherogenesis, given that it (i) inhibits smooth
muscle cell proliferation by inhibiting protein kinase C(329);
(ii) inhibits platelet adhesion, aggregation and release(330);
(iii) decreases monocyte adhesion to the endothelium by
downregulating the expression of adhesion molecules and
reducing monocyte superoxide production(331); (iv) increases
prostacyclin synthesis in human endothelial cells, which is a
potent vasodilator and inhibitor of platelet aggregation(332,333);
(v) mediates upregulation of the expression of cytosolic phos-
pholipase A2 and COX(334); and (vi) inhibits the expression of
ICAM-1 and VCAM-1 in endothelial cells in culture(335).
While epidemiological studies consistently showed an
inverse correlation between vitamin E status and risk of
CVD, the results of vitamin E supplementation trials have
been much less convincing regarding prevention of CVD.
A possible explanation could be the fact that only a-toco-
pherol, which is almost exclusively present in vitamin E sup-
plements, has been taken in these studies. This is further
supported by the observation that g-, not a-tocopherol serum
levels are reduced in CHD(336). It is known from several inter-
vention trials(337,338) that a-tocopherol supplementation causes
a marked drop in g-tocopherol concentrations in plasma and
lipoproteins.
Carotenoids
Description, sources, normal intakes and roles. Carotenoids
represent a group of over 600 coloured pigments found in
nature that are responsible for the typical colour of fruits
and vegetables as well as some animals. Carotenoids are com-
posed of a 40-carbon atom skeleton and are either hydrocar-
bons (also called xanthophylls) that contain only H and C
(a-, b-carotene, lycopene), or oycarotenoids that contain
also O (lutein, zeaxanthin). Provitamin A carotenoids (a-
and b-carotene, and b-cryptoxanthin) are carotenoids that
can be cleaved in the intestine either by central cleavage,
giving rise to two molecules of retinol from one molecule
b-carotene, or excentric cleavage, giving rise to one molecule
of retinol and carotenoid cleavage products.
Plasma carotenoid concentrations are useful biomarkers
of the consumption of fruits and vegetables(339). The most
prevalent carotenoids in the Western diet are a-carotene,
b-carotene, lycopene, b-cryptoxanthin, lutein and zeaxanthin.
Dietary sources of a-carotene are carrots, sweet potatoes, cab-
bage, spinach, pumpkin, broccoli and pepper; of b-carotene
are carrots, pumpkin, red pepper, green beans, green salad,
broccoli and melon; of b-cryptoxanthin are avocado, green
olives, peach, mandarin, mango, papaya and orange; of lyco-
pene are tomatoes and tomato products, and guave; of lutein
are dark green leafy vegetables such as cabbage, spinach,
broccoli, peas, cauliflower and green salad; of zeaxanthin is
maize. Most of the naturally occuring carotenoids are present
as all-trans isomers and are transformed into the cis isomers
during food processing (heating; lycopene) or in the intestinal
mucosa cells (b-carotene). Astaxanthin is found in marine
animals and vegetables.
As suggested by Krinsky(340), the biological activities of
carotenoids should be diffentiated as:
(i) functions, including acting as accessory pigments in
photosynthesis, protection against photosensitisation
and role as provitamin A;
(ii) actions, including antioxidant, immunoenhancing, anti-
mutagenic and anti-carcinogenic actions;
(iii) associations, including decreasing risk of macular
degeneration and cataracts, some cancers and some car-
diovascular events.
Even though carotenoids are recognised mainly for
their provitamin A functions, less than 10 % of them exert
provitamin A activities in mammals. Of the carotenoids, b-
carotene has the highest provitamin A activity. The efficiency
of b-carotene conversion to vitamin A decreases with
higher b-carotene intake. Lutein is among the most
prevalent carotenoids found in normal skin and a major caro-
tenoid in the macular pigment and effectively filters blue light
and thus protects the retina from light-induced oxidative
damage(341).
Effects on inflammatory processes and mechanisms of
action. Carotenoids possess immunomodulatory activities
in human subjects and animals, including, for instance, stimu-
lation of the phagocytic and bacteria-killing ability of periph-
eral blood neutrophils and peritoneal macrophages and of
lymphocyte blastogenesis, increasing the population of
specific lymphocyte subsets and lymphocyte cytotoxic
activity, as well as stimulation of the production of various
cytokines. b-Carotene inhibits inflammatory gene expression
by suppressing the activation of the redox-sensitive transcrip-
tion factor, NF-kB(342,343).
Effects in inflammatory conditions. While b-carotene has
been studied quite extensively, data are limited for other caro-
tenoids. In Table 2, the effects of carotenoids as well as of
vitamins C and E are listed. Biomarkers of inflammation
have been included in a variety of studies and quite
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Table 2. Summary of studies investigating the anti-inflammatory actions of vitamins C and E and of carotenoids
Compounds Model/study subjects Effects Reference
Cell culture studies
g-Tocopherol, g-CEHC Macrophages, epithelial cells # PGE2, LTB4, TNF-a, COX activity 319,322
Lycopene Dendritic cells # NF-kB, IL-2, IL-12, ERK 1/2, p38, JNK 348
Animal studies
Vitamin E Transgenic mouse model of RA, fish oil treated # Serum IL-6, IL-10, IL-12, TNF-a 325
RRR a-tocopherol Transgenic mouse model of RA Prevention of joint destruction, # IL-1b 324
b-Carotene Mice, LPS-treated # NO, PGE2, iNOS, COX-2, TNF-a, IL-1b, NF-kB, iNOS promoter activity 342
Lycopene Rats, induced colitis # Colonic thickness, area of inflammation, myeloperoxidase 354
Lutein Mice, UV irradiation # Ear swelling 350
Astaxanthin Rats, induced uveitis # PGE2, TNF-a, NO, iNOS enzyme activity 349
Observational studies in human subjects
Vitamin E Pregnancy, children with asthma # Maternal vitamin E intake associated with " asthma and wheezing in children 286
Association studies in human subjects
b-Carotene Patients with RA # Serum b-carotene preceding diagnosis 358
Different carotenoids General population " Plasma lutein, lycopene associated with # sICAM-1;
" b-carotene associated with # CRP, leucocytes;
" zeaxanthin: # flow-mediated vasodilation
293
Different carotenoids Critically ill patients " Carotenoids associated with # CRP 346
Different carotenoids NHANES III, non-smokers " Plasma carotenoids (all) associated with # CRP;
" b-cryptoxanthin associated with # fibrinogen;
" b-carotene, lycopene associated with # WBC
345
Different carotenoids Abdominal obesity # Serum canthaxanthin, b-carotene, a-carotene associated with " waist and waist:hip ratio 361
Case-control studies in human subjects
Vitamin C, a-carotene NHANES III, asthmatic children # serum vitamin C, a-carotene associated with " risk of asthma 285
Vitamin E, b-carotene
(þselenium)
Control group for cancer study # Antioxidant index associated with " risk of RA 323
Lycopene Women’s Health Study " Plasma lycopene associated with # risk of CVD 359
Different carotenoids EPIC Study " b-Cryptoxanthin or " zeaxanthin intake associated with # risk of inflammatory polyarthritis 357
Intervention studies in human subjects
a-tocopherol Patients with RA # Pain 326
Vitamin C þ a-tocopherol Patients with hypertension Flow-mediated dilation, central pulse wave velocity 294
Vitamin C þ a-tocopherol Patients with IBD # Oxidative stress 279
Carotenoid-rich fruits &
vegetables
Healthy non-smoking men # CRP 351
Lycopene Healthy young volunteers # TNF-a production 352
Vitamin A, C, E þ selenium
þ fish oil
Patients with IBD # PGE2, IFN-g 280
Mediterranean diet Patients with RA " plasma vitamin C associated with # disease activity score 290
LT, leukotriene; COX, cyclo-oxygenase; CEHC, carboxyethyl hydroxychroman; ERK, extracellular signal-regulated kinase; JNK, jun N-terminal kinase; iNOS, inducible NO synthase; RA, rheumatoid arthritis; ICAM, intercellular
adhesion molecule; CRP, C-reactive protein; WBC, white blood cell count; NHANES, National Health and Nutrition Examination Survey; EPIC, European Prospective Investigation of Cancer; IBD, inflammatory bowel disease; IFN,
interferon; MDA, malondialdehyde.
In
fl
am
m
ato
ry
p
ro
cesses
an
d
n
u
tritio
n
S
2
5
British Journal of Nutrition
https:/w
w
w
.cam
bridge.org/core/term
s. https://doi.org/10.1017/S0007114509377867
D
ow
nloaded from
 https:/w
w
w
.cam
bridge.org/core. U
niversity of B
asel Library, on 10 Jul 2017 at 15:35:15, subject to the C
am
bridge C
ore term
s of use, available at
consistently either showed an inverse relation between status
of different carotenoids and inflammation or reduction in elev-
ated biomarkers in response to intervention using carotenoid-
rich foods or supplements. Clinical end point studies are
particularly scarce. Like other serum antioxidants such as vita-
min C, plasma carotenoid concentrations decline during the
acute-phase response to infection and injury in the presence
of increased levels of biomarkers of inflammation(344). Inverse
relations between plasma b-carotene concentrations and bio-
markers of inflammation have been shown in a re-evaluation
study of the National Health and Nutrition Examination
Survey III study(345), as well as in studies in critically ill
patients(346). The underlying mechanisms are not known, but
may involve a cellular carotenoid-binding protein(347). Most
importantly, however, b-carotene and retinol levels are
restored after resolution of the inflammatory state in the
absence of b-carotene and/or retinol supplements. Study of
the effects of lycopene on murine bone marrow-derived DC,
which are the most potent antigen-presenting cells, revealed
that lycopene downregulates NF-kB as well as mitogen-
activated kinases such as extracellular signal-regulated
kinase 1/2, p38 and jun N-terminal kinase(348). Astaxanthin
showed a dose-dependent anti-inflammatory effect in endo-
toxin-induced uveitis in rats by suppressing NO, PGE2 and
TNF-a production(349). Mice fed lycopene showed significant
inhibition of ear swelling induced by UV radiation(350). In a
RCT, high intake of carotenoid-rich fruits and vegetables
reduced CRP concentrations(351). In another RCT, dietary
intake of a tomato-based drink (providing 5·7 mg lycopene,
1 mg b-carotene, 3·7 mg phytoene and 2·7 mg phytofluene
and 1·8 mg a-tocopherol per day), was associated with 34 %
decrease in TNF-a in whole blood(352).
Inflammatory bowel diseases. Plasma concentrations of
different carotenoids are decreased in patients with
CD(277,353). In a rat model of colitis, lycopene efficiently coun-
teracted the inflammatory response and mucosal damage in
iron-supplemented animals(354), which can be explained by
the fact that transition metal iron can give rise to the formation
of hydroxyl radical, the most reactive and cytotoxic ROS that
has the capacity of oxidising biomolecules including PUFA,
proteins and DNA bases and that lycopene acts as an
antioxidant.
Asthma. Whole blood concentrations of total carotenoids
and lycopene were decreased in patients with asthma com-
pared with controls and correlated with sputum concentrations
of carotenoids(355).
Rheumatoid arthritis. An inverse association between
serum b-cryptoxanthin levels and RA has been reported in
women aged 55–69 years(356). A nested case-control
study within the European Prospective Investigation of
Cancer Incidence study focused on dietary intake and occur-
rence of new cases of inflammatory polyarthritis and showed
that subjects with dietary intake of zeaxanthin and b-cryptox-
anthin in the highest tertile were at lower risk of developing
inflammatory polyarthritis compared with those in the lowest
tertile. The effect of b-cryptoxanthin remained significant
also after adjustments for total energy and protein intakes as
well as for smoking(357). In another study, plasma b-carotene
concentrations preceding diagnosis of RA by 2–15
years were lower in patients who developed RA compared
with controls(358).
CVD. Association between antioxidants and markers
of endothelial function (sICAM-1 and flow-mediated vasodila-
tion) and inflammation (CRP, fibrinogen and white blood cell
count) were studied in subjects recruited from the general
population. Lutein and lycopene were inversely related to
sICAM-1 and b-carotene was inversely related to white
blood cell count and CRP(293). In a nested case-control study
within the Women’s Health Study, CVD risk was associated
with plasma lycopene concentrations such that women in the
upper three quartiles of plasma lycopene concentrations had
a 50 % risk reduction(359). Similar results were not observed
in men participating in the Physicians’ Health Study(360).
Obesity. Low carotenoid and elevated CRP concentrations
are frequently observed in obesity, and are attributed to
unfavourable dietary habits and low-grade inflam-
mation(361,362). An inverse correlation between plasma caro-
tenoid concentrations and BMI was reported in obese
children and adolescents(363).
Flavonoids
Description, sources, normal intakes and roles. Polyphenols
are secondary metabolites of plants involved in pigmentation,
reproduction and protection against pathogens(364). Presently
there are more than 8000 known polyphenolic substances shar-
ing a common chemical structure (hydroxyl group on aromatic
ring) with different constituents. Flavonoids are the most
abundant polyphenols present in the human diet and represents
a subclass of molecules characterised with a C6–C3–C6
backbone structure(364). Flavonoids can be divided into several
classes according to different constituents such as flavanones,
flavone, flavanols and flavonols. They can be found in almost
all plant foods and, among the flavonols, myricetin, kaemp-
ferol and quercetin are the most representative, while
catechins are the most abundant flavanols contained in tea
leaves. Flavanones are mainly represented in the diet by
taxifolin, naringinin and hesperitin. The main sources of flava-
nones are citrus fruits. Flavones, luteolin, wogonin and
apigenin, are less common and identified in sweet red
pepper and celery. In addition to these, other classes of flavo-
noids are present in the diet such as proanthocyanidins and
their oligomers.
Dietary intake of flavonoids, calculated in 1976 in the
US(365), was 1 g/d with 16 % as flavonols, flavones and flava-
nones; 20 % as catechins; 17 % as anthocyanins and 45 % as
bisflavones. However, the high variability of polyphenol
intake, the lack of homogeneous database and reliable bio-
markers of exposure make it difficult to provide a reliable
estimate of flavonoid intake in the different countries.
Over the last years, there have been significative advances in
the understanding of the absorption and metabolism of flavo-
noids. In order to be absorbed, flavonoid glycosides, the most
abundant form in food, are hydrolysed by intestinal enzymes
or colon microflora. During the process of absorption, flavonoids
are conjugated in the small intestine and later in the liver to
increase their hydrophilicity and facilitate their elimination
from the body in urine and bile. The circulating forms of flavo-
noids are mainly conjugated and evidence regarding their
accumulation in specific target tissues is still lacking.
Flavonoids have been suggested to have anti-inflammatory
activity through several action mechanisms involving the
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reduction in the concentration of prostanoids and leukotrienes
through the inhibition of eicosanoid generating enzymes such
as phospholipase A2, COX and LOX(366).
Anti-inflammatory actions of flavonoids. Quercetin was
the first flavonoid shown to inhibit neutrophil phospholipase
A2(367) with an IC50 of 57–100mM. Flavanones such as
hesperitin and naringenin were shown to be less effective
inhibitors of snake venom phospholipase A2 compared with
the flavonols quercetin, kaempferol and myricetin(368). Bifla-
vonoids such as amentoflavone, ginkgetin, ochnaflavone and
iso-ginkgetin were shown to be good inhibitors, with an
IC50 of about 10mM for phospholipase A2 from several
sources. Luteolin, 3,4-dihydroxy-flavone, galangin, apigenin
and morin were the first flavonoids to be shown to inhibit
COX(366). Quercetin and kaempferol are potent inhibitors of
COX from rat peritoneal macrophages(368). The flavones api-
genin, luteolin, galangin, kaempferol and quercetin and the
biflavonoids amentoflavone, broussochalcone A and kuraridin
are potent COX-1 inhibitors, although with different poten-
cies. Catechin weakly inhibited COX-2 but at very high con-
centration (100mM)(369). Flavonols such as kaemferol,
quercetin, morin and myricetin were found to be better LOX
inhibitors than flavones and with a preferential effect on
5-LOX compared with 12-LOX. Flavanones such as narin-
genin were not inhibitory against 5- and 12-LOX. Endothelial
NOS was inhibited weakly by quercetin at very high concen-
tration (IC50 220mM)(370) with a lack of effect on nNOS and
iNOS. Several flavonoids (rutin, hepseridin, catechin and
tricin) had no effect on the three forms of NOS. Using LPS-
or cytokine-treated macrophages or macrophage cell lines
for stimulated NO production, quercetin, apigenin and luteolin
were found to inhibit NO production(371), downregulating
iNOS expression. Catechins and flavanones at concentrations
below 100mM did not affect NO production by LPS-treated
RAW 264·7 cells(372). Glycosylated flavonoids, such as
vitexin, had little effect on NO production with no effect at
a concentration of 100mM. Flavones such as apigenin, wogo-
nin and luteolin were the most efficient inhibitors (IC50
10–20mM). Furthermore, studies(373) showed that the inhibi-
tory effect of apigenin, genistein and kaempferol on NO pro-
duction is mediated by an effect on induction of iNOS
expression. Taken together, these results suggest that some
flavonoids are natural inhibitors of iNOS induction, but not
inhibitors of iNOS activity. With regard to inflammatory cyto-
kines, genistein was reported to inhibit IL-1b, IL-6 and TNF-a
production by LPS-stimulated human blood monocytes(374).
Genistein and silybin were shown to inhibit TNF-a production
from LPS-treated RAW cells(375). Flavonoids appear to inhibit
the expression of inflammation-related enzymes/proteins
partly by suppressing activation of NF-kB and AP-1, an
effect potentially mediated by the inhibition of different
protein kinases (e.g. mitogen-activated protein kinase;
extracellular signal-regulated kinase 1/2) involved in signal
transduction pathway.
Quercetin has been shown to affect iNOS expression by
inhibiting p38 MAPK and TNF-a from LPS-induced RAW
cells by inhibiting jun N-terminal kinase/SAPK and Ap-1
DNA binding(376,377). TNF-a was also inhibited through inhi-
bition of extracellular signal-regulated kinase 1/2 and p38
MAPK. Quercetin was shown also to affect NF-kB activation
by extracellular signal-regulated kinase and p38 kinase
inhibition(378). The effect on NF-kB was shown also for gen-
istein, apigenin, kaempferol and epigallocatechin 3-gallate.
The evidence so far shows that flavonoids are able to inhibit
the expression of inflammation-related enzymes/proteins
partly by suppressing activation of NF-kB and AP-1, an
effect potentially mediated by the inhibition of different pro-
tein kinases involved in the signal transduction pathway.
Regarding the effect of flavonoids on the expression of
inflammatory markers and processes in vivo, scientific evi-
dence is largely lacking. Quercetin inhibited release of TNF-
a from carrageenan-induced air-pouch exudates in rats(379).
Quercetin and rutin were found to suppress lethal endotoxic
shock induced by LPS in mice(380). Orally administered luteo-
lin was showed to inhibit TNF-a production in LPS-treated
mice(381).
Human studies investigating the effect of flavonoids on
markers of inflammation are scarce and most of them focus on
the use of flavonoid-rich foods and not on pure molecules.
One month of supplementation with 30 g/d ethanol as wine or
as gin in healthy men was able to decrease plasma levels of
IL-1a and fibrinogen(383). However, expression of the several
adhesion molecules on monocytes and T-lymphocytes was
significantly decreased only after wine ingestion. Wine also
decreased serum concentrations of sVCAM-1, sICAM-1 and
CRP. In another study(383), supplementation with a grape poly-
phenol extract containing anthocyanins, quercetin, myricetin,
kaempferol and resveratrol (36 g/d for 4 week) produced a sig-
nificant decrease in plasma TNF-a with no effect on CRP and
IL-6 concentrations in both pre- and post-menopausal women.
In both studies described earlier, the lack of measurement of
polyphenol levels in body fluids does not allow any conclusion
about the molecules responsible for the anti-inflammatory
effect to be made. In an intervention study where plasma
levels of flavonoids were measured, daily black tea supplemen-
tation (900 ml) for 4 weeks significantly increased plasma cate-
chin levels (29 %) compared with baseline values but without
any changes on CRP and TAC(384). Moreover, in a prospective
study in non-diabetic women, the intake of flavonols and fla-
vones was not significantly associated to plasma concentrations
of CRP and IL-6 or with the development of type 2 diabetes(385).
Recently, in the attempt to investigate diet-induced postprandial
oxidative and inflammatory stress, acute ingestion of 50 ml of
extra virgin olive oil has been shown to decrease plasma levels
of inflammatory molecules (LTB4 and TXB2) together with
an increase in serum TAC(386).
As overall, only about 1 % of the polyphenol that is con-
sumed is absorbed, with large differences according to the
different categories, the plasma concentration that is achieved
after eating polyphenol rich food is about 1mM(364). The low
concentration of flavonoids in biological fluids might present
an obstacle in exerting the putative anti-inflammatory action
in vivo. Human studies involving food items need to be
linked with a chemical characterisation of the flavonoid com-
position of the food and with the assessment of specific bio-
markers of single phenolics and antioxidant activity.
Moreover, information obtained on the basis of acute ingestion
studies might be extremely valuable for designing long-term
intervention trials. On the basis of the existing evidence, a
clear conclusion cannot be drawn and further human trials
are needed to elucidate the role of flavonoids as anti-
inflammatory agents in vivo.
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The gut microflora and inflammation
Gut microflora. The intestinal epithelium of the gastrointes-
tinal tract and its associated microflora are vital to the protec-
tion of the body(387,388). At birth, the gastrointestinal tracts of
babies are sterile but then rapidly become colonised by micro-
organisms from the mother’s faecal and vaginal microbiota
and the immediate environment. Consumption of oxygen
within the gut by the first colonising organisms, facultative
anaerobic bacteria, enables fully anaerobic bacteria to then
colonise the lower gut. Bifidobacteria are more predominant
in breast-fed babies, whereas a more complex population
(similar to that of adults) develops in formula-fed babies,
which comprises clostridia, bacteroides, enterobacteria,
streptococci and a lower level of bifidobacteria(389). SCFA
produced by bifidobacteria help to protect the baby against
infection. During the first year of life, the intestinal microbiota
stabilises and gradually resembles that of an adult. Up to 1014
micro-organisms are contained in the adult human body – ten
times more microbial cells than human – most of these micro-
organisms are located in the gastrointestinal tract(390). More
than 1 kg of bacteria is present in the gut and faeces typically
comprise 50 % bacteria, meaning that human subjects excrete
50–100 g of bacteria each day. Micro-organisms are at their
lowest numbers (,103 CFU/g) in the stomach due to its low
pH and fast transit time but reach levels as high as
1012 CFU/g in the colon, due to its much slower transit
time, less acidic pH and low oxygen levels. Faecal isolates
are generally representative of the microbiota of the distal
colon. At least 500 different bacterial species have been
cultured from faeces (including lactobacilli and bifidobac-
teria), yet just forty species account for 99 % of those that
have been identified. The microbial inhabitants of the intesti-
nal microbiota are still not fully identified due to the limi-
tations of identification techniques and individual variations.
New molecular typing methods are now enabling identifi-
cation of further gut-associated species.
Studies with germ-free animals have demonstrated the
importance of the gut microflora for the normal development
of the gastrointestinal tract and the education and stimulation
of the immune system(391 – 393). In the absence of an intestinal
microflora, the intestinal immune system is underdeveloped
and certain functional parameters, such as macrophage phago-
cytic ability and Ig production, are reduced(394). The intestinal
microflora may also be important in protection against atopic
disease(395 – 397), as demonstrated by Sudo et al. (398) who
showed that oral tolerance could be restored in germ-free
mice by reconstitution of the intestinal microflora with bifido-
bacteria at the neonatal stage. The intestinal microflora of
infants with atopic disease may differ from healthy infants,
with higher levels of clostridia and lower levels of bididobac-
teria in those with atopy(396).
The major function of the colonic microflora is the fer-
mentation of dietary substances that have passed undigested
through the small intestine and mucus produced within the
gut. Saccharolytic fermentation produces SCFA such as
acetate, propionate, butyrate, which are essential nutrients
for the colonocytes. The acids have an additional protective
benefit by lowering the pH of the intestinal lumen and by
their antimicrobial nature. Butyric acid (produced by bifido-
bacteria) is particularly important because it is the preferred
energy source of the epithelial cells in the colon and influ-
ences cell proliferation. It is thought to play a prominent
role in reducing the risk of colon cancer. By contrast,
some of the end products of proteolytic fermentation are
carcinogenic(399). A healthy, or balanced, intestinal micro-
flora is thought to be one that is predominantly saccharolytic
and that comprises significant numbers of bifidobacteria and
lactobacilli, such that their activities predominate over those
that may be harmful (e.g. clostridia, Staphylococcus aureus,
toxic E. coli, sulphate-reducers and certain Bacteroides
species)(10,400 – 402). Predominance of the latter groups of
bacteria may predispose the host to a number of clinical dis-
orders while increasing susceptibility to infections by transi-
ent enteropathogens(402).
Prebiotics
Description, sources, intakes and roles. The earliest definition
of a prebiotic was ‘a non-digestible food ingredient that
beneficially affects the host by selectively stimulating the
growth and/or activity of one or a limited number of bacteria
in the colon, and thus improves host health’(400). As research
has progressed, this definition has been refined. There are
now three accepted criteria for classifying a food ingredient
as a prebiotic.
(i) It should be non-digestible and non-absorbable – it
should be resistant to gastric acidity, hydrolysis by
intestinal brush border/pancreatic digestive enzymes
and gastrointestinal absorption. This makes ‘prebiotics’
completely available for intestinal microflora.
(ii) It should be selectively fermented by the intestinal
(mainly colonic) microflora, meaning that the growth
of some groups of bacteria is promoted (such as mem-
bers of the genus Bifidobacterium and Lactobacillus to
which most probiotics belong), others are not affected
(commensals such as Bacteroides, Fusarium) and still
others are suppressed (pathogenic organisms such as
Clostridium perfringens group, Salmonella, coliforms,
etc.). This selective interaction with intestinal fermenta-
tion also results in additional production of bacterial
metabolites (mainly SCFA such as acetate, propionate
and butyrate) that are absorbed in the blood of the
host and that interact in various ways (e.g. cell signal-
ling function, energy substrate for certain cell types)
with the host metabolism.
(iii) It should result in improvement of health-related mar-
kers, this being a direct consequence of the selective
interaction of prebiotics with intestinal fermentation.
Selective prebiotic interaction with the colonic bacterial
ecosystem represents a potentially important improvement of
the ‘external environment’ of the host. This observation is at
the basis of prebiotic action: prebiotics selectively interact
with resident intestinal microflora and thereby stimulate the
development and metabolic activity of organisms that belong
to bacterial genera to which the most common ‘probiotics’
also belong. Moreover, while being fermented, prebiotics
themselves are converted into biologically active molecules
that pass into the systemic environment. These metabolites
may be responsible for at least part of nutritional benefits
observed upon eating prebiotics.
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Inulin-type fructans are b(2-1)-linked fructose oligomers
with chain length ranging between three and hundred depend-
ing on the plant source(403). These complex carbohydrates are
present in most plants that occur in regions with a moderately
cold climate, characterised by periods of frost. As a
consequence, they are present not only in various foodplants
such as wheat, onions, garlic, chicory root, Jerusalem arti-
choke, etc., but also in fruits such as banana and tomato(404).
It has been estimated that via the consumption of food
plants, people consume between 1 and 4 g of inulin per day.
At present, inulin (with average chain length of ten) and its
partial hydrolysate oligofructose (average chain length of
four) are produced on a commercial scale via extraction
from the chicory root. The latter is also enzymatically syn-
thesised from sucrose. These products are used globally and
are applied in thousands of prepared food products such as
dairy, meat products, bakery, drinks, spreads, etc.
Galacto-oligosaccharides are enzymatically synthesised
from lactose mainly with transferase enzymes. The link
between the galactose moieties depends on the enzyme
system used. Galacto-oligosaccharides formed this way are
always short-chain molecules, with an average chain length
of three. They do not occur as such in nature, although
more complex but structurally related forms are present in
mammalian breast milk. Combined with long-chain inulin
fractions in milk formulations, they were shown to shift the
composition of the intestinal microflora of babies close to
that seen in breast-fed babies, and at the same time to
induce some immunological and anti-inflammatory
effects(405). There also is evidence that lactulose has prebiotic
properties. However, lactulose induces osmotic effects in the
intestine and acts as a laxative; consequently, it is not con-
sidered a useful food ingredient. There are various other can-
didate prebiotics for which evidence of prebiotic properties,
and certainly of potential health benefits, needs to be demon-
strated (isomalt, xylo-oligosaccharides, lactosucrose, soyabean
oligosaccharides, isomalto-oligosaccharides, etc.).
Prebiotics and experimental models of inflammation.
Inulin increased colonic lactobacilli and decreased cecal pH
in rats subjected to DSS-induced intestinal inflammation(406).
Inulin decreased the lesion score of the colonic mucosa,
which correlated very well with the reduction in intraluminal
release of inflammatory markers such as PGE2, TXB2 and
LTB4 and reduction in mucosal myeloperoxidase activity, a
marker of neutrophil accumulation within the tissue.
Schultz et al. (407) used two groups of HLA-B27 transgenic
rats that spontaneously develop immune-mediated colitis and
administered both a prebiotic (oligofructose) and probiotics
(L. acidophilus and Bifidobacterium lactis). They observed a
significant improvement of the histologic score, which was
correlated to prebiotic effects on the ceco-colonic microflora.
No probiotic bacterial strains were detected in the faeces. In a
similar model, Hoentjen et al. (408) administered a combination
of rapidly and slowly fermented fructoligosaccharides and
observed significant improvement of histologic score in the
cecum and colon. The authors observed a concomitant
improvement of inflammation markers such as a decrease in
IL-1b and an increase in TGF-b in the cecal tissue, and a
decrease in IFN-g in the mesenteric lymph nodes. These
effects again correlated with the impact of the dietary
prebiotics on cecal microflora (increased lactobacilli and
bifidobacteria), implying that the selective prebiotic interaction
with the intestinal flora was the basis of the observations.
A long-term (33 week) study of tumour formation and
immune function in AOM-treated rats revealed that prebiotics
(inulin), and a combination of prebiotics and probiotics, had
different effects on the gut-associated lymphoid tissue than
probiotics (Lactobacillus rhamnosus and B. lactis)(409).
Prebiotics and inflammatory conditions. Saavedra
et al. (410) showed reduced absenteeism, visits to the physician
and fever-associated diarrhoea in kindergarten-aged children
given prebiotics. These results have been recently confirmed
by Waligora-Dupriet(411) in 6- to 24-month-old infants who
were given a rapidly fermented prebiotic (oligofructose).
Reduced flatulence and diarrhoea, as well as vomiting and
fever – clinical observable consequences of inflammation –
were correlated with the typical selective prebiotic modification
of the intestinal flora (increased bifidobacteria and decreased
C. perfringens and Staphylococcus spp.). In another study, a
combination of galacto-oligosaccharides and long-chain inulin
decreased the incidence of atopic dermatitis in babies at high
risk(412). This effect was accompanied by a significant modifi-
cation of the composition of the intestinal microflora, character-
ised by higher Bifidobacterium spp. counts.
The anti-inflammatory effects of prebiotics have been inves-
tigated in patients suffering from inflammatory conditions.
Welters et al. (413) administered prebiotic chicory inulin to
familial adenomatous polyposis patients with ileal pouch-
anal anastomosis. There was a significant decrease in the
pouchitis disease activity index, confirmed by a decrease in
endoscopic score, which correlated with a modified faecal
short-chain fatty acid pattern (increased butyrate), which is a
direct consequence of selective interaction of the administered
prebiotics on intestinal flora. In an exploratory study, Casellas
et al. (414) administered either oligofructose-enriched inulin or
placebo (maltodextrin) to patients with active UC and on stan-
dard drug therapy (mesalazine). The prebiotic induced a faster
reduction in faecal calprotectin levels than that seen in the
control group. However, the rate of clinical remission was
similar in both placebo and prebiotic groups, as all patients
were on standard medical therapy with mesalazine. Furrie
et al. (27) administered a synbiotic composed of oligofruc-
tose-enriched inulin as a prebiotic and Bifidobacterium
longum as a probiotic to patients with UC. Sigmoidoscopy
scores were reduced in the synbiotic group as compared
with control. Mucosal mRNA levels for human b-defensins
(hBD2, hBD3 and hBD4) that are upregulated in active UC
were reduced in the synbiotic group as were inflammatory
cytokines such as TNF-a and IL1-a. Biopsies in the synbiotic
group had reduced inflammation and epithelial tissue was
regenerated. These anti-inflammatory effects of the synbiotic
combination were accompanied by a typical prebiotic-type
shift in composition of the intestinal microflora, characterised
by a 42-fold increase in numbers of Bifidobacterium spp.
associated with the mucosa.
Probiotics
Description, sources, normal intakes and roles. The FAO of
the UN (FAO) and the WHO have recognised the potential
of probiotic foods to provide health benefits and the use of
specific strains as safe supplements for human consumption.
Probiotics are defined as ‘live micro-organisms, which, when
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administered in sufficient amounts, confer a health benefit to
the host’(415). Lactic acid-producing bacteria, including
lactobacilli and bifidobacteria from human origin, are the
most commonly used probiotics. Foods containing probiotic
bacteria range from dairy fermented milk products to probiotic
powders, drinks or supplements in a lyophilised form. Probio-
tic effects can be direct or indirect through modulation of the
endogenous intestinal microflora or immune system. Their fate
in the gastrointestinal tract and their effects differ among
strains. For most of the strains, the effective dose is between
108 and 1010 cfu/d. Over the past decade, progress has been
made to provide scientifically and clinically valid evidence
on the impact of defined probiotic strains on human health.
Mechanisms of anti-inflammatory action. Experimental
models have revealed that probiotics differ greatly in their
mechanism of action, including modification of the local
microflora, epithelial barrier function, inflammation or the
immune system. Several probiotic bacteria adhere to mucosal
tissue in a strain-dependent manner, and by this transiently
enhance intestinal persistence and limit pathogen access to
the epithelium(416,417). Modulation of the gastrointestinal
microenvironment and inhibition of pathogen growth by pro-
biotics was demonstrated via the release of antimicrobial fac-
tors, such as defensins, bacteriocins, hydrogen peroxide, nitric
oxide, and SCFA and reduction in the luminal pH(418). Several
probiotics, such as L. acidophilus ATCC4356 or VSL#3, a
mixture of four different lactobacilli, three bifidobacteria
and Streptococcus thermophilus, have been shown to success-
fully preserve epithelial barrier function by induction of mucin
secretion, maintenance of cytoskeletal integrity, tight junction
protein phosphorylation or induction of heat-shock pro-
teins(419,420). The anti-inflammatory effect of a number of
probiotic bacteria, including lactobacilli and bifidobacteria,
seems to be based on their properties to directly interact
with intestinal epithelial cells, which have a key role in sen-
sing danger signals within the luminal microenvironment.
Some probiotic bacteria antagonise NF-kB activation by
degradation of IkB-a, or regulating the nuclear export of
NF-kB relA or NF-kB p65 subunits in a PPAR-g-dependent
manner(421,422). Also, expression of pro-inflammatory genes,
such as TNF-a, IL-1 or neutrophil-recruiting and activating
IL-8, which are transcriptionally regulated by NF-kB, was
shown to be decreased by several probiotic strains, including
VSL#3, Lactobacillus salivarius UCC118, Bifidobacterium
infantis 35 624 and Lactobacillus johnsonii La1(423). On the
other hand, in a recent study, B. lactis Bb12 has been shown
to target the toll-like receptor-2 signalling cascade, suggesting
that probiotics themselves may trigger innate pro-inflamma-
tory responses(424). Similar pro-inflammatory effects by the
activation of cytokines via toll-like receptor-2 are also
reported for probiotic strains L. rhamnosus GG(425) and
L. casei Shirota(426).
The induction of protective responses by probiotics is high-
lighted by the capacity of some strains (or their components)
to interact with gut-residing DC, e.g. via DC-SIGN, to induce
their maturation and predominant secretion of IL-10, which is
thought to favour the induction of regulatory T-cells(427). In
addition to regulatory T-cells, TGF-b signalling in IECs plays
a crucial role in maintaining mucosal immune homeostasis, as
TGF-b regulates expression of MHC class II molecules
and activity of metalloproteinases(428). Inhibition of TGF-b
signalling due to overexpression of the Smad7 protein, a
negative regulator of TGF-b, in IECs was shown to perpetuate
the production of pro-inflammatory cytokines(429). VSL#3
improved Th1-mediated experimental murine colitis by restor-
ing the cytokine balance through induction of IL-10 and TGF-b
bearing regulatory T-cells(430). Also, increased TGF-b signal-
ling induced by Bifidobacterium breve in preterm infants has
been associated with reduced expression of Smad 7(431).
Effects in inflammatory conditions
Inflammatory bowel diseases. A large body of evidence from
both experimental animal work and clinical observations
suggests that the enteric microflora may play an important
role in driving the abnormal inflammatory response in the
genetically susceptible host leading to chronic inflammation
in IBD. This has led to the interest and increasing scientific
evaluation of the use of probiotics as means to reconstitute
microbial and immunological homeostasis. Although there
are promising results for certain single probiotic strains in
experimental models of colitis, the picture is more variable
for the emerging human intervention studies using probiotic
micro-organisms or combinations thereof as therapeutic inter-
ventions in IBD. Combinations of several probiotic strains
have demonstrated efficacy in the control of pouchitis, an
inflammation of the ileal-anal anastomosis, surgically pro-
duced after colorectomy for UC. In the present context, a ran-
domised, placebo-controlled study with high dose of VSL#3
was shown to be effective in the maintenance of antibiotic-
induced remission in chronic pouchitis(432). By contrast, the
use of single probiotic strains, such as L. rhamnosus GG or
a combination of L. acidophilus and B. lactis did not show
clinical improvement in acute active pouchitis(433). In the
treatment of acute CD, in a small number of children with
mild to moderate disease activity, L. rhamnosus GG in combi-
nation with prednisone and immunomodulatory drugs showed
clinical improvement(434). However, in adult patients with
active CD L. rhamnosus GG was ineffective, although patients
were on tapering steroid diet regimen and received antibiotics
before starting the probiotic supplementation(435). In the
maintenance of surgically-induced remission, a few studies
with divergent outcomes are reported. In a randomised
placebo-controlled prospective study, oral administration of
L. rhamnosus GG for 1 year could neither prevent Crohn’s
recurrent lesions after surgery nor reduce their severity(436).
By contrast, administration of VSL#3 demonstrated efficacy
in preventing post-operative recurrence when compared to
mesalamine(31) up to 1-year post-surgery. Two recent studies
have shown no benefit from L. johnsonii La1 supplementation
for prophylaxis of post-operative recurrence of inflammatory
lesions in adult CD patients(437,438). The therapeutic efficacy
of E. coli Nissle 1917 in maintaining remission in UC patients
has been demonstrated in human trials (equally efficacious as
the standard mesalazine), while the same probiotic treatment
lacked convincing data in active disease(439,440). A random-
ised, open-label, multicentre trial showed that VSL#3 in com-
bination with low-dose balsalazide (a prodrug of mesalazine)
was more effective than standard doses of basalazide or mesa-
lazine monotherapy in the treatment of acute mild to moderate
UC(441). The efficacy of Lactobacillus GG in combination
with mesazaline to sustain remission in patients
with quiescent UC has been shown recently(442). The role of
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bifidobacteria in medically induced remission of UC was eval-
uated in a small human trial showing less relapses in the bifi-
dobacteria-supplemented patients during a 2-month follow-up.
Inflammatory activity in the colon, assessed by NF-kB, IkB
and pro-inflammatory cytokine analysis (IL-1b, TNF-a), was
significantly decreased in the probiotic treatment group(443).
Similarly, a fermented milk product with probiotic bifidobac-
teria had a positive effect on UC patients(444). Finally, a ran-
domised controlled pilot trial with B. longum in combination
with a inulin-type prebiotics showed resolution of inflam-
mation in UC patients and reduced inflammatory activity in
the mucosal tissue (less TNF-a, IL-1a, and defensins)(27).
Taken together, the human study results demonstrate that
the therapeutic intervention with probiotics in IBD is encoura-
ging, but not as straightforward as expected from experiences
with experimental animal models of colitis. Single probiotic
strains have been demonstrated to successfully prevent or
treat experimental colitis. However, the overall picture of pro-
biotic therapy in human IBD is by far more complex. To date
only a few randomised, double-blind placebo-controlled trials
are published, which (so far) impose the conclusion that high
doses of probiotics and most likely a combination of different
lactobacilli and bifidobacteria (or prebiotics) are more effec-
tive in decreasing clinical inflammatory score and maintaining
patients in medically induced remission than a single probiotic
strain. Future research might identify clinical phenotypes of
IBD patients (based on insights in genetic predisposition,
microbiota asset and immune response) that are likely to
respond to probiotic therapy. As a result of the emerging
understanding of microbial activities in different parts of the
intestine (in health and disease) and increasing scientific evi-
dence of probiotic mechanisms, an educated and targeted
selection of specific probiotic strains and combinations thereof
will be possible in the future to apply probiotic therapy in con-
junction with medical treatments to maintain clinical
remission.
Rheumatoid arthritis. The treatment of experimental
adjuvant arthritis with a combination of methotrexate and
lyophilised Enterococcus faecium enriched with organic sel-
enium was shown to be beneficial in reducing inflammation
(serum albumin, serum nitrite/nitrate concentrations, changes
in hind paw swelling, arthrogram score) and bone erosion in
rats(445). However, the probiotic alone was not effective.
One small-scale human trial on L. rhamnosus GG in human
RA did not show a clinical benefit(446).
Atopic eczema. Studies with animal models reveal that
several lactobacilli strains including plantarum and casei
have the potential to inhibit pro-allergic immune
responses(447 – 450). Infants with atopy show a different profile
of gut microflora than non-atopic controls(64,451) and a low
number of bifidobacteria and lactobacilli predicted atopy
development in Finnish infants(396,452). Studies in pregnant
women and infants have demonstrated that probiotics
(L. casei GG) lower the risk of development of atopic
eczema in infants(452 – 455), this effect being associated with
lowered levels of inflammatory markers in faeces. Rosenfeldt
et al. (457) showed that the combination of L. rhamnosus and
L. reuteri reduced atopy severity and serum eosinophil
cationic protein in 13-year-old atopic children.
CVD. Probiotic interventions in CVD are restricted to a
few reports on modulation of risk factors associated with
atherosclerosis, such as antioxidant defences or atherosclerotic
lipid profiles. Hlivak et al. (458) showed a reduction in LDL
cholesterol after administration of Enterococcus faecium
M-74 enriched with selenium. No significant alterations in
HDL and TAG were observed. A second study reported a
reduction in CVD risk factors (systolic blood pressure;
leptin, fibrinogen, F(2)-isoprostanes, IL-6) in hyper-cholester-
olaemic patients (heavy smokers) after consumption of
L. plantarum 299v. Monocytes from the probiotic-treated
group showed significantly reduced adhesion to native and
stimulated human umbilical vein endothelial cells(459).
Conclusions
Inflammation is a stereotypical physiological response to infec-
tions and tissue injury; it initiates pathogen killing as well as
tissue repair processes and helps to restore homeostasis at
infected or damaged sites. Acute inflammatory reactions are
usually self-limiting and resolve rapidly. This involves the acti-
vation of negative feedback mechanisms such as the secretion of
immunoregulatory cytokines (e.g. IL-10 and TGF-b), inhibition
of pro-inflammatory signalling cascades, receptor shedding (e.g.
TNF-R) and activation of regulatory cells. Thus, regulated
inflammatory responses are essential to remain healthy and
maintain homeostasis. However, inflammatory responses that
fail to regulate themselves can become chronic and contribute
to the perpetuation and progression of disease.
Characteristics typical of chronic inflammatory responses
underlying the pathophysiology of several disorders include
loss of barrier function, responsiveness to a normally benign
stimulus, infiltration of inflammatory cells into compartments
where they are not normally found in such high numbers, and
overproduction of oxidants, cytokines, chemokines, eicosa-
noids and matrix metalloproteinases (Table 1). The levels of
these mediators amplify the inflammatory response, are
destructive and contribute to the clinical symptoms. Why res-
olution of inflammation is absent or abnormal in so many
pathophysiological processes remains largely unknown.
Different factors including Western lifestyle (pollution,
stress) and diet (low intake of fruits and vegetables, polyphe-
nols and other antioxidants) have been postulated to reduce the
efficiency of antioxidant defences, shifting the redox balance
and thus increase the risk of inflammatory responses becoming
chronic (Fig. 6). This may partially explain why many inflam-
matory disorders are more prevalent in Western countries and
that in many cases prevalence increases with the level of wes-
ternisation(460).
Various dietary components have been suggested to impact
on inflammatory conditions, but the number of studies asses-
sing therapeutic benefits of dietary interventions in established
inflammatory disorders is still fairly limited. There is good
evidence of efficacy of n-3 PUFA in RA with less strong evi-
dence in CD and psoriasis and rather weak evidence in UC,
asthma and eczema (Table 3). These fatty acids are also ben-
eficial in established CVD, but the extent to which this is
attributable to their anti-inflammatory effects is not clear.
Dietary antioxidants represent a crucial line of defence against
oxidative and inflammatory insult common to the develop-
ment of many pathological disorders and a potentially protec-
tive role of dietary antioxidants in disease prevention is
supported by much basic scientific evidence. The common
Inflammatory processes and nutrition S31
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509377867
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:35:15, subject to the Cambridge Core terms of use, available at
mechanism of oxidative stress development in most of the
here-described pathologies make the role of dietary antioxi-
dants crucial for an optimal preventive action. Despite these
considerations, trials in patients suggest little clinical benefit
from antioxidant vitamins and polyphenolics in the disorders
considered here, although there is some evidence for benefit
from vitamin E in RA (Table 3). In order to optimise the
levels of protection against oxidative and inflammatory
stress, the concept of antioxidant efficiency should be
re-evaluated investigating the synergistic interactions among
Fig. 6. Proposed link between Western lifestyle and chronic inflammation. Different factors associated with a Western lifestyle such as pollution, (psychological)
stress and an unbalanced diet (low intake of fruits and vegetables, polyphenols and other antioxidants) reduce the efficiency of antioxidant defences, shifting the
redox balance thus increasing the risk of inflammatory responses becoming chronic.
Table 3. Summary of the effects of VLC n-3 PUFA, antioxidant vitamins, flavonoids, prebiotics and probiotics on immune/
inflammatory markers and conditions
Effect on VLC n-3 PUFA Antioxidant vitamins Flavonoids Prebiotics Probiotics
Epithelial barrier ? ? ? Yes (gut) Yes (gut)
Cell function
Th1 v. Th2 balance Yes Yes Yes Yes Yes
T cell function Yes Yes Yes Yes Yes
Treg cell function ? ? ? ? Yes
NK cell function ? ? Yes Yes Yes
Dendritic cell function Yes Yes ?Yes Yes Yes
Macrophage function Yes Yes Yes Yes Yes
PMN function Yes Yes Yes Yes Yes
Cellular recruitment
Adhesion molecule expression Yes Yes Yes ? ?
Chemokine production Yes Yes Yes ? ?
Inflammatory mediator production
Inflammatory cytokines Yes Yes Yes Yes Yes
Arachidonic acid-derived eicosanoids Yes Yes Yes ?Yes ?
Matrix metalloproteinases Yes ? Yes ? ?
Transcription factors
NF-kB Yes Yes Yes Yes Yes
PPAR-g Yes ? Yes ? ?
Others Yes Yes Yes ? ?
Human disease outcome
Crohns Disease ?Yes ? ? Yes Yes
Ulcerative colitis ?Yes ? ? Yes Yes
COPD ?Yes Yes ? ? ?
Asthma ?Yes ?Yes ? ? ?
Eczema ?Yes ? ? Yes Yes
Psoriasis Yes ? ? ? ?
Rheumatoid arthritis Yes ? ? ? ?
Atherosclerosis Yes ?Yes ?Yes ? ?
Yes indicates an effect has been demonstrated; ?Yes indicates effects on a clinical condition have been shown but that these are not conclusive;
? indicates not known.
Th, helper T-cell; NK, natural killer; PMN, polymorphonuclear cell; COPD, chronic obstructive pulmonary disease.
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components of the redox network of the body. Efforts should
be focused on the identification of the composition of redox
network and of the mechanism(s) underlying its homeostatic
modulation. The link between inflammatory and antioxidant
status needs to be more deeply investigated with well-tailored
in vivo studies. Particular attention needs to be paid towards
the interactions between the two systems in healthy subjects
and during the different phases of the inflammatory response
in the development of pathologies.
The intestinal flora is in intimate contact with the most
developed immunological organ of the human body imbedded
in the intestinal membranes. There is a continuous intensive
interaction established between the intestinal bacterial ecosys-
tem and the host. The composition of this ecosystem can be
improved either by selectively stimulating the resident bac-
terial populations that contribute to the protection against
inflammatory processes (with prebiotics) or by adding external
bacteria that are known to protect against inflammation
(certain probiotics). Another important aspect is to locally
stimulate the metabolic activity in a selective way (with
prebiotics) so as to optimise the interaction with the immune
system. There is evidence that consumption of prebiotics
leads to clinical improvement in UC and CD, with limited
or no evidence in the other conditions described here (Table
3). There is good evidence that probiotics bring about clini-
cally relevant improvements in UC and CD and protect against
development of atopic dermatitis in infancy (Table 3). There is
little or no evidence of efficacy in the other conditions
described here. It is possible that nutrition may have a
bigger impact on prevention rather than treatment of chronic
inflammatory conditions. Studies with different dietary com-
ponents in various models and clinical settings have demon-
strated that dietary compounds modulate pathways involved
in controlling inflammation including intracellular signalling
pathways, transcription factor activity and generation of
inflammatory mediators (Table 3). Bioavailability and tissue
accumulation of antioxidant vitamins and n-3 PUFA are not
a problem, but low bioavailability of flavanoids and the lack
of studies showing a specific accumulation of flavonoids in
blood and target tissues raise concerns about their role as
anti-inflammatory agents in vivo. More studies and a larger
body of evidence are needed for these phytochemicals.
By reinforcing the regulatory pathways controlling inflam-
matory responses, nutrition may contribute to the robustness
of homeostatic control and may help to reduce the risk that
acute inflammatory responses, which initiate pathogen killing
as well as tissue repair processes, derail into uncontrolled
chronic inflammatory responses that contribute to perpetuation
and progression of disease (Fig. 7). Nutrition may thus help to
widen the boundaries within which the inflammatory
responses can deal with the challenges posed by exposure to
pathogens, allergens, toxins, tissue damage, etc., without spir-
alling into degenerative chronic inflammatory responses
(Fig. 7). Among the dietary components considered here,
long-chain n-3 PUFA, antioxidant vitamins, plant flavonoids,
prebiotics and probiotics all have the potential to modulate
predisposition to chronic inflammatory conditions and may
have a role in their therapy.
There is a clear need for more good-quality studies asses-
sing the impact of nutrition and specific nutrients on chronic
inflammatory responses. Ideally, such studies should assess
relevant clinical symptoms of chronic inflammation as well
as selected markers of inflammation. Not only will this help
to understand the underlying mechanism, but it will also
help to predict which other inflammatory conditions may ben-
efit from particular (combinations of) anti-inflammatory diet-
ary compounds. The putative effect of nutritional
compounds in strengthening the regulatory networks control-
ling inflammatory responses should be studied in more detail
using conditions and models in which a stress is applied to
the homeostatic control of inflammation.
Acknowledgements
This work was commissioned by the Nutrition and Immunity
Task Force of the European branch of the International Life
Sciences Institute (ILSI Europe). Industry members of this
task force are: FrieslandCampina, Groupe Danone, Nestle´,
Seven Seas, Su¨dzucker/BENEO Group, Royal Cosun,
Fig. 7. Concept of how nutrients might act in an anti-inflammatory manner. By reinforcing the regulatory pathways controlling inflammatory responses, nutrition
may contribute to the robustness of homeostatic control and may help to reduce the risk that acute inflammatory responses persist as uncontrolled chronic inflam-
matory responses. Nutrition may thus help to widen the boundaries within which the inflammatory responses can deal with the challenges posed by exposure to
pathogens, allergens, toxins, tissue damage, etc., without spiralling into degenerative chronic inflammatory responses.
Inflammatory processes and nutrition S33
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509377867
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:35:15, subject to the Cambridge Core terms of use, available at
Unilever, Valio, Yakult. The opinions expressed herein are
those of the authors and do not necessarily represent the
views of ILSI Europe.
Author contributions
Authors drafted sections of the review as follows: F. G. (Gut:
Celiac disease), S. M. (Gut: Inflammatory bowel diseases),
M. L. (Lungs: Airways and allergic inflammation), W. v. E.
(Joints: Rheumatoid arthritis), P. S. F. (Skin: Atopic eczema
and psoriasis), G. A. F. (The vascular wall: CVD), G. S. F.
(Adipose tissue: Obesity), P. C. C. (Fatty acids), B. M. W.- R.
(Antioxidant vitamins), M. S. (Flavonoids), J. v. L.
(Prebiotics), J. Z. and S. B. (Probiotics). All authors contributed
to discussions at the Workshop and had input into the final
version of the review. P. C. C. chaired the workshop and led
the writing of the review.
Conflict of interest statement
P. C. C. has research funding from Beneo-Orafti and B. Braun
Melsungen, at the time of drafting the review was a consultant
to Equazen and Royal Dutch Numico and has received
speaking fees from Solvay Healthcare, B. Braun Melsungen,
Fresenius Kabi and Seven Seas Limited. R. A. is an employee
of Unilever. J.- M. A. and R. B.- S. are employees of Danone
Vitapole. S. B. is an employee of Nestle. G. A. F. has received
speaking fees from Pfizer, Fournier, Astra-Zeneca and Roche.
G. F. is an employee of Curax. F. G. is a member of the Beneo
Scientific Committee sponsored by Orafti and of the Cimizia
Advisory Board sponsored by UCB Pharma. P. D. M. is an
employee of Sensus. At the time of the Workshop, L. M.
was an employee of Royal Numico, now known as Danone
Research Centre for Specialised Nutrition. M. S. has research
funding from Coca-Cola and BPW. J. v. L. is an employee
of Su¨dzucker/BENEO Group. W. V. D. is an employee of
Seven Seas Limited. S. V. is an employee of ILSI Europe.
B. M. W.- R. has a research collaboration with DSM Nutritional
Products. J. Z. is an employee of Yakult. P. S. F., G. S. F., S. M.
and W. v. E. have no conflicts of interest to declare.
References
1. Aderem A & Ulevitch RJ (2000) Toll-like receptors in the
induction of the innate immune response. Nature 406,
782–787.
2. Elewaut D, DiDonato JA, Kim JM, et al. (1999) NF-kappa B is
a central regulator of the intestinal epithelial cell innate
immune response induced by infection with enteroinvasive
bacteria. J Immunol 163, 1457–1466.
3. Maaser C & Kagnoff MF (2002) Role of the intestinal epi-
thelium in orchestrating innate and adaptive mucosal immu-
nity. Z Gastroenterol 40, 525–529.
4. Haller D, Bode C, Hammes WP, et al. (2000) Non-pathogenic
bacteria elicit a differential cytokine response by intestinal
epithelial cell/leucocyte co-cultures. Gut 47, 79–87.
5. Borruel N, Casellas F, Antolin M, et al. (2003) Effects of non-
pathogenic bacteria on cytokine secretion by human intestinal
mucosa. Am J Gastroenterol 98, 865–870.
6. Brandtzaeg P, Farstad IN, Johansen FE, et al. (1999) The
B-cell system of human mucosae and exocrine glands.
Immunol Rev 171, 45–87.
7. Shanahan F (1994) The intestinal immune system. In
Physiology of the Gastrointestinal Tract, pp. 643–684 [LR
Johnson, J Christensen, E Jacobsen and JH Walsh, editors].
New York: Raven Press.
8. Scott H, Rognum TO, Midvedt T, et al. (1985) Age related
changes of human serum antibodies to dietary and colonic bac-
terial antigens measured by an enzyme linked immunosorbent
assay. Acta Pathol Microbiol Immunol Scand 93, 65–70.
9. Brandtzaeg PE (2002) Current understanding of gastrointesti-
nal immunoregulation and its relation to food allergy. Ann N
Y Acad Sci 964, 13–45.
10. Cummings JH, Antoine JM, Azpiroz F, et al. (2004) PASS-
CLAIM- Gut health and immunity. Eur J Nutr 43, II118–II173.
11. Mulder CJ & Cellier C (2005) Coeliac disease: changing
views. Best Pract Res Clin Gastroenterol 19, 313–321.
12. Marsh MN (1992) Gluten, major histocompatibility complex,
and the small intestine. A molecular and immunobiologic
approach to the spectrum of gluten sensitivity (‘celiac
sprue’). Gastroenterology 102, 330–354.
13. Rostom A, Dube C, Cranney A, et al. (2005) The diagnostic
accuracy of serologic tests for celiac disease: a systematic
review. Gastroenterology 128, S38–S46.
14. Rewers M (2005) Epidemiology of celiac disease: what are the
prevalence, incidence, and progression of celiac disease?
Gastroenterology 128, S47–S51.
15. Dube C, Rostom A, Sy R, et al. (2005) The prevalence of
celiac disease in average-risk and at-risk Western European
populations: a systematic review. Gastroenterology 128,
S57–S67.
16. Liu E, Rewers M & Eisenbarth GS (2005) Genetic testing:
who should do the testing and what is the role of genetic test-
ing in the setting of celiac disease? Gastroenterology 128,
S33–S37.
17. Ivarsson A (2005) The Swedish epidemic of coeliac disease
explored using an epidemiological approach – some lessons
to be learnt. Best Pract Res Clin Gastroenterol 19, 426–440.
18. Kagnoff MF (2005) Overview and pathogenesis of celiac dis-
ease. Gastroenterology 128, S10–S18.
19. Sollid LM & Khosla C (2005) Future therapeutic options for
celiac disease. Nat Clin Pract Gastroenterol Hepatol 2,
140–147.
20. Duchmann R, Kaiser I, Hermann E, et al. (1995) Tolerance
exists towards resident intestinal flora but is broken in active
inflammatory bowel disease (IBD). Clin Exp Immunol 102,
448–455.
21. Farrell RJ & Peppercorn MA (2002) Ulcerative colitis. Lancet
359, 331–340.
22. Shanahan F (2002) Crohn’s disease. Lancet 359, 62–69.
23. Carter MJ, Lobo AJ & Travis SP (2004) Guidelines for the
management of inflammatory bowel disease in adults. Gut
53, Suppl. 5, V1–V16.
24. Ogura Y, Bonen DK, Inohara N, et al. (2001) A frameshift
mutation in NOD2 associated with susceptibility to Crohn’s
disease. Nature 411, 603–606.
25. Taurog JD, Richardson JA, Croft JT, et al. (1994) The
germfree state prevents development of gut and joint inflamma-
tory disease in HLA-B27 transgenic rats. J Exp Med 180,
2359–2364.
26. Macfarlane S, Furrie E, Kennedy A, et al. (2005) Mucosal bac-
teria in ulcerative colitis. Br J Nutr 93, S67–S72.
27. Furrie E, Macfarlane S, Kennedy A, et al. (2005) Synbiotic
therapy (Bifidobacterium longum/Synergy 1) initiates resol-
ution of inflammation in patients with active ulcerative colitis:
a randomised controlled pilot trial. Gut 54, 242–249.
28. Seksik P, Rigottier-Gois L, Gramet G, et al. (2003) Alterations
of the dominant faecal bacterial groups in patients with
Crohn’s disease of the colon. Gut 52, 237–242.
P. C. Calder et al.S34
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509377867
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:35:15, subject to the Cambridge Core terms of use, available at
29. Macfarlane S, Furrie E, Cummings JH, et al. (2004) Chemo-
taxonomic analysis of bacterial populations colonizing the
rectal mucosa in patients with ulcerative colitis. Clin Infect
Dis 38, 1690–1699.
30. Famularo G, Moretti S, Marcellini S, et al. (1997) Stimulation
of immunity by probiotics. In Probiotics: therapeutic and
Other Beneficial Effects, pp. 133–161 [R Fuller, editor].
London: Chapman & Hall.
31. Gionchetti P, Rizzello F, Venturi A, et al. (2000) Oral bacter-
iotherapy as maintenance treatment in patients with chronic
pouchitis: a double-blind, placebo-controlled trial. Gastro-
enterology 119, 305–309.
32. Musso A, Dentelli P, Carlino A, et al. (2005) Signal transdu-
cers and activators of transcription 3 signaling pathway: an
essential mediator of inflammatory bowel disease and other
forms of intestinal inflammation. Inflamm Bowel Dis 11,
91–98.
33. von Lampe B, Barthel B, Coupland SE, et al. (2000) Differen-
tial expression of matrix metalloproteinases and their tissue
inhibitors in colon mucosa of patients with inflammatory
bowel disease. Gut 47, 63–73.
34. Rahman I, Biswas SK & Kode A (2006) Oxidant and
antioxidant balance in the airways and airway diseases. Eur
J Pharmacol 533, 222–239.
35. Hargreave FE & Parameswaran K (2006) Asthma, COPD and
bronchitis are just components of airway disease. Eur Respir J
28, 264–267.
36. Elias J (2004) The relationship between asthma and COPD.
Lessons from transgenic mice. Chest 126, 111S–116S.
37. Agusti AG, Noguera A, Sauleda J, et al. (2003) Systemic
effects of chronic obstructive pulmonary disease. Eur Respir
J 21, 347–360.
38. Agusti AG (2005) Systemic effects of chronic obstructive
pulmonary disease. Proc Am Thorac Soc 2, 367–370.
39. Gan WQ, Man SF, Senthilselvan A, et al. (2004) Association
between chronic obstructive pulmonary disease and systemic
inflammation: a systematic review and a meta-analysis.
Thorax 59, 574–580.
40. Phipatanakul W (2005) Allergic rhinoconjunctivitis: epide-
miology. Immunol Allergy Clin North Am 25, 263–281.
41. Scadding G & Mitchell D (2004) Rhinitis and sinusitis. In
Clinical Respiratory Medicine, pp. 339–350 [RK Albert,
SG Spiro and JR Jett, editors]. Philadelphia, PA: Mosby.
42. Strachan D, Sibbald B, Weiland S, et al. (1997) Worldwide
variations in prevalence of symptoms of allergic rhinoconjunc-
tivitis in children: the International Study of Asthma and Aller-
gies in Childhood (ISAAC). Pediatr Allergy Immunol 8,
161–176.
43. Maziak W, Behrens T, Brasky TM, et al. (2003) Are asthma
and allergies in children and adolescents increasing? Results
from ISAAC phase I and phase III surveys in Munster,
Germany. Allergy 58, 572–579.
44. Postma DS, Kerstjens HAM & Ten Hacken NHT (2004)
Asthma: Epidemiology and risk factors. In Clinical Respiratory
Medicine, pp. 457–465 [RK Albert, SG Spiro and JR Jett,
editors]. Philadelphia, PA: Mosby.
45. The International Study of Asthma and Allergies in Childhood
(ISAAC) Steering Committee (1998) Worldwide variations in
the prevalence of asthma symptoms: the International Study of
Asthma and Allergies in Childhood (ISAAC). Eur Respir J 12,
315–335.
46. The International Study of Asthma and Allergies in Childhood
(ISAAC) Steering Committee (1998) Worldwide variation in
prevalence of symptoms of asthma, allergic rhinoconjunctivi-
tis, and atopic eczema: ISAAC. Lancet 351, 1225–1232.
47. Russel G (2006) The childhood asthma epidemic. Thorax 61,
276–278.
48. Zollner IK, Weiland SK, Piechotowski I, et al. (2005) No
increase in the prevalence of asthma, allergies, and atopic sen-
sitisation among children in Germany: 1992–2001. Thorax 60,
545–548.
49. Lodrup Carlsen KC, Haland G, Devulapalli CS, et al. (2006)
Asthma in every fifth child in Oslo, Norway: a 10-year
follow up of a birth cohort study. Allergy 61, 454–460.
50. Murray CJ & Lopez AD (1997) Mortality by cause for eight
regions of the world: Global Burden of Disease Study.
Lancet 349, 1269–1276.
51. MacNee W (2004) Chronic obstructive pulmonary disease:
Epidemiology, pathophysiology, and clinical evaluation. In
Clinical Respiratory Medicine, pp. 415–435 [RK Albert,
SG Spiro and JR Jett, editors]. Philadelphia, PA: Mosby.
52. Leung R & Ho P (1994) Asthma, allergy, and atopy in three
South-East Asian populations. Thorax 49, 1205–1210.
53. von Mutius E, Martinez FD, Fritzsch C, et al. (1994) Preva-
lence of asthma and atopy in two areas of West and East
Germany. Am J Respir Crit Care Med 149, 358–364.
54. Strachan DP (1989) Hay fever, hygiene, and household size.
BMJ 299, 1259–1260.
55. Umetsu DT (2004) Flu strikes the hygiene hypothesis. Nat Med
10, 232–234.
56. Umetsu DT (2005) Revising the immunological theories of
asthma and allergy. Lancet 365, 98–100.
57. Cullinan P (2006) Childhood allergies, birth order and family
size. Thorax 61, 3–5.
58. von Mutius E (2000) The environmental predictors of allergic
disease. J Allergy Clin Immunol 105, 9–19.
59. von Mutius E, Martinez FD, Fritzsch C, et al. (1994) Skin test
reactivity and number of siblings. BMJ 308, 692–695.
60. Ball TM, Castro-Rodriguez JA, Griffith KA, et al. (2000)
Siblings, day-care attendance, and the risk of asthma and
wheezing during childhood. N Engl J Med 343, 538–543.
61. Riedler J, Braun-Fahrlander C, Eder W, et al. (2001) Exposure
to farming in early life and development of asthma and allergy:
a cross-sectional survey. Lancet 358, 1129–1133.
62. Floistrup H, Swartz J, Bergstrom A, et al. (2006) Allergic dis-
ease and sensitization in Steiner school children. J Allergy Clin
Immunol 117, 59–66.
63. Platts-Mills T, Vaughan J, Squillace S, et al. (2001) Sensitis-
ation, asthma, and a modified Th2 response in children exposed
to cat allergen: a population-based cross-sectional study. Lancet
357, 752–756.
64. Bjorksten B, Naaber P, Sepp E, et al. (1999) The intestinal
microflora in allergic Estonian and Swedish 2-year-old
children. Clin Exp Allergy 29, 342–346.
65. McKeever TM, Lewis SA, Smith C, et al. (2002) The importance
of prenatal exposures on the development of allergic disease: a
birth cohort study using the West Midlands General Practice
Database. Am J Respir Crit Care Med 166, 827–832.
66. Wong GW, Ko FW, Hui DS, et al. (2004) Factors associated with
difference in prevalence of asthma in children from three cities
in China: multicentre epidemiological survey. BMJ 329, 486.
67. Chen R, Hu Z & Seaton A (2004) Eating more vegetables
might explain reduced asthma symptoms. BMJ 328, 1380.
68. Mickleborough TD & Rundell KW (2005) Dietary polyunsatu-
rated fatty acids in asthma- and exercise-induced bronchocon-
striction. Eur J Clin Nutr 59, 1335–1346.
69. Beuther DA & Sutherland ER (2007) Overweight, obesity, and
incident asthma: a meta-analysis of prospective epidemiologic
studies. Am J Respir Crit Care Med 175, 661–666.
70. Shaaban R, Leynaert B, Soussan D, et al. (2007) Physical
activity and bronchial hyperresponsiveness: European Commu-
nity Respiratory Health Survey II. Thorax 62, 403–410.
71. Umetsu DT, McIntire JJ, Akbari O, et al. (2002) Asthma: an
epidemic of dysregulated immunity. Nat Immunol 3, 715–720.
Inflammatory processes and nutrition S35
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509377867
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:35:15, subject to the Cambridge Core terms of use, available at
72. Watson L, Margetts B, Howarth P, et al. (2002) The association
between diet and chronic obstructive pulmonary disease in sub-
jects selected from general practice. Eur Respir J 20, 313–318.
73. Kingma PS & Whitsett JA (2006) In defense of the lung: surfac-
tant protein A and surfactant protein D. Curr Opin Pharmacol 6,
277–283.
74. Van Wetering S, Hiemstra PS & Rabe KF (2004) Asthma: cell
biology. In Clinical Respiratory Medicine, pp. 467–473
[RK Albert, SG Spiro and JR Jett, editors]. Philadelphia, PA:
Mosby.
75. Akbari O, Stock P, Meyer E, et al. (2003) Essential role of
NKT cells producing IL-4 and IL-13 in the development of
allergen-induced airway hyperreactivity. Nat Med 9, 582–588.
76. Erin EM, Leaker BR, Nicholson GC, et al. (2006) The effects
of a monoclonal antibody directed against tumour necrosis
factor-a (TNF-a) in asthma. Am J Respir Crit Care Med
174, 763–771.
77. Ray A & Cohn L (1999) Th2 cells and GATA-3 in asthma: new
insights into the regulation of airway inflammation. J Clin Invest
104, 985–993.
78. Barrios RJ, Kheradmand F, Batts L, et al. (2006) Asthma:
pathology and pathophysiology. Arch Pathol Lab Med 130,
447–451.
79. Steinman L (2007) A brief history of T(H)17, the first major
revision in the T(H)1/T(H)2 hypothesis of T cell-mediated
tissue damage. Nat Med 13, 139–145.
80. Hansen G, Berry G, DeKruyff RH, et al. (1999) Allergen-
specific Th1 cells fail to counterbalance Th2 cell-induced
airway hyperreactivity but cause severe airway inflammation.
J Clin Invest 103, 175–183.
81. Randolph DA, Carruthers CJ, Szabo SJ, et al. (1999) Modu-
lation of airway inflammation by passive transfer of allergen-
specific Th1 and Th2 cells in a mouse model of asthma. J
Immunol 162, 2375–2383.
82. Heaton T, Rowe J, Turner S, et al. (2005) An immunoepide-
miological approach to asthma: identification of in vitro
T-cell response patterns associated with different wheezing
phenotypes in children. Lancet 365, 142–149.
83. Saetta M, Di SA, Turato G, et al. (2005) CD8 þ T-lympho-
cytes in peripheral airways of smokers with chronic obstruc-
tive pulmonary disease. Am J Respir Crit Care Med 157,
822–826.
84. van Oosterhout AJ & Bloksma N (2005) Regulatory
T-lymphocytes in asthma. Eur Respir J 26, 918–932.
85. Finotto S, Neurath MF, Glickman JN, et al. (2002) Develop-
ment of spontaneous airway changes consistent with human
asthma in mice lacking T-bet. Science 295, 336–338.
86. Nassenstein C, Schulte-Herbruggen O, Renz H, et al. (2006)
Nerve growth factor: the central hub in the development of
allergic asthma? Eur J Pharmacol 533, 195–206.
87. De Swert KO & Joos GF (2006) Extending the understanding
of sensory neuropeptides. Eur J Pharmacol 533, 171–181.
88. Tracey KJ (2005) Fat meets the cholinergic antiinflammatory
pathway. J Exp Med 202, 1017–1021.
89. Van Eerdewegh P, Little RD, Dupuis J, et al. (2002)
Association of the ADAM33 gene with asthma and bronchial
hyperresponsiveness. Nature 418, 426–430.
90. Fahy JV, Corry DB & Boushey HA (2000) Airway inflam-
mation and remodeling in asthma. Curr Opin Pulmonary
Med 6, 15–20.
91. Lee KS, Park HS, Park SJ, et al. (2006) An antioxidant modu-
lates expression of receptor activator of NF-kappaB in asthma.
Exp Mol Med 38, 217–229.
92. Fujisawa T (2005) Role of oxygen radicals on bronchial
asthma. Curr Drug Targets Inflamm Allergy 4, 505–509.
93. Dworski R (2000) Oxidant stress in asthma. Thorax 55,
Suppl. 2, S51–S53.
94. Chan RC, Wang M, Li N, et al. (2006) Pro-oxidative diesel
exhaust particle chemicals inhibit LPS-induced dendritic cell
responses involved in T-helper differentiation. J Allergy Clin
Immunol 118, 455–465.
95. Vinzents PS, Moller P, Sorensen M, et al. (2005) Personal
exposure to ultrafine particles and oxidative DNA damage.
Environ Health Perspect 113, 1485–1490.
96. Lee CG, Link H, Baluk P, et al. (2004) Vascular endothelial
growth factor (VEGF) induces remodeling and enhances
TH2-mediated sensitization and inflammation in the lung.
Nat Med 10, 1095–1103.
97. Kharitonov SA & Barnes PJ (2002) Biomarkers of some
pulmonary diseases in exhaled breath. Biomarkers 7, 1–32.
98. Kostikas K, Papatheodorou G, Psathakis K, et al. (2003)
Oxidative stress in expired breath condensate of patients with
COPD. Chest 124, 1373–1380.
99. Paredi P, Kharitonov SA & Barnes PJ (2002) Analysis of
expired air for oxidation products. Am J Respir Crit Care
Med 166, S31–S37.
100. Shapiro SD (2003) Proteolysis in the lung. Eur Respir J Suppl
44, 30s–32s.
101. D’Armiento J, Dalal SS, Okada Y, et al. (1992) Collagenase
expression in the lungs of transgenic mice causes pulmonary
emphysema. Cell 71, 955–961.
102. van Eden W, van der Zee R & Prakken B (2005) Heat-shock
proteins induce T-cell regulation of chronic inflammation.
Nat Rev Immunol 5, 318–330.
103. van Amelsfort JM, Jacobs KM, Bijlsma JW, et al. (2004)
CD4(þ )CD25(þ) regulatory T cells in rheumatoid arthritis:
differences in the presence, phenotype, and function between
peripheral blood and synovial fluid. Arthritis Rheum 50,
2775–2785.
104. Lee DM & Weinblatt ME (2001) Rheumatoid arthritis. Lancet
358, 903–911.
105. Pincus T & Callahan LF (1989) Reassessment of twelve tra-
ditional paradigms concerning the diagnosis, prevalence, mor-
bidity and mortality of rheumatoid arthritis. Scand J
Rheumatol Suppl 79, 67–96.
106. Silman AJ & Pearson JE (2002) Epidemiology and genetics of
rheumatoid arthritis. Arthritis Res 4, Suppl. 3, S265–S272.
107. Uhlig T & Kvien TK (2005) Is rheumatoid arthritis disappear-
ing? Ann Rheum Dis 64, 7–10.
108. Woo P & Wedderburn LR (1998) Juvenile chronic arthritis.
Lancet 351, 969–973.
109. de Kleer I, Wedderburn LR, Taams LS, et al. (2004) CD4 þ
CD25bright regulatory T cells actively regulate inflammation
in the joints of patients with the remitting form of juvenile
idiopathic arthritis. J Immunol 172, 6435–6443.
110. de Kleer I, Kamphuis SM, Rijkers GT, et al. (2003) The spon-
taneous remission of juvenile idiopathic arthritis is character-
ized by CD30 þ T cells directed to human heat-shock
protein 60 capable of producing the regulatory cytokine inter-
leukin-10. Arthritis Rheum 48, 2001–2010.
111. Nielsen HE, Dorup J, Herlin T, et al. (1999) Epidemiology of
juvenile chronic arthritis: risk dependent on sibship, parental
income, and housing. J Rheumatol 26, 1600–1605.
112. van der Helm-van Mil AH, Wesoly JZ & Huizinga TW (2005)
Understanding the genetic contribution to rheumatoid arthritis.
Curr Opin Rheumatol 17, 299–304.
113. Begovich AB, Carlton VE, Honigberg LA, et al. (2004) A mis-
sense single-nucleotide polymorphism in a gene encoding a
protein tyrosine phosphatase (PTPN22) is associated with
rheumatoid arthritis. Am J Hum Genet 75, 330–337.
114. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al.
(2005) Antibodies to citrullinated proteins and differences in
clinical progression of rheumatoid arthritis. Arthritis Res
Ther 7, R949–R958.
P. C. Calder et al.S36
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509377867
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:35:15, subject to the Cambridge Core terms of use, available at
115. Firestein GS (2003) Evolving concepts of rheumatoid arthritis.
Nature 423, 356–361.
116. Panayi GS, Lanchbury JS & Kingsley GH (1992) The import-
ance of the T cell in initiating and maintaining the chronic
synovitis of rheumatoid arthritis. Arthritis Rheum 35,
729–735.
117. Weyand CM, Seyler TM & Goronzy JJ (2005) B cells in rheu-
matoid synovitis. Arthritis Res Ther 7, Suppl. 3, S9–S12.
118. Bridges SL (2004) Update on autoantibodies in rheumatoid
arthritis. Curr Rheumatol Rep 6, 343–350.
119. Vossenaar ER & van Venrooij WJ (2004) Citrullinated pro-
teins: sparks that may ignite the fire in rheumatoid arthritis.
Arthritis Res Ther 6, 107–111.
120. Edwards JC, Leandro MJ & Cambridge G (2004) B lympho-
cyte depletion therapy with rituximab in rheumatoid arthritis.
Rheum Dis Clin North Am 30, 393–403.
121. Firestein GS, varo-Gracia JM & Maki R (1990) Quantitative
analysis of cytokine gene expression in rheumatoid arthritis.
J Immunol 144, 3347–3353.
122. Kinne RW, Brauer R, Stuhlmuller B, et al. (2000) Macro-
phages in rheumatoid arthritis. Arthritis Res 2, 189–202.
123. Kontoyiannis D & Kollias G (2000) Fibroblast biology. Syno-
vial fibroblasts in rheumatoid arthritis: leading role or chorus
line? Arthritis Res 2, 342–343.
124. Ehrenstein MR, Evans JG, Singh A, et al. (2004) Compromised
function of regulatory T cells in rheumatoid arthritis and reversal
by anti-TNFalpha therapy. J Exp Med 200, 277–285.
125. Williams HC (2000) Epidemiology of atopic dermatitis. Clin
Exp Dermatol 25, 522–529.
126. Krutmann J & Grewe M (1996) Sequential activation of Th1 and
Th2 cells in the immunopathogenesis of atopic eczema – the
2-phase model. Allergologie 19, 449–451.
127. Thepen T, Langeveld-Wildschut EG, Bihari IC, et al. (1996)
Biphasic response against aeroallergen in atopic dermatitis
showing a switch from an initial TH2 response to a TH1
response in situ: an immunocytochemical study. J Allergy
Clin Immunol 97, 828–837.
128. Saito S (2000) Cytokine network at the feto-maternal interface.
J Reprod Immunol 47, 87–103.
129. von Mutius E, Braun-Fahrlander C, Schierl R, et al. (2000)
Exposure to endotoxin or other bacterial components might
protect against the development of atopy. Clin Exp Allergy
30, 1230–1234.
130. Gehring U, Bolte G, Borte M, et al. (2001) Exposure to endo-
toxin decreases the risk of atopic eczema in infancy: a cohort
study. J Allergy Clin Immunol 108, 847–854.
131. Romagnani S (2004) The increased prevalence of allergy and
the hygiene hypothesis: missing immune deviation, reduced
immune suppression, or both? Immunology 112, 352–363.
132. Chan SC, Kim JW, Henderson WR Jr, et al. (1993) Altered
prostaglandin E2 regulation of cytokine production in atopic
dermatitis. J Immunol 151, 3345–3352.
133. Chan S, Henderson WR Jr, Li SH, et al. (1996) Prostaglandin
E2 control of T cell cytokine production is functionally related
to the reduced lymphocyte proliferation in atopic dermatitis.
J Allergy Clin Immunol 97, 85–94.
134. Ena P, Madeddu P, Glorioso N, et al. (1985) High prevalence
of cardiovascular diseases and enhanced activity of the renin-
angiotensin system in psoriatic patients. Acta Cardiol 40,
199–205.
135. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. (2001) Disli-
pidemia and oxidative stress in mild and in severe psoriasis as a
risk for cardiovascular disease. Clin Chim Acta 303, 33–39.
136. Bernstein CN, Wajda A & Blanchard JF (2005) The clustering
of other chronic inflammatory diseases in inflammatory
bowel disease: a population-based study. Gastroenterology
129, 827–836.
137. Allen BR & Littlewood SM (1983) The aetiology of psoriasis:
clues provided by benoxaprofen. Br J Dermatol 109, Suppl. 25,
126–129.
138. Kragballe K & Herlin T (1983) Benoxaprofen improves
psoriasis. A double-blind study. Arch Dermatol 119, 548–552.
139. Anggard E (1994) Nitric oxide: mediator, murderer, and
medicine. Lancet 343, 1199–1206.
140. Penn MS, Rangaswamy S, Saidel GM, et al. (1997) Macro-
molecular transport in the arterial intima: comparison of
chronic and acute injuries. Am J Physiol 272, H1560–H1570.
141. Rangaswamy S, Penn MS, Saidel GM, et al. (1997) Exogen-
ous oxidized low-density lipoprotein injures and alters the
barrier function of endothelium in rats in vivo. Circ Res 80,
37–44.
142. Scalia R, Pearlman S, Campbell B, et al. (1996) Time course
of endothelial dysfunction and neutrophil adherence and infil-
tration during murine traumatic shock. Shock 6, 177–182.
143. Kupatt C, Zahler S, Seligmann C, et al. (1996) Nitric oxide
mitigates leukocyte adhesion and vascular leak after myocar-
dial ischemia. J Mol Cell Cardiol 28, 643–654.
144. Ohara Y, Peterson TE & Harrison DG (1993) Hypercholester-
olemia increases endothelial superoxide anion production.
J Clin Invest 91, 2546–2551.
145. Steinberg D, Parthasarathy S, Carew TE, et al. (1989) Beyond
cholesterol. Modifications of low-density lipoprotein that
increase its atherogenicity. N Engl J Med 320, 915–924.
146. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. (2005) Meta-
analysis: high-dosage vitamin E supplementation may increase
all-cause mortality. Ann Intern Med 142, 37–46.
147. Bjelakovic G, Nikolova D, Gluud LL, et al. (2007) Mortality
in randomized trials of antioxidant supplements for primary
and secondary prevention: systematic review and meta-anal-
ysis. JAMA 297, 842–857.
148. Masuda J & Ross R (1990) Atherogenesis during low level
hypercholesterolemia in the nonhuman primate. I. Fatty
streak formation. Arteriosclerosis 10, 164–177.
149. Masuda J & Ross R (1990) Atherogenesis during low level
hypercholesterolemia in the nonhuman primate. II. Fatty streak
conversion to fibrous plaque. Arteriosclerosis 10, 178–187.
150. Stary HC (2000) Lipid and macrophage accumulations in
arteries of children and the development of atherosclerosis.
Am J Clin Nutr 72, 1297S–1306S.
151. Stary HC (2000) Natural history and histological classification
of atherosclerotic lesions: an update. Arterioscler Thromb Vasc
Biol 20, 1177–1178.
152. Ross R (1993) The pathogenesis of atherosclerosis: a perspec-
tive for the 1990s. Nature 362, 801–809.
153. Lendon CL, Davies MJ, Born GV, et al. (1991) Atherosclerotic
plaque caps are locally weakened when macrophages density is
increased. Atherosclerosis 87, 87–90.
154. George SJ (1998) Tissue inhibitors of metalloproteinases and
metalloproteinases in atherosclerosis. Curr Opin Lipidol 9,
413–423.
155. Katsuda S, Boyd HC, Fligner C, et al. (1992) Human athero-
sclerosis. III. Immunocytochemical analysis of the cell
composition of lesions of young adults. Am J Pathol 140,
907–914.
156. Hansson GK (2005) Inflammation, atherosclerosis, and coron-
ary artery disease. N Engl J Med 352, 1685–1695.
157. Rifai N & Ridker PM (2002) Inflammatory markers and coron-
ary heart disease. Curr Opin Lipidol 13, 383–389.
158. Hulthe J, Wikstrand J & Fagerberg B (2001) Relationship
between C-reactive protein and intima-media thickness in
the carotid and femoral arteries and to antibodies against
oxidized low-density lipoprotein in healthy men: The
Atherosclerosis and Insulin Resistance (AIR) Study. Clin Sci
100, 371–378.
Inflammatory processes and nutrition S37
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509377867
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:35:15, subject to the Cambridge Core terms of use, available at
159. Mohamed-Ali V & Coppack S (2005) Adipose tissue derived
factors. In Cardiovascular Disease: Diet, Nutrition and
Emerging Risk Factors, pp. 160–176 [S Stanner, editor].
Blackwell Publishers: Oxford.
160. Vaudo G, Marchesi S, Gerli R, et al. (2004) Endothelial dys-
function in young patients with rheumatoid arthritis and low
disease activity. Ann Rheum Dis 63, 31–35.
161. Bruce IN, Urowitz MB, Gladman DD, et al. (2003) Risk fac-
tors for coronary heart disease in women with systemic lupus
erythematosus: The Toronto Risk Factor Study. Arthritis
Rheum 48, 3159–3167.
162. Kannel WB, D’Agostino RB, Sullivan L, et al. (2004) Concept
and usefulness of cardiovascular risk profiles. Am Heart J 148,
16–26.
163. Unal B, Critchley JA & Capewell S (2005) Modelling the
decline in coronary heart disease deaths in England and
Wales, 1981–2000: comparing contributions from primary
prevention and secondary prevention. BMJ 331, 614.
164. Unal B, Critchley JA & Capewell S (2005) Small changes in
United Kingdom cardiovascular risk factors could halve coron-
ary heart disease mortality. J Clin Epidemiol 58, 733–740.
165. Lampe FC, Morris RW, Walker M, et al. (2005) Trends in
rates of different forms of diagnosed coronary heart disease,
1978 to 2000: prospective, population based study of British
men. BMJ 330, 1046.
166. Report of the Cardiovascular Review Group, Committee on
Medical Aspects of Food Policy (2004) Nutritional Aspects
of Cardiovascular Disease. London: HMSO.
167. Zatonski WA & Willett W (2005) Changes in dietary fat and
declining coronary heart disease in Poland: population based
study. BMJ 331, 187–188.
168. British Heart Foundation Health Promotion Research Group
(2003) Coronary Heart Disease Statistics. London: British
Heart Foundation.
169. Frayn K & Stanner S (2007) The aetiology and epidemiology
of cardiovascular disease. In Cardiovascular Disease: Diet,
Nutrition and Emerging Factors, pp. 1–21 [S Stanner,
editor]. Oxford: Blackwell Publishing.
170. Baigent C, Keech A, Kearney PM, et al. (2005) Efficacy and
safety of cholesterol-lowering treatment: prospective meta-
analysis of data from 90,056 participants in 14 randomised
trials of statins. Lancet 366, 1267–1278.
171. Baigent C, Sudlow C, Collins R, et al. (2002) Collaborative
meta-analysis of randomised trials of antiplatelet therapy for
prevention of death, myocardial infarction, and stroke in
high risk patients. BMJ 324, 71–86.
172. Taylor-Robinson D & Boman J (2005) The failure of anti-
biotics to prevent heart attacks. BMJ 331, 361–362.
173. Calder PC (2006) n-3 Polyunsaturated fatty acids, inflammation,
and inflammatory diseases. Am J Clin Nutr 83, 1505S–1519S.
174. Thies F, Garry JM, Yaqoob P, et al. (2003) Association of n-3
polyunsaturated fatty acids with stability of atherosclerotic pla-
ques: a randomised controlled trial. Lancet 361, 477–485.
175. GISSI Prevenzione (1999) Dietary supplementation with n-3
polyunsaturated fatty acids and vitamin E after myocardial
infarction: results of the GISSI-Prevenzione trial. Lancet 354,
447–455.
176. Marchioli R, Barzi F, Bomba E, et al. (2002) Early protection
against sudden death by n-3 polyunsaturated fatty acids
after myocardial infarction: time-course analysis of the results
of the Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 105,
1897–1903.
177. Bucher HC, Hengstler P, Schindler C, et al. (2002) n-3
polyunsaturated fatty acids in coronary heart disease: a meta-
analysis of randomized controlled trials. Am J Med 112,
298–304.
178. Studer M, Briel M, Leimenstoll B, et al. (2005) Effect of
different antilipidemic agents and diets on mortality: a sys-
tematic review. Arch Intern Med 165, 725–730.
179. World Health Organisation (2006) Obesity http://www.who.
int/dietphysicalactivity/publications/facts/obesity/en/2006
180. Hutley L & Prins JB (2005) Fat as an endocrine organ:
relationship to the metabolic syndrome. Am J Med Sci 330,
280–289.
181. Fantuzzi G (2005) Adipose tissue, adipokines, and inflam-
mation. J Allergy Clin Immunol 115, 911–919.
182. Halaas JL, Gajiwala KS, Maffei M, et al. (1995) Weight-
reducing effects of the plasma protein encoded by the obese
gene. Science 269, 543–546.
183. Montague CT, Farooqi IS, Whitehead JP, et al. (1997) Conge-
nital leptin deficiency is associated with severe early-onset
obesity in humans. Nature 387, 903–908.
184. Greenberg AS & Obin MS (2006) Obesity and the role of
adipose tissue in inflammation and metabolism. Am J Clin
Nutr 83, 461S–465S.
185. Hotamisligil GS, Peraldi P, Budavari A, et al. (1996) IRS-1-
mediated inhibition of insulin receptor tyrosine kinase activity
in TNF-alpha- and obesity-induced insulin resistance. Science
271, 665–668.
186. Coppack SW (2001) Pro-inflammatory cytokines and adipose
tissue. Proc Nutr Soc 60, 349–356.
187. Gil-Campos M, Can˜ete RR & Gil A (2004) Adiponectin, the
missing link in insulin resistance and obesity. Clin Nutr 23,
963–974.
188. Hausman DB, DiGirolamo M, Bartness TJ, et al. (2001) The
biology of white adipocyte proliferation. Obes Rev 2, 239–254.
189. Neels JG & Olefsky JM (2006) Inflamed fat: what starts the
fire? J Clin Invest 116, 33–35.
190. Unger RH (2003) Lipid overload and overflow: metabolic
trauma and the metabolic syndrome. Trends Endocrinol
Metab 14, 398–403.
191. Unger RH (2003) Minireview: weapons of lean body mass
destruction: the role of ectopic lipids in the metabolic syn-
drome. Endocrinology 144, 5159–5165.
192. McGarry JD (2002) Banting lecture 2001: dysregulation of
fatty acid metabolism in the etiology of type 2 diabetes.
Diabetes 51, 7–18.
193. Alessi MC, Lijnen HR, Bastelica D, et al. (2003) Adipose
tissue and atherothrombosis. Pathophysiol Haemost Thromb
33, 290–297.
194. Bougoulia M, Triantos A & Koliakos G (2006) Effect of
weight loss with or without orlistat treatment on adipocyto-
kines, inflammation, and oxidative markers in obese women.
Hormones (Athens) 5, 259–269.
195. Cancello R & Clement K (2006) Is obesity an inflammatory
illness? Role of low-grade inflammation and macrophage infil-
tration in human white adipose tissue. BJOG 113, 1141–1147.
196. Zagorski SM, Papa NN & Chung MH (2005) The effect of
weight loss after gastric bypass on C-reactive protein levels.
Surg Obes Relat Dis 1, 81–85.
197. Reinehr T, Stoffel-Wagner B, Roth CL, et al. (2005) High-
sensitive C-reactive protein, tumor necrosis factor alpha, and
cardiovascular risk factors before and after weight loss in
obese children. Metabolism 54, 1155–1161.
198. Hansen EN, Torquati A & Abumrad NN (2006) Results of
bariatric surgery. Annu Rev Nutr 26, 481–511.
199. Knowler WC, Barrett-Connor E, Fowler SE, et al. (2002)
Reduction in the incidence of type 2 diabetes with lifestyle
intervention or metformin. N Engl J Med 346, 393–403.
200. Tuomilehto J, Lindstrom J, Eriksson JG, et al. (2001) Preven-
tion of type 2 diabetes mellitus by changes in lifestyle among
subjects with impaired glucose tolerance. N Engl J Med 344,
1343–1350.
P. C. Calder et al.S38
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509377867
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:35:15, subject to the Cambridge Core terms of use, available at
201. Calder PC & Burdge GC (2004) Fatty acids. In Bioactive
Lipids, pp. 1–36 [A Nicolaou and G Kokotos, editors]. Bridge-
water: The Oily Press.
202. Calder PC (2001) n-3 Polyunsaturated fatty acids, inflam-
mation and immunity: pouring oil on troubled waters or
another fishy tale? Nutr Rev 21, 309–341.
203. Hulshof KF, van Erp-Baart MA, Anttolainen M, et al. (1999)
Intake of fatty acids in western Europe with emphasis on
trans fatty acids: the TRANSFAIR Study. Eur J Clin Nutr
53, 143–157.
204. Burdge GC & Calder PC (2005) Conversion of alpha-linolenic
acid to longer-chain polyunsaturated fatty acids in human
adults. Reprod Nutr Dev 45, 581–597.
205. Frayn K (2003) Metabolic Regulation: A Human Perspective.
Oxford: Blackwell Science.
206. Lewis RA, Austen KF & Soberman RJ (1990) Leukotrienes
and other products of the 5-lipoxygenase pathway. Biochemis-
try and relation to pathobiology in human diseases. N Engl J
Med 323, 645–655.
207. Tilley SL, Coffman TM & Koller BH (2001) Mixed messages:
modulation of inflammation and immune responses by prosta-
glandins and thromboxanes. J Clin Invest 108, 15–23.
208. Kelley DS, Taylor PC, Nelson GJ, et al. (1998) Arachidonic
acid supplementation enhances synthesis of eicosanoids with-
out suppressing immune functions in young healthy men.
Lipids 33, 125–130.
209. Thies F, Miles EA, Nebe-von-Caron G, et al. (2001) Influence
of dietary supplementation with long-chain n-3 or n-6 polyun-
saturated fatty acids on blood inflammatory cell populations
and functions and on plasma soluble adhesion molecules in
healthy adults. Lipids 36, 1183–1193.
210. Healy DA, Wallace FA, Miles EA, et al. (2000) Effect of low-
to-moderate amounts of dietary fish oil on neutrophil lipid
composition and function. Lipids 35, 763–768.
211. Rees D, Miles EA, Banerjee T, et al. (2006) Dose-related
effects of eicosapentaenoic acid on innate immune function
in healthy humans: a comparison of young and older men.
Am J Clin Nutr 83, 331–342.
212. Kelley DS, Taylor PC, Nelson GJ, et al. (1999) Docosahexae-
noic acid ingestion inhibits natural killer cell activity and
production of inflammatory mediators in young healthy men.
Lipids 34, 317–324.
213. Serhan CN, Arita M, Hong S, et al. (2004) Resolvins, docosa-
trienes, and neuroprotectins, novel omega-3-derived mediators,
and their endogenous aspirin-triggered epimers. Lipids 39,
1125–1132.
214. Serhan CN (2005) Novel eicosanoid and docosanoid
mediators: resolvins, docosatrienes, and neuroprotectins. Curr
Opin Clin Nutr Metab Care 8, 115–121.
215. Hughes DA, Pinder AC, Piper Z, et al. (1996) Fish oil sup-
plementation inhibits the expression of major histocompatibil-
ity complex class II molecules and adhesion molecules on
human monocytes. Am J Clin Nutr 63, 267–272.
216. Miles EA, Thies F, Wallace FA, et al. (2001) Influence of age
and dietary fish oil on plasma soluble adhesion molecule con-
centrations. Clin Sci 100, 91–100.
217. Caughey GE, Mantzioris E, Gibson RA, et al. (1996) The
effect on human tumor necrosis factor alpha and interleukin
1 beta production of diets enriched in n-3 fatty acids from
vegetable oil or fish oil. Am J Clin Nutr 63, 116–122.
218. Mori TA, Woodman RJ, Burke V, et al. (2003) Effect of
eicosapentaenoic acid and docosahexaenoic acid on oxidative
stress and inflammatory markers in treated-hypertensive type
2 diabetic subjects. Free Radic Biol Med 35, 772–781.
219. Burdge GC & Calder PC (2006) Dietary a-linolenic acid and
health-related outcomes: a metabolic perspective. Nutr Res
Rev 19, 26–52.
220. Lopez-Garcia E, Schulze MB, Fung TT, et al. (2004) Major
dietary patterns are related to plasma concentrations of markers
of inflammation and endothelial dysfunction. Am J Clin Nutr
80, 1029–1035.
221. Rallidis LS, Paschos G, Papaioannou ML, et al. (2004) The
effect of diet enriched with alpha-linolenic acid on soluble
cellular adhesion molecules in dyslipidaemic patients.
Atherosclerosis 174, 127–132.
222. Bemelmans WJ, Lefrandt JD, Feskens EJ, et al. (2004)
Increased alpha-linolenic acid intake lowers C-reactive protein,
but has no effect on markers of atherosclerosis. Eur J Clin Nutr
58, 1083–1089.
223. Rallidis LS, Paschos G, Liakos GK, et al. (2003) Dietary
alpha-linolenic acid decreases C-reactive protein, serum
amyloid A and interleukin-6 in dyslipidaemic patients. Athero-
sclerosis 167, 237–242.
224. Zhao G, Etherton TD, Martin KR, et al. (2004) Dietary alpha-
linolenic acid reduces inflammatory and lipid cardiovascular
risk factors in hypercholesterolemic men and women. J Nutr
134, 2991–2997.
225. Arita M, Yoshida M, Hong S, et al. (2005) Resolvin E1, an
endogenous lipid mediator derived from omega-3 eicosapen-
taenoic acid, protects against 2,4,6-trinitrobenzene sulfonic
acid-induced colitis. Proc Natl Acad Sci U S A 102,
7671–7676.
226. Calder PC (2003) n-3 Polyunsaturated fatty acids and inflam-
mation: from molecular biology to the clinic. Lipids 38,
342–352.
227. Calder PC (2004) n-3 fatty acids, inflammation, and immunity –
relevance to postsurgical and critically ill patients. Lipids 39,
1147–1161.
228. Lee JY, Plakidas A, Lee WH, et al. (2003) Differential modu-
lation of Toll-like receptors by fatty acids: preferential inhi-
bition by n-3 polyunsaturated fatty acids. J Lipid Res 44,
479–486.
229. Lee JY, Ye J, Gao Z, et al. (2003) Reciprocal modulation of
Toll-like receptor-4 signaling pathways involving MyD88
and phosphatidylinositol 3-kinase/AKT by saturated and poly-
unsaturated fatty acids. J Biol Chem 278, 37041–37051.
230. Lee JY, Zhao L, Youn HS, et al. (2004) Saturated fatty acid
activates but polyunsaturated fatty acid inhibits Toll-like
receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol
Chem 279, 16971–16979.
231. Weatherill AR, Lee JY, Zhao L, et al. (2005) Saturated and
polyunsaturated fatty acids reciprocally modulate dendritic
cell functions mediated through TLR4. J Immunol 174,
5390–5397.
232. Shoda R, Matsueda K, Yamato S, et al. (1996) Epidemiologic
analysis of Crohn disease in Japan: increased dietary intake of
n-6 polyunsaturated fatty acids and animal protein relates to
the increased incidence of Crohn disease in Japan. Am J Clin
Nutr 63, 741–745.
233. Belluzzi A, Brignola C, Campieri M, et al. (1996) Effect of an
enteric-coated fish-oil preparation on relapses in Crohn’s dis-
ease. N Engl J Med 334, 1557–1560.
234. MacLean CH, Mojica WA, Morton SC, et al. (2004) Effects of
Omega-3 Fatty Acids on Inflammatory Bowel Disease, Rheu-
matoid Arthritis, Renal Disease, Systemic Lupus Erythemato-
sus, and Osteoporosis. Rockville, IN: Agency for Healthcare
Research and Quality.
235. Dunstan JA, Mori TA, Barden A, et al. (2003) Maternal fish oil
supplementation in pregnancy reduces interleukin-13 levels in
cord blood of infants at high risk of atopy. Clin Exp Allergy 33,
442–448.
236. Dunstan JA, Mori TA, Barden A, et al. (2003) Fish oil sup-
plementation in pregnancy modifies neonatal allergen-specific
immune responses and clinical outcomes in infants at high
Inflammatory processes and nutrition S39
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509377867
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:35:15, subject to the Cambridge Core terms of use, available at
risk of atopy: a randomized, controlled trial. J Allergy Clin
Immunol 112, 1178–1184.
237. Thien FCK, Woods R, De Luca S, et al. (2002) Dietary marine
fatty acids (fish oil) for asthma in adults and children,
Cochrane Database of Systematic Reviews, CD001283.
238. Nagakura T, Matsuda S, Shichijyo K, et al. (2000) Dietary
supplementation with fish oil rich in omega-3 polyunsaturated
fatty acids in children with bronchial asthma. Eur Respir J 16,
861–865.
239. Schachter H, Reisman J, Tran K, et al. (2004) Health Effects of
Omega-3 Fatty Acids on Asthma. Rockville, IN: Agency for
Healthcare and Quality.
240. Broughton KS, Johnson CS, Pace BK, et al. (1997) Reduced
asthma symptoms with n-3 fatty acid ingestion are related to
5-series leukotriene production. Am J Clin Nutr 65, 1011–1017.
241. Broekhuizen R, Wouters EF, Creutzberg EC, et al. (2005)
Polyunsaturated fatty acids improve exercise capacity in
chronic obstructive pulmonary disease. Thorax 60, 376–382.
242. Matsuyama W, Mitsuyama H, Watanabe M, et al. (2005)
Effects of omega-3 polyunsaturated fatty acids on inflamma-
tory markers in COPD. Chest 128, 3817–3827.
243. Adam O, Beringer C, Kless T, et al. (2003) Anti-inflammatory
effects of a low arachidonic acid diet and fish oil in patients
with rheumatoid arthritis. Rheumatol Int 23, 27–36.
244. Fortin PR, Lew RA, Liang MH, et al. (1995) Validation of a
meta-analysis: the effects of fish oil in rheumatoid arthritis.
J Clin Epidemiol 48, 1379–1390.
245. Mayser P, Mrowietz U, Arenberger P, et al. (1998) Omega-3
fatty acid-based lipid infusion in patients with chronic plaque
psoriasis: results of a double-blind, randomized, placebo-
controlled, multicenter trial. J Am Acad Dermatol 38, 539–547.
246. Ziboh V (1998) The role of n-3 fatty acids in psoriasis. In Med-
icinal Fatty Acids in Inflammation, pp. 45–53 [J Kremer,
editor]. Basel: Birkhauser Verlag.
247. Rhodes LE, O’Farrell S, Jackson MJ, et al. (1994) Dietary fish
oil supplementation in humans reduces UVB-erythemal sensi-
tivity but increases epidermal lipid peroxidation. J Invest
Dermatol 103, 151–154.
248. Rhodes LE, Durham B, Fraser W, et al. (1994) Fish oil reduces
PGE2 levels in skin and increases the threshold to provocation
of polymorphic light eruption. J Invest Dermatol 103, 404.
249. Kris-Etherton PM, Harris WS & Appel LJ (2002) Fish con-
sumption, fish oil, omega-3 fatty acids, and cardiovascular
disease. Circulation 106, 2747–2757.
250. Calder PC (2004) n-3 Fatty acids and cardiovascular disease: evi-
dence explained and mechanisms explored. Clin Sci 107, 1–11.
251. Serafini M & Del RD (2004) Understanding the association
between dietary antioxidants, redox status and disease: is the
Total Antioxidant Capacity the right tool? Redox Rep 9,
145–152.
252. Serafini M, Bugianesi R, Maiani G, et al. (2003) Plasma anti-
oxidants from chocolate. Nature 424, 1013.
253. Vassalle C, Petrozzi L, Botto N, et al. (2004) Oxidative stress
and its association with coronary artery disease and different
atherogenic risk factors. J Intern Med 256, 308–315.
254. Ching S, Ingram D, Hahnel R, et al. (2002) Serum levels of
micronutrients, antioxidants and total antioxidant status predict
risk of breast cancer in a case control study. J Nutr 132,
303–306.
255. Serafini M, Bellocco R, Wolk A, et al. (2002) Total antioxi-
dant potential of fruit and vegetables and risk of gastric
cancer. Gastroenterology 123, 985–991.
256. Agudo A, Cabrera L, Amiano P, et al. (2007) Fruit and veg-
etable intakes, dietary antioxidant nutrients, and total mortality
in Spanish adults: findings from the Spanish cohort of the
European Prospective Investigation into Cancer and Nutrition
(EPIC-Spain). Am J Clin Nutr 85, 1634–1642.
257. Brighenti F, Valtuena S, Pellegrini N, et al. (2005) Total anti-
oxidant capacity of the diet is inversely and independently
related to plasma concentration of high-sensitivity C-reactive
protein in adult Italian subjects. Br J Nutr 93, 619–625.
258. Food and Nutrition Board IoM (2000) Dietary Reference
Intakes for Vitamin C, Vitamin E, Selenium and Carotenoids.
Washington.
259. Levine M, Conry-Cantilena C, Wang Y, et al. (1996) Vitamin
C pharmacokinetics in healthy volunteers: evidence for a rec-
ommended dietary allowance. Proc Natl Acad Sci U S A 93,
3704–3709.
260. Frei B, England L & Ames BN (1989) Ascorbate is an out-
standing antioxidant in human blood plasma. Proc Natl Acad
Sci U S A 86, 6377–6381.
261. Levine M, Dhariwal KR, Wang Y, et al. (1994) Ascorbic acid
in neutrophils. In Natural Antioxidants in Health and Disease,
pp. 469–488 [B Frei, editor]. San Diego, CA: Academic Press.
262. Frei B, Stocker R & Ames BN (1988) Antioxidant defenses
and lipid peroxidation in human blood plasma. Proc Natl
Acad Sci U S A 85, 9748–9752.
263. Jialal I, Vega GL & Grundy SM (1990) Physiologic levels of
ascorbate inhibit the oxidative modification of low density
lipoprotein. Atherosclerosis 82, 185–191.
264. Halpner AD, Handelman GJ, Belmont CA, et al. (1998) Pro-
tection by vitamin C of oxidant-induced loss of vitamin E in
rat hepatocytes. J Nutr Biochem 9, 355–359.
265. Horrobin DF (1996) Ascorbic acid and prostaglandin synthesis.
Subcell Biochem 25, 109–115.
266. Halliwell B, Wasil M & Grootveld M (1987) Biologically
significant scavenging of the myeloperoxidase-derived oxidant
hypochlorous acid by ascorbic acid. Implications for antioxi-
dant protection in the inflamed rheumatoid joint. FEBS Lett
213, 15–17.
267. Anderson R & Lukey PT (1987) A biological role for ascor-
bate in the selective neutralization of extracellular phago-
cyte-derived oxidants. Ann N Y Acad Sci 498, 229–247.
268. Goetzl EJ, Wasserman SI, Gigli I, et al. (1974) Enhancement
of random migration and chemotactic response of human leu-
kocytes by ascorbic acid. J Clin Invest 53, 813–818.
269. Sanchez-Moreno C, Cano MP, de Ancos B, et al. (2004)
Consumption of high-pressurized vegetable soup increases
plasma vitamin C and decreases oxidative stress and inflamma-
tory biomarkers in healthy humans. J Nutr 134, 3021–3025.
270. Sanchez-Moreno C, Dashe JF, Scott T, et al. (2004) Decreased
levels of plasma vitamin C and increased concentrations of
inflammatory and oxidative stress markers after stroke. Stroke
35, 163–168.
271. Evans RM, Currie L & Campbell A (1982) The distribution of
ascorbic acid between various cellular components of blood, in
normal individuals, and its relation to the plasma concentration.
Br J Nutr 47, 473–482.
272. Lunec J & Blake DR (1985) The determination of dehydroas-
corbic acid and ascorbic acid in the serum and synovial fluid of
patients with rheumatoid arthritis (RA). Free Radic Res
Commun 1, 31–39.
273. Cross CE, Forte T, Stocker R, et al. (1990) Oxidative stress
and abnormal cholesterol metabolism in patients with adult
respiratory distress syndrome. J Lab Clin Med 115, 396–404.
274. Imes S, Dinwoodie A, Walker K, et al. (1986) Vitamin C
status in 137 outpatients with Crohn’s disease. Effect of diet
counseling. J Clin Gastroenterol 8, 443–446.
275. Hoffenberg EJ, Deutsch J, Smith S, et al. (1997) Circulating
antioxidant concentrations in children with inflammatory
bowel disease. Am J Clin Nutr 65, 1482–1488.
276. Filippi J, Al-Jaouni R, Wiroth JB, et al. (2006) Nutritional
deficiencies in patients with Crohn’s disease in remission.
Inflamm Bowel Dis 12, 185–191.
P. C. Calder et al.S40
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509377867
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:35:15, subject to the Cambridge Core terms of use, available at
277. Wendland BE, Aghdassi E, Tam C, et al. (2001) Lipid peroxi-
dation and plasma antioxidant micronutrients in Crohn disease.
Am J Clin Nutr 74, 259–264.
278. Buffinton GD & Doe WF (1995) Altered ascorbic acid status in
the mucosa from inflammatory bowel disease patients. Free
Radic Res 22, 131–143.
279. Aghdassi E, Wendland BE, Steinhart AH, et al. (2003) Anti-
oxidant vitamin supplementation in Crohn’s disease decreases
oxidative stress. a randomized controlled trial. Am J Gastroen-
terol 98, 348–353.
280. Trebble TM, Arden NK, Wootton SA, et al. (2004) Fish oil and
antioxidants alter the composition and function of circulating
mononuclear cells in Crohn disease. Am J Clin Nutr 80,
1137–1144.
281. Kelly FJ, Mudway I, Blomberg A, et al. (1999) Altered lung
antioxidant status in patients with mild asthma. Lancet 354,
482–483.
282. Winklhofer-Roob BM, Ellemunter H, Fruhwirth M, et al.
(1997) Plasma vitamin C concentrations in patients with
cystic fibrosis: evidence of associations with lung inflam-
mation. Am J Clin Nutr 65, 1858–1866.
283. Schwartz J & Weiss ST (1994) Relationship between dietary
vitamin C intake and pulmonary function in the First National
Health and Nutrition Examination Survey (NHANES I). Am J
Clin Nutr 59, 110–114.
284. Britton JR, Pavord ID, Richards KA, et al. (1995) Dietary
antioxidant vitamin intake and lung function in the general
population. Am J Respir Crit Care Med 151, 1383–1387.
285. Harik-Khan RI, Muller DC & Wise RA (2004) Serum vitamin
levels and the risk of asthma in children. Am J Epidemiol 159,
351–357.
286. Devereux G, Turner SW, Craig LC, et al. (2006) Low
maternal vitamin E intake during pregnancy is associated
with asthma in 5-year-old children. Am J Respir Crit Care
Med 174, 499–507.
287. Aderele WI, Ette SI, Oduwole O, et al. (1985) Plasma vitamin
C (ascorbic acid) levels in asthmatic children. Afr J Med Med
Sci 14, 115–120.
288. Bucca C, Rolla G & Farina JC (1992) Effect of vitamin C on
transient increase of bronchial responsiveness in conditions
affecting the airways. Ann N Y Acad Sci 669, 175–186.
289. Cohen HA, Neuman I & Nahum H (1997) Blocking effect of
vitamin C in exercise-induced asthma. Arch Pediatr Adolesc
Med 151, 367–370.
290. Tecklenburg SL, Mickleborough TD, Fly AD, et al. (2007)
Ascorbic acid supplementation attenuates exercise-induced
bronchoconstriction in patients with asthma. Respir Med 101,
1770–1778.
291. Hagfors L, Leanderson P, Skoldstam L, et al. (2003) Antiox-
idant intake, plasma antioxidants and oxidative stress in a
randomized, controlled, parallel, Mediterranean dietary inter-
vention study on patients with rheumatoid arthritis. Nutr J
2, 5.
292. Traber MG (2007) Heart disease and single-vitamin
supplementation. Am J Clin Nutr 85, 293S–299S.
293. van Herpen-Broekmans WM, Klopping-Ketelaars IA, Bots
ML, et al. (2004) Serum carotenoids and vitamins in relation
to markers of endothelial function and inflammation. Eur J
Epidemiol 19, 915–921.
294. Plantinga Y, Ghiadoni L, Magagna A, et al. (2007) Sup-
plementation with vitamins C and E improves arterial stiffness
and endothelial function in essential hypertensive patients.
Am J Hypertens 20, 392–397.
295. Tahir M, Foley B, Pate G, et al. (2005) Impact of vitamin E
and C supplementation on serum adhesion molecules in
chronic degenerative aortic stenosis: a randomized controlled
trial. Am Heart J 150, 302–306.
296. Traber MG, Burton GW, Ingold KU, et al. (1990) RRR- and
SRR-alpha-tocopherols are secreted without discrimination in
human chylomicrons, but RRR-alpha-tocopherol is preferen-
tially secreted in very low density lipoproteins. J Lipid Res
31, 675–685.
297. Schultz M, Leist M, Elsner A, et al. (1997) Alpha-carboxy-
ethyl-6-hydroxychroman as urinary metabolite of vitamin E.
Methods Enzymol 282, 297–310.
298. Lodge JK, Ridlington J, Leonard S, et al. (2001) Alpha- and
gamma-tocotrienols are metabolized to carboxyethyl-hydroxy-
chroman derivatives and excreted in human urine. Lipids 36,
43–48.
299. McLaughlin PJ & Weihrauch JL (1979) Vitamin E content of
foods. J Am Diet Assoc 75, 647–665.
300. Lehmann J, Martin HL, Lashley EL, et al. (1986) Vitamin E in
foods from high and low linoleic acid diets. J Am Diet Assoc
86, 1208–1216.
301. Murphy SP, Subar AF & Block G (1990) Vitamin E intakes
and sources in the United States. Am J Clin Nutr 52,
361–367.
302. Slesinski MJ, Subar AF & Kahle LL (1996) Dietary intake of
fat, fiber and other nutrients is related to the use of vitamin and
mineral supplements in the United States: the 1992 National
Health Interview Survey. J Nutr 126, 3001–3008.
303. Burton GW & Ingold KU (1986) Vitamin E: Application of the
principles of physical organic chemistry to the exploration of
its structure and functions. Acc Chem Rec 19, 194–201.
304. Kamal-Eldin A & Appelqvist LA (1996) The chemistry and
antioxidant properties of tocopherols and tocotrienols. Lipids
31, 671–701.
305. Jiang Q, Christen S, Shigenaga MK, et al. (2001) Gamma-
tocopherol, the major form of vitamin E in the US diet,
deserves more attention. Am J Clin Nutr 74, 714–722.
306. Winklhofer-Roob BM, Rock E, Ribalta J, et al. (2003) Effects
of vitamin E and carotenoid status on oxidative stress in health
and disease. Evidence obtained from human intervention
studies. Mol Aspects Med 24, 391–402.
307. Winklhofer-Roob BM, Ziouzenkova O, Puhl H, et al. (1995)
Impaired resistance to oxidation of low density lipoprotein in
cystic fibrosis: improvement during vitamin E supplemen-
tation. Free Radic Biol Med 19, 725–733.
308. Saldeen T, Li D & Mehta JL (1999) Differential effects of
alpha- and gamma-tocopherol on low-density lipoprotein oxi-
dation, superoxide activity, platelet aggregation and arterial
thrombogenesis. J Am Coll Cardiol 34, 1208–1215.
309. Liu M, Wallin R, Wallmon A, et al. (2002) Mixed tocopher-
ols have a stronger inhibitory effect on lipid peroxidation
than alpha-tocopherol alone. J Cardiovasc Pharmacol 39,
714–721.
310. Devaraj S, Hugou I & Jialal I (2001) Alpha-tocopherol
decreases CD36 expression in human monocyte-derived
macrophages. J Lipid Res 42, 521–527.
311. Bieri JG & Evarts RP (1974) Vitamin E activity of gamma-
tocopherol in the rat, chick and hamster. J Nutr 104, 850–857.
312. Cooney RV, Franke AA, Harwood PJ, et al. (1993) Gamma-
tocopherol detoxification of nitrogen dioxide: superiority to
alpha-tocopherol. Proc Natl Acad Sci U S A 90, 1771–1775.
313. Christen S, Woodall AA, Shigenaga MK, et al. (1997)
Gamma-tocopherol traps mutagenic electrophiles such as
NO(X) and complements alpha-tocopherol: physiological
implications. Proc Natl Acad Sci U S A 94, 3217–3222.
314. Devaraj S & Jialal I (2000) Alpha tocopherol supplementation
decreases serum C-reactive protein and monocyte interleukin-6
levels in normal volunteers and type 2 diabetic patients. Free
Radic Biol Med 29, 790–792.
315. Sundl I, Gruber HJ & Roob JM (2005) Effects of mixed
tocopherols versus alpha-tocopherol on nuclear factor kappa
Inflammatory processes and nutrition S41
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509377867
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:35:15, subject to the Cambridge Core terms of use, available at
B activation in mononuclear leukocytes of healthy male
volunteers. Clin Nutr 24, 595.
316. Tasinato A, Boscoboinik D, Bartoli GM, et al. (1995) D-alpha-
tocopherol inhibition of vascular smooth muscle cell prolifer-
ation occurs at physiological concentrations, correlates with
protein kinase C inhibition, and is independent of its
antioxidant properties. Proc Natl Acad Sci U S A 92,
12190–12194.
317. Devaraj S & Jialal I (1999) Alpha-tocopherol decreases inter-
leukin-1 beta release from activated human monocytes by inhi-
bition of 5-lipoxygenase. Arterioscler Thromb Vasc Biol 19,
1125–1133.
318. Jiang Q, Lykkesfeldt J, Shigenaga MK, et al. (2002) Gamma-
tocopherol supplementation inhibits protein nitration and
ascorbate oxidation in rats with inflammation. Free Radic
Biol Med 33, 1534–1542.
319. Grammas P, Hamdheydari L, Benaksas EJ, et al. (2004)
Anti-inflammatory effects of tocopherol metabolites. Biochem
Biophys Res Commun 319, 1047–1052.
320. Jiang Q & Ames BN (2003) Gamma-tocopherol, but not
alpha-tocopherol, decreases proinflammatory eicosanoids and
inflammation damage in rats. FASEB J 17, 816–822.
321. Li D, Saldeen T & Mehta JL (1999) Gamma-tocopherol
decreases ox-LDL-mediated activation of nuclear factor-
kappaB and apoptosis in human coronary artery endothelial
cells. Biochem Biophys Res Commun 259, 157–161.
322. Jiang Q, Elson-Schwab I, Courtemanche C, et al. (2000)
Gamma-tocopherol and its major metabolite, in contrast to
alpha-tocopherol, inhibit cyclooxygenase activity in
macrophages and epithelial cells. Proc Natl Acad Sci U S A
97, 11494–11499.
323. Heliovaara M, Knekt P, Aho K, et al. (1994) Serum
antioxidants and risk of rheumatoid arthritis. Ann Rheum Dis
53, 51–53.
324. De Bandt M, Grossin M, Driss F, et al. (2002) Vitamin E
uncouples joint destruction and clinical inflammation in a
transgenetic mouse model of rheumatoid arthritis. Arthritis
Rheum 46, 522–532.
325. Venkatraman JT & Chu WC (1999) Effects of dietary omega-3
and omega-6 lipids and vitamin E on serum cytokines, lipid
mediators and anti-DNA antibodies in a mouse model for rheu-
matoid arthritis. J Am Coll Nutr 18, 602–613.
326. Edmonds SE, Winyard PG, Guo R, et al. (1997) Putative
analgesic activity of repeated oral doses of vitamin E in
the treatment of rheumatoid arthritis. Results of a prospective
placebo controlled double blind trial. Ann Rheum Dis 56,
649–655.
327. Dieber-Rotheneder M, Puhl H, Waeg G, et al. (1991) Effect of
oral supplementation with D-alpha-tocopherol on the vitamin E
content of human low density lipoproteins and resistance to
oxidation. J Lipid Res 32, 1325–1332.
328. Steinbrecher UP, Parthasarathy S, Leake DS, et al. (1984)
Modification of low density lipoprotein by endothelial
cells involves lipid peroxidation and degradation of low density
lipoprotein phospholipids. Proc Natl Acad Sci U S A 81,
3883–3887.
329. Azzi A, Boscoboinik D & Marilley D (1995) Vitamin E: a
sensor and an information transducer of the cell oxidation
state. Am J Clin Nutr 62, 1337S–1346S.
330. Freedman JE, Farhat JH, Loscalzo J, et al. (1996) Alpha-
tocopherol inhibits aggregation of human platelets by a
protein kinase C-dependent mechanism. Circulation 94,
2434–2440.
331. Devaraj S, Li D & Jialal I (1996) The effects of alpha toco-
pherol supplementation on monocyte function. Decreased
lipid oxidation, interleukin 1 beta secretion, and monocyte
adhesion to endothelium. J Clin Invest 98, 756–763.
332. Chan AC & Leith MK (1981) Decreased prostacyclin synthesis
in vitamin E-deficient rabbit aorta. Am J Clin Nutr 34,
2341–2347.
333. Tran K & Chan AC (1990) R,R,R-alpha-tocopherol potentiates
prostacyclin release in human endothelial cells. Evidence for
structural specificity of the tocopherol molecule. Biochim
Biophys Acta 1043, 189–197.
334. Chan AC, Wagner M, Kennedy C, et al. (1998) Vitamin E
up-regulates arachidonic acid release and phospholipase A2
in megakaryocytes. Mol Cell Biochem 189, 153–159.
335. Cominacini L, Garbin U, Pasini AF, et al. (1997) Antioxidants
inhibit the expression of intercellular cell adhesion molecule-1
and vascular cell adhesion molecule-1 induced by oxidized
LDL on human umbilical vein endothelial cells. Free Radic
Biol Med 22, 117–127.
336. Ohrvall M, Sundlof G & Vessby B (1996) Gamma, but not
alpha, tocopherol levels in serum are reduced in coronary
heart disease patients. J Intern Med 239, 111–117.
337. Handelman GJ, Machlin LJ, Fitch K, et al. (1985) Oral alpha-
tocopherol supplements decrease plasma gamma-tocopherol
levels in humans. J Nutr 115, 807–813.
338. Sundl I, Resch U, Bergmann AR, et al. (2004) The decrease in
gamma-tocopherol in plasma and lipoprotein fractions levels
off within two days of vitamin E supplementation. Ann N Y
Acad Sci 1031, 378–380.
339. Drewnowski A, Rock CL, Henderson SA, et al. (1997) Serum
beta-carotene and vitamin C as biomarkers of vegetable and
fruit intakes in a community-based sample of French adults.
Am J Clin Nutr 65, 1796–1802.
340. Krinsky NI (1993) Actions of carotenoids in biological sys-
tems. Annu Rev Nutr 13, 561–587.
341. Krinsky NI (2002) Possible biologic mechanisms for a protec-
tive role of xanthophylls. J Nutr 132, 540S–542S.
342. Bai SK, Lee SJ, Na HJ, et al. (2005) beta-Carotene inhibits
inflammatory gene expression in lipopolysaccharide-stimulated
macrophages by suppressing redox-based NF-kappaB acti-
vation. Exp Mol Med 37, 323–334.
343. Flohe´ L, Brigelius-Flohe´ R, Saliou C, et al. (1997) Redox
regulation of NF-kB activation. Free Radic Biol Med 22,
1115–1126.
344. Louw JA, Werbeck A, Louw ME, et al. (1992) Blood vitamin
concentrations during the acute-phase response. Crit Care Med
20, 934–941.
345. Kritchevsky SB, Bush AJ, Pahor M, et al. (2000) Serum
carotenoids and markers of inflammation in nonsmokers. Am
J Epidemiol 152, 1065–1071.
346. Quasim T, McMillan DC, Talwar D, et al. (2003) Lower con-
centrations of carotenoids in the critically ill patient are related
to a systemic inflammatory response and increased lipid per-
oxidation. Clin Nutr 22, 459–462.
347. Lakshman MR & Rao MN (1999) Purification and characteriz-
ation of cellular carotenoid-binding protein from mammalian
liver. Methods Enzymol 299, 441–456.
348. Kim GY, Kim JH, Ahn SC, et al. (2004) Lycopene suppresses
the lipopolysaccharide-induced phenotypic and functional
maturation of murine dendritic cells through inhibition of mito-
gen-activated protein kinases and nuclear factor-kappaB.
Immunology 113, 203–211.
349. Ohgami K, Shiratori K, Kotake S, et al. (2003) Effects of
astaxanthin on lipopolysaccharide-induced inflammation
in vitro and in vivo. Invest Ophthalmol Vis Sci 44,
2694–2701.
350. Lee EH, Faulhaber D, Hanson KM, et al. (2004) Dietary lutein
reduces ultraviolet radiation-induced inflammation and immu-
nosuppression. J Invest Dermatol 122, 510–517.
351. Watzl B, Kulling SE, Mo¨seneder J, et al. (2005) A 4-week
intervention with high intake of carotenoid-rich vegetables
P. C. Calder et al.S42
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509377867
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:35:15, subject to the Cambridge Core terms of use, available at
and fruit reduces plasma C-reactive protein in healthy, non-
smoking men. Am J Clin Nutr 82, 1052–1058.
352. Riso P, Visioli F, Grande S, et al. (2006) Effect of a tomato-
based drink on markers of inflammation, immunomodulation,
and oxidative stress. J Agric Food Chem 54, 2563–2566.
353. Rumi G Jr, Szabo I, Vincze A, et al. (2000) Decrease of serum
carotenoids in Crohn’s disease. J Physiol Paris 94, 159–161.
354. Reifen R, Nur T, Matas Z, et al. (2001) Lycopene supplemen-
tation attenuates the inflammatory status of colitis in a rat
model. Int J Vitam Nutr Res 71, 347–351.
355. Wood LG, Garg ML, Blake RJ, et al. (2004) Carotenoid con-
centrations in asthmatics versus healthy controls. Asia Pac J
Clin Nutr 13, S74.
356. Cerhan JR, Saag KG, Merlino LA, et al. (2003) Antioxidant
micronutrients and risk of rheumatoid arthritis in a cohort of
older women. Am J Epidemiol 157, 345–354.
357. Pattison DJ, Symmons DP, Lunt M, et al. (2005) Dietary beta-
cryptoxanthin and inflammatory polyarthritis: results from a
population-based prospective study. Am J Clin Nutr 82,
451–455.
358. Comstock GW, Burke AE, Hoffman SC, et al. (1997) Serum
concentrations of alpha tocopherol, beta carotene, and retinol
preceding the diagnosis of rheumatoid arthritis and systemic
lupus erythematosus. Ann Rheum Dis 56, 323–325.
359. Sesso HD, Buring JE, Norkus EP, et al. (2004) Plasma lyco-
pene, other carotenoids, and retinol and the risk of cardiovas-
cular disease in women. Am J Clin Nutr 79, 47–53.
360. Sesso HD, Buring JE, Norkus EP, et al. (2005) Plasma lyco-
pene, other carotenoids, and retinol and the risk of cardiovas-
cular disease in men. Am J Clin Nutr 81, 990–997.
361. Suzuki K, Inoue T, Hioki R, et al. (2006) Association of
abdominal obesity with decreased serum levels of carotenoids
in a healthy Japanese population. Clin Nutr 25, 780–789.
362. Wallstrom P, Wirfalt E, Lahmann PH, et al. (2001) Serum con-
centrations of beta-carotene and alpha-tocopherol are associ-
ated with diet, smoking, and general and central adiposity.
Am J Clin Nutr 73, 777–785.
363. Winklhofer-Roob BM, Sargsyan K & Maritschnegg M (2005)
Relations between antioxidants and biomarkers of consump-
tion of fruits and vegetables and body mass index in the
STYrian Juvenile Obesity Study (STYJOBS). Int J Obes 29,
S150.
364. Manach C, Scalbert A, Morand C, et al. (2004) Polyphenols:
food sources and bioavailability. Am J Clin Nutr 79, 727–747.
365. Kuhnau J (1976) The flavonoids. A class of semi-essential food
components: their role in human nutrition. World Rev Nutr
Diet 24, 117–191.
366. Baumann J, von Bruchhausen F & Wurm G (1980) Flavonoids
and related compounds as inhibition of arachidonic acid per-
oxidation. Prostaglandins 20, 627–639.
367. Lee TP, Matteliano ML & Middleton E Jr (1982) Effect of
quercetin on human polymorphonuclear leukocyte lysosomal
enzyme release and phospholipid metabolism. Life Sci 31,
2765–2774.
368. Welton AF, Tobias LD, Fiedler-Nagy C, et al. (1986) Effect of
flavonoids on arachidonic acid metabolism. Prog Clin Biol Res
213, 231–242.
369. Noreen Y, Serrano G, Perera P, et al. (1998) Flavan-3-ols iso-
lated from some medicinal plants inhibiting COX-1 and COX-
2 catalysed prostaglandin biosynthesis. Planta Med 64,
520–524.
370. Chiesi M & Schwaller R (1995) Inhibition of constitutive
endothelial NO-synthase activity by tannin and quercetin. Bio-
chem Pharmacol 49, 495–501.
371. Kim OK, Murakami A, Nakamura Y, et al. (1998) Screening
of edible Japanese plants for nitric oxide generation inhibitory
activities in RAW 264.7 cells. Cancer Lett 125, 199–207.
372. Liang YC, Huang YT, Tsai SH, et al. (1999) Suppression of
inducible cyclooxygenase and inducible nitric oxide synthase
by apigenin and related flavonoids in mouse macrophages.
Carcinogenesis 20, 1945–1952.
373. Kim HK, Cheon BS, Kim YH, et al. (1999) Effects of naturally
occurring flavonoids on nitric oxide production in the macro-
phage cell line RAW 264.7 and their structure-activity
relationships. Biochem Pharmacol 58, 759–765.
374. Geng Y, Zhang B & Lotz M (1993) Protein tyrosine kinase
activation is required for lipopolysaccharide induction of
cytokines in human blood monocytes. J Immunol 151,
6692–6700.
375. Cho JY, Kim PS, Park J, et al. (2000) Inhibitor of tumor
necrosis factor-alpha production in lipopolysaccharide-
stimulated RAW264.7 cells from Amorpha fruticosa. J Ethno-
pharmacol 70, 127–133.
376. Wadsworth TL, McDonald TL & Koop DR (2001) Effects of
Ginkgo biloba extract (EGb 761) and quercetin on lipopolysac-
charide-induced signaling pathways involved in the release
of tumor necrosis factor-alpha. Biochem Pharmacol 62,
963–974.
377. Wadsworth TL & Koop DR (2003) Effects of Ginkgo biloba
extract (EGb 761) and quercetin on lipopolysaccharide-
induced release of nitric oxide. Chem Biol Interact 137,
43–58.
378. Cho SY, Park SJ, Kwon MJ, et al. (2003) Quercetin suppresses
proinflammatory cytokines production through MAP kinases
and NF-kappaB pathway in lipopolysaccharide-stimulated
macrophage. Mol Cell Biochem 243, 153–160.
379. Morikawa K, Nonaka M, Narahara M, et al. (2003) Inhibitory
effect of quercetin on carrageenan-induced inflammation in
rats. Life Sci 74, 709–721.
380. Takahashi K, Morikawa A, Kato Y, et al. (2001) Flavonoids
protect mice from two types of lethal shock induced by endo-
toxin. FEMS Immunol Med Microbiol 31, 29–33.
381. Ueda H, Yamazaki C & Yamazaki M (2004) A hydroxyl group
of flavonoids affects oral anti-inflammatory activity and inhi-
bition of systemic tumor necrosis factor-alpha production.
Biosci Biotechnol Biochem 68, 119–125.
382. Estruch R, Sacanella E, Badia E, et al. (2004) Different effects
of red wine and gin consumption on inflammatory biomarkers
of atherosclerosis: a prospective randomized crossover trial.
Effects of wine on inflammatory markers. Atherosclerosis
175, 117–123.
383. Zern TL, Wood RJ, Greene C, et al. (2005) Grape polyphenols
exert a cardioprotective effect in pre- and postmenopausal
women by lowering plasma lipids and reducing oxidative
stress. J Nutr 135, 1911–1917.
384. Widlansky ME, Duffy SJ, Hamburg NM, et al. (2005) Effects
of black tea consumption on plasma catechins and markers of
oxidative stress and inflammation in patients with coronary
artery disease. Free Radic Biol Med 38, 499–506.
385. Song Y, Manson JE, Buring JE, et al. (2005) Associations of
dietary flavonoids with risk of type 2 diabetes, and markers
of insulin resistance and systemic inflammation in women: a
prospective study and cross-sectional analysis. J Am Coll
Nutr 24, 376–384.
386. Bogani P, Galli C, Villa M, et al. (2007) Postprandial anti-
inflammatory and antioxidant effects of extra virgin olive oil.
Atherosclerosis 190, 181–186.
387. Rolfe R (1996) Colonization resistance. In Gastrointentestinal
Microbiology, 501-536, , [RI Mackie, BA White and RE Isaac-
son, editors]. New York: Chapman & Hall.
388. Holzapfel WH (2006) Introduction to prebiotics and probiotics.
In Probiotics in Food Safety and Human Health, pp. 1–33
[I Goktepe, VK Juneja and M Ahmedna, editors]. Boca
Raton, FL: CRC Press.
Inflammatory processes and nutrition S43
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509377867
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:35:15, subject to the Cambridge Core terms of use, available at
389. Edwards CA & Parrett AM (2002) Intestinal flora during
the first months of life: new perspectives. Br J Nutr 88,
Suppl. 1, S11–S18.
390. Holzapfel WH, Haberer P, Snel J, et al. (1998) Overview of
gut flora and probiotics. Int J Food Microbiol 41, 85–101.
391. Rhee KJ, Sethupathi P, Driks A, et al. (2004) Role of commen-
sal bacteria in development of gut-associated lymphoid tissues
and preimmune antibody repertoire. J Immunol 172,
1118–1124.
392. Tanaka K & Ishikawa H (2004) Role of intestinal bacterial
flora in oral tolerance induction. Histol Histopathol 19,
907–914.
393. Yamanaka T, Helgeland L, Farstad IN, et al. (2003) Microbial
colonization drives lymphocyte accumulation and differen-
tiation in the follicle-associated epithelium of Peyer’s patches.
J Immunol 170, 816–822.
394. Wostmann BS (1996) Germfree and Gnotobiotic Animal
Models. Boca Raton, FL: CRC Press.
395. Ouwehand A, Isolauri E & Salminen S (2002) The role of the
intestinal microflora for the development of the immune
system in early childhood. Eur J Nutr 41, Suppl. 1, I32–I37.
396. Kalliomaki M, Kirjavainen P, Eerola E, et al. (2001) Distinct
patterns of neonatal gut microflora in infants in whom atopy
was and was not developing. J Allergy Clin Immunol 107,
129–134.
397. Rautava S, Ruuskanen O, Ouwehand A, et al. (2004) The
hygiene hypothesis of atopic disease–an extended version.
J Pediatr Gastroenterol Nutr 38, 378–388.
398. Sudo N, Sawamura S, Tanaka K, et al. (1997) The requirement
of intestinal bacterial flora for the development of an IgE
production system fully susceptible to oral tolerance induction.
J Immunol 159, 1739–1745.
399. Macfarlane S & Macfarlane GT (2003) Food and the large
intestine. In Gut Flora, Nutrition, Immunity and Health,
[R Fuller and G Perdigon, editors]. Oxford: Blackwell
Publishing.
400. Gibson GR & Roberfroid MB (1995) Dietary modulation of
the human colonic microbiota: introducing the concept of pre-
biotics. J Nutr 125, 1401–1412.
401. Fuller R & Gibson GR (1997) Modification of the intestinal
microflora using probiotics and prebiotics. Scand J Gastroen-
terol Suppl 222, 28–31.
402. Fooks LJ, Fuller R & Gibson GR (1999) Prebiotics, probiotics
and human gut microbiology. Int Dairy J 9, 53–61.
403. van Loo J (2006) Inulin-type fructans as prebiotics. In Prebio-
tics: Development & Application, pp. 57–100 [GR Gibson and
RA Rastall, editors]. Chichester: John Wiley & Sons.
404. van Loo J, Coussement P, de Leenheer L, et al. (1995) On the
presence of inulin and oligofructose as natural ingredients in
the western diet. Crit Rev Food Sci Nutr 35, 525–552.
405. Rastall RA (2006) Galacto-oligosaccharides as prebiotics. In
Prebiotics: Development & Application, pp. 101–110 [GR
Gibson and RA Rastall, editors]. Chichester: John Wiley & Sons.
406. Videla S, Vilaseca J, Antolin M, et al. (2001) Dietary inulin
improves distal colitis induced by dextran sodium sulfate in
the rat. Am J Gastroenterol 96, 1486–1493.
407. Schultz M, Munro K, Tannock GW, et al. (2004) Effects of
feeding a probiotic preparation (SIM) containing inulin on
the severity of colitis and on the composition of the intestinal
microflora in HLA-B27 transgenic rats. Clin Diagn Lab Immu-
nol 11, 581–587.
408. Hoentjen F, Welling GW, Harmsen HJ, et al. (2005) Reduction
of colitis by prebiotics in HLA-B27 transgenic rats is associ-
ated with microflora changes and immunomodulation. Inflamm
Bowel Dis 11, 977–985.
409. Femia AP, Luceri C, Dolara P, et al. (2002) Antitumorigenic
activity of the prebiotic inulin enriched with oligofructose in
combination with the probiotics Lactobacillus rhamnosus and
Bifidobacterium lactis on azoxymethane-induced colon car-
cinogenesis in rats. Carcinogenesis 23, 1953–1960.
410. Saavedra JM, Tschernia A, Moore N, et al. (1999) Gastro-
intestinal function in infants consuming a weaning food
supplemented with oligo-fructose, a prebiotic. J Pediatr
Gastroenterol Nutr 29, A95.
411. Waligora-Dupriet AJ, Campeotto F, Nicolis I, et al. (2007)
Effect of oligofructose supplementation on gut microflora
and well-being in young children attending a day care
centre. Int J Food Microbiol 113, 108–113.
412. Moro G, Arslanoglu S, Stahl B, et al. (2006) A mixture of
prebiotic oligosaccharides reduces the incidence of atopic
dermatitis during the first six months of age. Arch Dis Child
91, 814–819.
413. Welters CF, Heineman E, Thunnissen FB, et al. (2002) Effect
of dietary inulin supplementation on inflammation of pouch
mucosa in patients with an ileal pouch-anal anastomosis. Dis
Colon Rectum 45, 621–627.
414. Casellas F, Borruel N, Torrejon A, et al. (2007) Oral oligofruc-
tose-enriched inulin supplementation in acute ulcerative colitis
is well tolerated and associated with lowered faecal calprotec-
tin. Aliment Pharmacol Ther 25, 1061–1067.
415. FAO-WHO (2001) Joint FAO/WHO Expert Consultation on
Health and Nutritional Properties of Probiotics in Food includ-
ing Powder Milk with Live Lactic Acid Bacteria
416. Bergonzelli GE, Granato D, Pridmore RD, et al. (2006) GroEL of
Lactobacillus johnsonii La1 (NCC 533) is cell surface associ-
ated: potential role in interactions with the host and the gastric
pathogen Helicobacter pylori. Infect Immun 74, 425–434.
417. Buck BL, Altermann E, Svingerud T, et al. (2005) Functional
analysis of putative adhesion factors in Lactobacillus acidophi-
lus NCFM. Appl Environ Microbiol 71, 8344–8351.
418. Penner R, Fedorak RN & Madsen KL (2005) Probiotics and
nutraceuticals: non-medicinal treatments of gastrointestinal
diseases. Curr Opin Pharmacol 5, 596–603.
419. Petrof EO, Kojima K, Ropeleski MJ, et al. (2004) Probiotics
inhibit nuclear factor-kappaB and induce heat shock proteins
in colonic epithelial cells through proteasome inhibition. Gas-
troenterology 127, 1474–1487.
420. Cario E, Gerken G & Podolsky DK (2004) Toll-like receptor 2
enhances ZO-1-associated intestinal epithelial barrier integrity
via protein kinase C. Gastroenterology 127, 224–238.
421. Neish AS, Gewirtz AT, Zeng H, et al. (2000) Prokaryotic regu-
lation of epithelial responses by inhibition of IkappaB-alpha
ubiquitination. Science 289, 1560–1563.
422. Kelly D, Campbell JI, King TP, et al. (2004) Commensal
anaerobic gut bacteria attenuate inflammation by regulating
nuclear-cytoplasmic shuttling of PPAR-gamma and RelA.
Nat Immunol 5, 104–112.
423. O’Hara AM, O’Regan P, Fanning A, et al. (2006) Functional
modulation of human intestinal epithelial cell responses by
Bifidobacterium infantis and Lactobacillus salivarius. Immu-
nology 118, 202–215.
424. Ruiz PA, Hoffmann M, Szcesny S, et al. (2005) Innate
mechanisms for Bifidobacterium lactis to activate transient
pro-inflammatory host responses in intestinal epithelial cells
after the colonization of germ-free rats. Immunology 115,
441–450.
425. Miettinen M, Lehtonen A, Julkunen I, et al. (2000)
Lactobacilli and streptococci activate NF-kappa B and
STAT signaling pathways in human macrophages. J Immunol
164, 3733–3740.
426. Matsuguchi T, Takagi A, Matsuzaki T, et al. (2003) Lipoteichoic
acids from Lactobacillus strains elicit strong tumor necrosis
factor alpha-inducing activities in macrophages through Toll-
like receptor 2. Clin Diagn Lab Immunol 10, 259–266.
P. C. Calder et al.S44
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509377867
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:35:15, subject to the Cambridge Core terms of use, available at
427. Smits HH, Engering A, van der Kleij D, et al. (2005) Selective
probiotic bacteria induce IL-10-producing regulatory T cells
in vitro by modulating dendritic cell function through dendritic
cell-specific intercellular adhesion molecule 3-grabbing non-
integrin. J Allergy Clin Immunol 115, 1260–1267.
428. Hahm KB, Im YH, Lee C, et al. (2000) Loss of TGF-beta
signaling contributes to autoimmune pancreatitis. J Clin
Invest 105, 1057–1065.
429. Monteleone G, Kumberova A, Croft NM, et al. (2001) Block-
ing Smad7 restores TGF-beta1 signaling in chronic
inflammatory bowel disease. J Clin Invest 108, 601–609.
430. Di Giocinto C, Marinaro M, Sanchez M, et al. (2005) Probio-
tics ameliorate recurrent Th1-mediated murine colitis by
inducing IL-10 and IL-10-dependent TGF-beta-bearing
regulatory cells. J Immunol 174, 3237–3246.
431. Fujii T, Ohtsuka Y, Lee T, et al. (2006) Bifidobacterium breve
enhances transforming growth factor beta1 signaling by
regulating Smad7 expression in preterm infants. J Pediatr
Gastroenterol Nutr 43, 83–88.
432. Mimura T, Rizzello F, Helwig U, et al. (2004) Once daily high
dose probiotic therapy (VSL#3) for maintaining remission in
recurrent or refractory pouchitis. Gut 53, 108–114.
433. Kuisma J, Mentula S, Jarvinen H, et al. (2003) Effect of
Lactobacillus rhamnosus GG on ileal pouch inflammation
and microbial flora. Aliment Pharmacol Ther 17, 509–515.
434. Gupta P, Andrew H, Kirschner BS, et al. (2000) Is
Lactobacillus GG helpful in children with Crohn’s disease?
Results of a preliminary, open-label study. J Pediatr Gastroen-
terol Nutr 31, 453–457.
435. Schultz M, Timmer A, Herfarth HH, et al. (2004)
Lactobacillus GG in inducing and maintaining remission of
Crohn’s disease. BMC Gastroenterol 4, 5.
436. Prantera C, Scribano ML, Falasco G, et al. (2002) Ineffective-
ness of probiotics in preventing recurrence after curative
resection for Crohn’s disease: a randomised controlled trial
with Lactobacillus GG. Gut 51, 405–409.
437. Marteau P, Lemann M, Seksik P, et al. (2006) Ineffectiveness of
Lactobacillus johnsonii LA1 for prophylaxis of postoperative
recurrence in Crohn’s disease: a randomised, double blind,
placebo controlled GETAID trial. Gut 55, 842–847.
438. Van Gossum A, Dewit O, Louis E, et al. (2007) Multicenter
randomized-controlled clinical trial of probiotics (Lacto-
bacillus johnsonii, LA1) on early endoscopic recurrence of
Crohn’s disease after lleo-caecal resection. Inflamm Bowel
Dis 13, 135–142.
439. Kruis W, Fric P, Pokrotnieks J, et al. (2004) Maintaining
remission of ulcerative colitis with the probiotic Escherichia
coli Nissle 1917 is as effective as with standard mesalazine.
Gut 53, 1617–1623.
440. Rembacken BJ, Snelling AM, Hawkey PM, et al. (1999)
Non-pathogenic Escherichia coli versus mesalazine for the
treatment of ulcerative colitis: a randomised trial. Lancet
354, 635–639.
441. Tursi A, Brandimarte G, Giorgetti GM, et al. (2004) Low-dose
balsalazide plus a high-potency probiotic preparation is more
effective than balsalazide alone or mesalazine in the treatment
of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10,
I126–I131.
442. Zocco MA, dal Verme LZ, Cremonini F, et al. (2006) Efficacy
of Lactobacillus GG in maintaining remission of ulcerative
colitis. Aliment Pharmacol Ther 23, 1567–1574.
443. Cui HH, Chen CL, Wang JD, et al. (2004) Effects of probiotic
on intestinal mucosa of patients with ulcerative colitis. World J
Gastroenterol 10, 1521–1525.
444. Ishikawa H, Akedo I, Umesaki Y, et al. (2003) Randomized
controlled trial of the effect of bifidobacteria-fermented milk
on ulcerative colitis. J Am Coll Nutr 22, 56–63.
445. Rovensky J, Svik K, Stancikova M, et al. (2002) Treatment
of experimental adjuvant arthritis with the combination of
methotrexate and lyophilized Enterococcus faecium enriched
with organic selenium. Folia Microbiol (Praha) 47,
573–578.
446. Hatakka K, Martio J, Korpela M, et al. (2003) Effects of
probiotic therapy on the activity and activation of mild
rheumatoid arthritis – a pilot study. Scand J Rheumatol 32,
211–215.
447. Shida K, Makino K, Morishita A, et al. (1998) Lactobacillus
casei inhibits antigen-induced IgE secretion through regulation
of cytokine production in murine splenocyte cultures. Int Arch
Allergy Immunol 115, 278–287.
448. Matsuzaki T, Yamazaki R, Hashimoto S, et al. (1998) The
effect of oral feeding of Lactobacillus casei strain Shirota on
immunoglobulin E production in mice. J Dairy Sci 81, 48–53.
449. Murosaki S, Yamamoto Y, Ito K, et al. (1998) Heat-killed
Lactobacillus plantarum L-137 suppresses naturally fed anti-
gen-specific IgE production by stimulation of IL-12 production
in mice. J Allergy Clin Immunol 102, 57–64.
450. Shida K, Takahashi R, Iwadate E, et al. (2002) Lactobacillus
casei strain Shirota suppresses serum immunoglobulin E and
immunoglobulin G1 responses and systemic anaphylaxis in a
food allergy model. Clin Exp Allergy 32, 563–570.
451. Bjo¨rkste´n B, Sepp E, Julge K, et al. (2001) Allergy develop-
ment and the intestinal microflora during the first year of
life. J Allergy Clin Immunol 108, 516–520.
452. Ouwehand AC, Isolauri E, He F, et al. (2001) Differences in
Bifidobacterium flora composition in allergic and healthy
infants. J Allergy Clin Immunol 108, 144–145.
453. Majamaa H & Isolauri E (1997) Probiotics: a novel approach
in the management of food allergy. J Allergy Clin Immunol
99, 179–185.
454. Isolauri E, Arvola T, Su¨tas Y, et al. (2000) Probiotics in the
management of atopic eczema. Clin Exp Allergy 30,
1604–1610.
455. Kallioma¨ki M, Salminen S, Arvilommi H, et al. (2001)
Probiotics in primary prevention of atopic disease: a random-
ised placebo-controlled trial. Lancet 357, 1076–1079.
456. Kallioma¨ki M, Salminen S, Poussa T, et al. (2003) Probiotics
and prevention of atopic disease: 4-year follow-up of a
randomised placebo-controlled trial. Lancet 361, 1869–1871.
457. Rosenfeldt V, Benfeldt E, Nielsen SD, et al. (2003) Effect of
probiotic Lactobacillus strains in children with atopic dermati-
tis. J Allergy Clin Immunol 111, 389–395.
458. Hlivak P, Odraska J, Ferencik M, et al. (2005) One-year appli-
cation of probiotic strain Enterococcus faecium M-74 decreases
serum cholesterol levels. Bratisl Lek Listy 106, 67–72.
459. Naruszewicz M, Johansson ML, Zapolska-Downar D, et al.
(2002) Effect of Lactobacillus plantarum 299v on cardiovascu-
lar disease risk factors in smokers. Am J Clin Nutr 76,
1249–1255.
460. Bach JF (2002) The effect of infections on susceptibility to
autoimmune and allergic diseases. New Engl J Med 347,
911–920.
Inflammatory processes and nutrition S45
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114509377867
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:35:15, subject to the Cambridge Core terms of use, available at
